The effect of endogenous and exogenous chemicals on drug metabolizing enzymes and drug transporters in human hepatocytes by Ranade, Aarati Ram
 
 
The effect of endogenous and exogenous chemicals on drug metabolizing enzymes and drug 
transporters in human hepatocytes 
 
 
 
 
 
by 
 
 
Aarati Ram Ranade 
 
 
Bachelor of Pharmacy (B. Pharm), University of Pune, INDIA, 1997 
 
 
Master of Pharmacy (M. Pharm), University of Pune, INDIA, 1999 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
 
 
The School of Pharmacy in partial fulfillment 
 
 
of the requirements for the degree of 
 
 
Doctor of Philosophy 
 
 
 
 
 
University of Pittsburgh 
 
 
2005 
 ii
  
 
UNIVERSITY OF PITTSBURGH 
 
 
SCHOOL OF PHARMACY  
 
 
 
This dissertation was presented  
 
 
by 
 
 
 
Aarati Ram Ranade 
 
 
 
It was defended on 
 
 
November 28, 2005 
 
 
and approved by 
 
 
Albert Donnenberg, Ph.D. 
 
 
Reginald F. Frye, Pharm.D., Ph.D. 
 
 
Regis R. Vollmer, Ph.D. 
 
 
Stephen C. Strom, Ph.D. 
 
 
Raman Venkataramanan, Ph.D. 
Major Advisor 
 
 iii
Acknowledgements 
 
First and foremost, I would like to express my heartfelt gratitude to my advisor, Dr. 
Venkat, for providing unstinting support throughout my research work. The valuable discussions 
during our road trip from Washington D.C to Pittsburgh in Summer 2002 triggered my interest in 
this highly challenging field!  The guidance and technical mentorship that he has provided is 
beyond any par. His technical insight and ease of communicating highly challenging technical 
concepts is truly commendable. This work would not have borne fruition without his efforts. 
Thank you, Dr. Venkat! 
 
I would like to thank Dr. Strom for providing me invaluable support and sustained 
guidance that was inspirational in completing this endeavour.  I would like to thank him 
sincerely for providing me the opportunity to work with a highly talented, motivated and one of 
the most friendly group of people that I have ever worked with. The camaraderie in his lab 
provided high degree of motivation to work tirelessly.  The experience of working with him has 
left an indelible impression on me.  
 
I would like to thank Dr. Donnenberg for providing me the first opportunity to work in 
his laboratory. His work has taught me highly valuable traits that a good scientist should possess.  
I would also like to acknowledge him for being highly supportive and accommodating in my 
Ph.D work. 
 
I would like to express my gratitude to Dr. Vollmer for providing constant 
encouragement, constructive feedback throughout my graduate studies. Working with him during 
my teaching assistantship semesters was one of the most pleasant experiences of graduate school. 
 
I would like to thank Dr. Frye for his guidance and help in this work. He has been highly 
accommodating and supportive as my committee member. 
 
I would like to sincerely thank all the members of Dr. Strom’s Lab namely Ken, Hongbo, 
Toshio, Thomas, Ewa, Keitaru for helping out in all aspects. Very special thanks are due to past 
and present members of Dr. Venkat’s lab namely Bernie, Shimin, Dr. Ou and Aarati Warty. 
 
I would like to take this opportunity to thank my parents and family members for never 
doubting my ability to achieve this goal. Their love, affection and selfless support has been 
highly instrumental in reaching this stage of life. I would also like to thank all my friends for 
being there with me in good as well as in difficult times.  
 
And last but most important, I would like to thank my husband, Mukul, for his constant 
encouragement, invaluable support and patience through all the phases of this work.  
 
Thank you all! 
 
 
 iv
The effect of endogenous and exogenous chemicals on drug metabolizing enzymes and drug 
transporters in human hepatocytes 
 
 
Aarati Ram Ranade  
 
University of Pittsburgh, 2005 
 
 
Preface 
 
Significant variability in the pharmacokinetics of drugs such as cyclosporine, tacrolimus, 
sirolimus and mycophenolic acid, is seen in liver transplant patients. These agents are primarily 
metabolized by CYP3A4 or UGT1A1, and are also substrates for drug transporters such as P-
glycoprotein, multidrug resistance protein 2 (MRP2) and bile salt export pump (BSEP). Factors 
modulating the expression and activity of these enzymes and transporters will lead to changes in 
the clearance of immunosuppressive agents. Inflammation associated with infection or organ 
rejection after transplantation can modulate the expression and activity of CYP3A4, UGT1A1 
and various drug transporters. HIV-protease inhibitors (HIV-PIs) used for the treatment of HIV 
infection are shown to modulate the blood levels of immunosuppressive agents.  
The primary goal of this dissertation research was to evaluate the effect of endogenous 
chemicals such as cytokines and exogenous compounds such as HIV-protease inhibitors on 
human hepatic drug metabolizing enzymes and transporters using primary cultures of human 
hepatocytes.  
The results from this research indicate that HIV-protease inhibitors generally decrease 
CYP3A4 activity inspite of increasing CYP3A4 mRNA and protein. The effect of PIs on 
CYP3A4 recovers over time. PIs also increased UGT1A1 mediated metabolism as well as 
mRNA expression of transporters. These effects are dependent on the HIV-protease inhibitor 
 v
used and its concentration. Additionally, HIV-PIs increased the expression and activity of 
hepatic efflux transporters. These effects of HIV-PIs are found to be potentially mediated 
through alteration in PXR and CAR expression. Cytokines, released during infection or 
inflammation process, were observed to downregulate the expression and activity of UGTs and 
transporters through modulation of PXR and CAR.  
As compared to cytokines, the effect of HIV-protease inhibitors on drug metabolizing 
enzymes and transporters contributes significantly towards the variability in pharmacokinetics of 
immunosuppressive agents. 
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1. Introduction 
 2
1.1.  Hepatic drug metabolism 
Liver is the major organ involved in the process of drug metabolism, although some 
metabolism also occurs in the gut wall, lungs and kidneys. Hepatocytes contain the enzymes 
necessary for the metabolism of drugs and endogenous chemicals. Overall, the metabolic 
processes convert drugs into more water-soluble compounds by increasing their polarity. This is 
an essential step before the drug can be excreted in bile or urine (Woolf, 1999). Conventionally, 
drug metabolism is broadly divided into phase I and phase II metabolism processes. Some drugs 
may undergo just phase I or phase II metabolism, but more often drugs undergo phase I and then 
phase II metabolism sequentially.  
Phase I metabolism includes processes such as oxidation, reduction, hydrolysis and 
hydration which result in the formation of functional groups (-OH, -SH, -NH2 or –COOH) 
making the metabolite more polar than the parent compound (Gibson and P, 2001). Cytochrome 
P450 (CYP) is the most important phase I enzyme and refers to a superfamily of heme-
containing enzymes, located in the membrane of endoplasmic reticulum of the cell and is 
responsible for the metabolism of a variety of xenobiotics and endobiotics (Woolf, 1999). 
Human CYP isoforms involved in the metabolism of xenobiotics include CYP1A1/2, CYP2B6, 
CYP2C8/9/19, CYP2D6, CYP2E1 and CYP3A4/5, of which CYP3A is the most abundant 
isoform (30 % of the hepatic CYPs) in human livers (Shimada et al., 1994; Eagling et al., 1998; 
Woolf, 1999).  Functionally, CYP3A is responsible for the metabolism of about 53% of 
commonly prescribed drugs, followed by CYP2D6, CYP2C, CYP1A2 and CYP2E1 accounting 
for 25%, 18%, 3% and 1% of drug metabolism, respectively (Shimada et al., 1994; Woolf, 
1999). The subfamily of CYP3A includes CYP3A4, CYP3A5 and CYP3A7. CYP3A4 and 
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CYP3A5 are expressed in adult livers, while CYP3A7 is expressed mainly in fetal liver 
(Venkatakrishnan et al., 2001).  
Phase II metabolism involves processes such as methylation, acetylation, sulfation, 
glutathione conjugation and glucuronidation (Woolf, 1999). Uridine diphosphate 
glucuronosyltransferases (UGTs) are the important phase II enzymes located in the membrane of 
endoplasmic reticulum. They are responsible for glucuronidation of endogenous and exogenous 
compounds, which involves the transfer of the glucuronic acid residue from uridine 
diphosphoglucuronic acid to hydroxy or carboxylic acid group of the compound (Mackenzie et 
al., 1997). To date, in humans, 16 different UGT isoforms have been identified, classified into 
1A or 2B subfamilies (Tukey and Strassburg, 2000). Among the UGT1A family, UGT1A1 is the 
most important isoform involved in the glucuronidation of bilirubin as well as estradiol, 
acetaminophen and irinotecan (Cheng et al., 1998; Court et al., 2001; Tukey et al., 2002). 
UGT1A6 and UGT1A9 are other isoforms involved in the metabolism of catechols, 
acetaminophen and 4-methylumbelliferone (Court et al., 2001). Table 1 lists selected drug 
metabolizing enzymes along with their respective substrates, inducers and inhibitors. 
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Table 1. Substrates, inducers and inhibitors for common drug metabolizing enzymes and hepatic canalicular transporters 
Hepatic canalicular transporters 
CYP3A4 UGT1A1 
MDR1 MRP2 BSEP 
Substrates 
testosterone estradiol 
HIV protease inhibitors; 
amprenavir, ritonavir, 
indinavir, saquinavir 
estradiol-17β-
glucuronide taurocholate 
midazolam bilirubin tacrolimus glutathione bilirubin conjugates 
conjugated  
and unconjugated bile acids 
erythromycin acetaminophen cyclosporine SN-38  
tacrolimus SN-38 digoxin glyburide  
cyclosporine  rhodamine 123 etoposide  
Inducers 
rifampicin phenobarbital rifampicin rifampicin CDCA 
phenobarbital rifampicin  phenobarbital  
hyperforin chrysin    
Inhibitors 
ketoconazole  cyclosporine cyclosporine cyclosporine 
ritonavir   rifampicin troglutazone 
verapamil   glyburide rifampicin 
(Kostrubsky et al., 1999; Bowen et al., 2000; Sueyoshi and Negishi, 2001; Asghar et al., 2002; Chandra and Brouwer, 2004) 
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1.2. Hepatic drug transporters 
Hepatobiliary transport and bile flow play important roles in the removal of endogenous 
and exogenous substances from the body, and adequate bile salt flow and recycling (Faber et al., 
2003). Lipophilic molecules may move from plasma to hepatic cytosol by simple or facilitated 
diffusion. However, numerous transport proteins located in the sinusoidal (basolateral) 
membrane of the hepatocyte mediate uptake of amphipathic and polar organic compounds, as 
well as some lipophilic molecules, from sinusoidal plasma to hepatic cytosol, where these 
compounds are metabolized by the hepatic drug metabolizing enzymes. Hepatic transport 
proteins also play an important role in the excretion of drugs and metabolites from the 
hepatocyte into the canalicular space that exists between adjoining hepatocytes. Hepatic 
elimination is thus a sequence of events involving uptake of xenobiotice from the sinusoidal 
blood followed by intracellular metabolism and ultimately excretion into bile. Figure 1 shows a 
schematic of the uptake and efflux transporters in human liver and their localization in human 
hepatocytes. Table 1 lists selected drug transporters, their substrates, inducers and inhibitors. 
Two classes of hepatic transporters are involved in the uptake and efflux of drugs, drug 
conjugates and endogenous substrates.  They are classified as the solute carrier family (SLC) and 
the ATP binding cassette family (ABC).  Na+-taurocholate cotransporting polypeptide (NTCP, 
SLC10A1) is the basolateral transporter preferentially involved sodium dependent transport of 
conjugated bile acids (Karpen et al., 1996; Kouzuki et al., 2000; Chandra and Brouwer, 2004). 
Bromosulphthalein, estrone-3-sulphate are non bile salt substrates for this protein (Meier et al., 
1997). The organic anion transporters (OATP, SLC21 subfamily) are uptake carrier proteins that 
are involved in the Na-independent transport of a variety of structurally diverse compounds such 
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as bromosulphophthalein, glycocholate, prostaglandin E2 and estradiol-17β-glucuronide (Kullak-
Ublick et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Hepatic uptake and efflux transporters in human liver 
Modified from: (Trauner et al., 1998; Faber et al., 2003; Chandra and Brouwer, 2004) 
  
The biliary excretion of drugs and metabolites occurs predominantly by uni-directional 
ATP-dependent export pumps that transport substrates across canalicular membrane into bile. 
The canalicular membrane transporters that have been described to date are multidrug resistance 
Hepatocyte 
NTCP 
OATP-A 
OATP-B 
OATP-C 
MDR1 
MRP2 
BSEP 
BCRP 
MRP6 
cytosol 
Canalicular space 
Hepatocyte 
BSEP, bile salt export pump; BCRP, breast cancer resistance protein; NTCP, 
sodium taurocholate cotransporting polypeptide; OATP, organic anion 
transporting polypeptides; MDR1, multidrug resistance protein 1; MRP, multidrug 
resistance associated protein 
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associated protein 2 (MRP2, ABCC2), bile salt export pump (BSEP, ABCB11), multidrug 
resistant protein 3 (MDR3, ABCB4), multidrug resistance protein 1 (MDR1, ABCB1) and breast 
cancer resistance protein (BCRP, ABCG2) (reviewed in (Faber et al., 2003)).  
The most widely recognized canalicular transporter is MDR1, the multidrug resistance 
protein, P-glycoprotein. It primarily mediates the transport of large variety of substrates usually 
containing planar aromatic motifs and having molecular weight greater than 400 (Oude Elferink 
RP, 1995).  In contrast to rodents, human hepatic expression of MDR1 is low compared to the 
intestine (Schuetz et al., 1995).  MRP2 is responsible for the biliary secretion of organic anions 
such as acetaminophen glucuronide, camptothecin, SN-38, bile salts, glutathione, glucuronide 
and sulfate conjugates (Koike et al., 1997).  MDR3 (ABCB4) plays an important role in 
phospholipids secretion. Patients classified with PFIC type 3 cholestasis exhibit mutations in 
ABCB4 genes but the physiological role of MDR3 as drug transporter remains to be identified 
(Smith et al., 2000). BCRP is a 72-kDa ABC half- transporter and is thought to play an important 
role in the biliary excretion of sulfated conjugates of steroids and xenobiotics. BSEP is 
responsible for the excretion of conjugated and unconjugated bile salts, such as taurocholate, into 
the canalicular spaces (Gerloff et al., 1998). Though its role in cellular handling of xenobiotics is 
not yet clear, BSEP may be an important site of drug interactions resulting in hepatotoxicity. 
MRP6 (ABCC6) is another transporter with high expression levels in liver and kidneys but fail to 
show expression in other tissues (Kool et al., 1999). Alterations in these transporters, through 
inhibition or induction, can affect the intracellular concentration of drugs, resulting in altered 
pharmacokinetic and pharmacodynamic profiles, or of endogenous substances, altering normal 
physiological processes in the liver. 
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1.3. Regulation of hepatic drug metabolizing enzymes and drug transporters 
Understanding of the regulation of hepatic drug metabolism and transporters is important 
to gain better knowledge of hepatic transport biology and facilitate predictions of how drugs 
and/or disease state that affect the intracellular regulatory mechanisms can alter hepatic 
metabolism and transport of exogenous and endogenous compounds. Mechanisms for regulation 
generally involve alteration in the function, expression or changes in the protein structure. Long-
term modulation of expression can occur at several different levels such as transcription, 
translation and post translation. Transcription factors play an important role in the regulation of 
drug metabolizing enzyme and transporter gene expression in hepatocytes (Muller, 1998). 
The regulation of drug metabolizing enzymes and transporters within the liver is complex 
and may involve multiple nuclear receptors that are able to converge on the same response 
element governing the expression of a single gene. Nuclear hormone receptors comprise a large 
superfamily of ligand activated transcription factors containing a conserved DNA-binding 
domain, a hinge region and a carboxy-terminal domain responsible for ligand binding and 
dimerization (Kumar and Thompson, 1999). Xenobiotics interact with these receptors, and the 
resulting complexes bind to the regulatory region of the gene to modulate its expression. Once a 
ligand binds to the receptor, the complex proceeds to bind to heterodimeric partner, retinoic X 
receptor (RAR), and this dimmer is then able to initiates the transcription. These transcription 
regulators serve to protect the liver against exogenous and endogenous toxic compounds.  To 
date, several nuclear hormone receptor types have been reported to be involved in the 
transcriptional regulation of drug metabolizing enzymes and transport proteins and can roughly 
be divided into four classes: aryl hydrocarbon receptor (AhR), constitutive androgen receptor 
(CAR), pregnane X receptor (PXR) and the farnesoid X receptor (FXR). Figure 2 shows the 
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important nuclear receptors involved in the regulation of drug metabolizing enzymes and drug 
transporters in human liver. 
The aryl hydrocarbon receptor (AhR) is a member of the PAS superfamily of 
transcription factors. It can be activated by a variety of chemicals including the aryl 
hydrocarbons, benzo(a)pyrene and 3-methylcholanthrene and the dietary plant constituents β-
naphthoflavone and chrysin (Nebert and Gonzalez, 1987; Sogawa and Fujii-Kuriyama, 1997; 
Galijatovic et al., 2000). Following heterodimerization with the AhR nuclear translocator 
(ARNT), the AhR-ARNT complex translocates to the nucleus where it binds to specific dioxin 
response elements (DREs) with a defined core nucleotide sequence TNGCGTG (Dolwick et al., 
1993; Lusska and Whitlock JP, 1993). While the mechanism for enzyme induction was first 
characterized for CYP1A, drug response elements (DREs) for AhR have also been identified in 
the promoter regions for human UGT1A1 and UGT1A6 (Munzel et al., 1998; Yueh et al., 2001). 
PXR is the most extensively studied of the nuclear receptors and has been cloned in a 
number of species including rabbit, pig, monkey and human (Zhang et al., 1999; Kliewer and 
Willson, 2002). Human PXR has been shown to play an important role in the induction of 
CYP3A4, UGT1A1, UGT1A6, MDR1, MRP2, and OATP-C (Kliewer, 1998; Schuetz et al., 
2001; Kast HR, 2002; Tirona et al., 2003). 
The constitutive androgen receptor (CAR), as with other orphan nuclear receptors, also 
partners as a heterodimer with RXR to AGGTCA-based DNA response element (Sueyoshi and 
Negishi, 2001). It is predominantly expressed in the intestine and liver (Baes M, 1994). Human 
CAR modulates phenobarbital mediated induction of CYP3A4, UGT1A1, MRP2 and OATP-C 
(Sueyoshi et al., 1999; Sugatani et al., 2001; Goodwin B, 2002; Kast HR, 2002). Profound 
species differences in ligand specificity exist between human and rodent PXR as well as CAR 
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(Poland A, 1980; Maglich JM, 2003). Both PXR and CAR bind similar ligands, such as 
phenobarbital, rifampicin and dexamethasone and are thought to modulate gene induction 
through similar response elements (Sueyoshi et al., 1999; Moore LB, 2000; Xie W, 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Nuclear receptors involved in the regulation of hepatic drug metabolizing 
enzymes and transporters 
Modified from: (Trauner et al., 1998; Faber et al., 2003; Chandra and Brouwer, 2004) 
 
Farnesoid X receptor (FXR), after heterodimerizing with retinoid X receptor (RXR), is 
largely involved in the induction of transporters responsible for the efflux of bile salts in 
conditions of accumulation of potentially hepatotoxic bile acids and bile acid conjugates 
AhR, aryl hydrocarbon receptor; Arnt, AhR nuclear translocator, CAR, constitutive 
androgen receptor; FXR, farnesoid X receptor; PXR, pregnane X receptor; RXR, retinoid X 
receptor 
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(Ananthanarayanan M, 2001). The FXR-RXR heterodimer preferentially binds to the IR-1 
element, consisting of an inverted repeat of AGGTCA hexamers, separated by one base pair, but 
has been shown to also bind to DR-3 and DR-4 motifs (Laffitte BA, 2000).  FXR has been 
shown to induce BSEP, MRP2 along with OATP8 (Schuetz et al., 2001; Kast HR, 2002; Jung D, 
2004). A summary of the above information is provided in Table 2. 
 
Table 2. Nuclear receptors involved in the regulation of common hepatic drug metabolizing 
enzymes drug transporters  
Nuclear receptor Ligands Some major target genes 
PXR Xenobiotics, Rifampicin, Ursodeoxycholic acid 
CYP3A4, UGTs, MDR1, MDR3, 
MRP2, MRP4, BSEP 
CAR Xenobiotics, phenobarbital CYP3A, UGTs, OATP-C, MRP2, MRP4, MDR1 
FXR Bile acids BSEP, UGTs, MRP2, MDR3 
VDR Vitamin D, lithocholic acid CYP3A 
RXRα 9-cis-retinoic acid Heterodimeric partner of all nuclear receptors 
PXR, pregnane X receptor; CAR, constitutive androgen receptor; FXR, farnesoid X receptor; 
AhR, aryl hydrocarbon receptor; RXR, retinoid X receptor; VDR, vitamin D receptor. 
 
1.4. Drug metabolism and transport in liver transplant patients 
Liver transplantation is considered as the treatment of choice for patients with end-stage 
liver disease and in some metabolic liver diseases where standard medical or surgical therapeutic 
alternatives are not readily available. More than 5000 liver transplants are performed on an 
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annual basis in the US. Common indications for liver transplantation are cholestatic diseases 
(primary biliary cirrhosis), chronic hepatitis (hepatitis B, hepatitis C infections, and chronic drug 
toxicity), alcoholic cirrhosis, metabolic disorders (Wilson’s disease, tyrosinemia, 
hemochromatosis) and hepatocellular carcinoma. Human immunodeficiency virus (HIV) 
infection was previously considered as an absolute contraindication to liver transplantation 
because of the high mortality rate due to opportunistic infection associated with HIV infection. 
However, the improvement in immune status and increased survival among individuals with HIV 
infection, which was made possible by the introduction of highly active antiretroviral therapy 
(HAART) in 1996, has made liver transplantation a possible treatment option even in patients 
who are HIV positive (Ragni et al., 2003; Neff et al., 2004). 
Management of patients post liver transplantation is critical as many acute complications 
are common. These include allograft dysfunction, vascular complication involving hepatic artery 
thrombosis, and allograft rejection along with occurrence of bacterial and fungal infections. 
Long-term management of hypertension, diabetes mellitus, and hyperlipidemia is also frequently 
needed after liver transplantation. Thus, liver transplant patients are generally treated with 
multiple drugs that include one or more immunosuppressive drugs, antibiotics, antiviral drugs 
and antifungal drugs. Table 3 lists the drugs commonly used as part of a therapeutic regimen in 
transplant patients.  
Importantly, the success of solid organ transplantation requires the use of 
immunosuppressive drugs that suppress the host response to an allograft enabling the 
transplantation of foreign organ into the recipient. Immunosuppression following transplantation 
is crucial to the survival of both allograft and patient. Major advancements in the field of 
immunosuppression involve introduction of cyclosporine in the early 1980s, followed by 
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tacrolimus and mycophenolic acid in the 1990s. During the late 1990s, a combination based 
approached using these immunosuppresive agents was introduced which was particularly 
effective in reducing graft rejection. For example, the combination of mycophenolic acid with 
cyclosporine and prednisone led to the reduction of acute rejection to 30-40 % in liver transplant 
patients. The most recent combination of immunosuppressive agents includes the use of low-
dose tacrolimus and sirolimus with or without prednisone and mycophenolic acid (Wiesner et al., 
2003). 
1.5. Variability in pharmacokinetics of immunosuppressive agents 
All the immunosuppressive agents currently used for prevention of rejection have a 
narrow therapeutic index. Under-dosing increases the risk of immunological rejection and the 
prospect of organ loss or damage, with potentially fatal consequences. Overdosing increases the 
risks associated with immunosuppression such as infection and malignant diseases, as well as 
drug specific adverse effects. These adverse effects can be serious such as development of 
diabetes mellitus with corticosteroids and calcineurin inhibitors (cyclosporine and tacrolimus), 
nephrotoxicity and hypertension with calcineurin inhibitors, and hyperlipidemia with sirolimus. 
Thus, it is extremely important to achieve and maintain target blood concentrations of the 
immunosuppressive agents during the treatment period.  
Some important factors responsible for the intra- and inter- patient variability in the 
pharmacokinetics of the immunosuppressive drugs, thus requiring close monitoring and 
adjustments in their dosing regimen, are discussed briefly in the following section. 
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Table 3. Drugs commonly used in patients undergoing liver transplantation 
Drug class Drugs  
Immunosuppressive agents 
Prednisone 
Cyclosporine A 
Tacrolimus 
Sirolimus 
Mycophenolic acid 
Antifungal agents 
Ketoconazole 
Itraconazole 
Fluconazole 
Voriconazole 
Antibiotics 
Sulfamethoxazole-trimethoprim 
Acyclovir 
Ganciclovir 
Antiviral agents 
Ritonavir 
Lopinavir 
Nelfinavir 
Indinavir 
Antihypertensive agents 
Nifedipine 
Diltiazem 
 
1.5.1. Ischemia /reperfusion injury and release of cytokines can alter drug metabolism 
A period of cold ischemia is inevitable during the procurement of an organ for 
transplantation. On restoring the blood supply, the liver is subjected to warm reperfusion injury 
in the donor. This ischemia-reperfusion injury (I-R) leads to a multitude of conditions with the 
common clinical outcome of a poorly functioning graft (Delva et al., 1989; Huguet et al., 1992; 
Henderson, 1999; Serracino-Inglott et al., 2001). Experimental animal models of hepatic 
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ischemia-reperfusion injury have shed considerable light on the cellular and molecular 
mechanisms by which this insult produces a local acute inflammatory response that can, in some 
cases, lead to a systemic inflammatory response.  
The initial phase initiated upon reperfusion that lasts for 2-3 hours is mediated by 
Kupffer-cell mediated production of reactive oxygen species (ROS) including superoxide anion 
and hydrogen peroxide. The severe injury that develops during the later phase (> 6 hours) is 
mediated primarily by activated neutrophils that accumulate in postischemic liver. 
The hepatic inflammatory response to ischemia appears to begin with the elaboration of 
the cytokine, interleukin –12 (IL-12), which further leads to increased expression of tumor 
necrosis factor-alpha (TNFα) and interleukin –1 (IL-1).  The cytokines interleukin – 6 (IL-6), 
interleukin –10 (IL-10) and interleukin –13 (IL-13) have been shown to be expressed during 
hepatic ischemia-reperfusion. Nitric oxide (NO) has also been shown to be another important 
regulatory mediator. 
Use of immunosuppressive agents in the therapy helps in reducing the damage caused by 
ischemia – reperfusion. Cyclosporine and tacrolimus, reduce both tissue free radical levels and 
neutrophil infiltration after ischemia- reperfusion (Garcia-Criado et al., 1997). A new 
immunosuppressive agent FTY720 has been shown to prolong the damage due to ischemia and 
reperfusion. Though the release of cytokines after ischemia-reperfusion occurs over a 
comparatively short period of time, it can lead to systemic inflammatory response.  
1.5.1.1. Pro-inflammatory cytokines - endogenous chemicals affecting drug metabolism 
and transporters 
The inflammatory response, or the acute phase response (APR), is a systemic process in 
which the liver plays an important regulatory role. During tissue injury or infection, the body 
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reacts immediately with a series of specific physiological processes that eventually lead to the 
restoration of homeostasis. This APR starts within the liver where the Kupffer cells produce 
different pro-inflammatory cytokines, including tumor necrosis factor alpha (TNFα), interleukin 
(IL)- 1β and IL-6. In addition, various inflammatory transcription factors such as NF-κB and AP-
1 are also activated. 
Various reports have shown that IL-1, IL-6 and TNFα have suppressive effects on the 
expression and activity of different CYPs in in-vivo and in-vitro systems such as primary rat and 
human hepatocytes and microsomes. In addition, nitric oxide generated from hepatocytes and 
Kupffer cells in response to cytokines is able to react with heme-containing proteins such as 
CYP enzymes and can decrease CYP mediated activities. Nitric oxide is shown to inhibit 
expression of some CYPs, thus contributing towards down-regulation of CYPs during 
inflammation. 
Compared to the studies describing the effects of cytokines on CYP expression and 
activity, there are limited reports published documenting the effect of cytokines or inflammation 
on phase II metabolizing enzymes such as UGTs. (Levesque et al., 1998) have reported IL-1α 
mediated inhibition of formation of dihydrotestosterone glucuronide in LNCaP cells. In rats, 
after injection of turpentine, the rate of p-nitrophenol glucuronidation (UGT1A6 marker) by 
hepatic microsomes remained unchanged, while the formation of testosterone glucuronide 
(UGT2B1/3/6 marker) was reduced to 65% of control. The mRNA expression of UGT1A1 and 
UGT2B3 was decreased after turpentine injection. The same study reported IL-6 (50 units/ml) 
mediated suppression of UGT1A1 and UGT2B3 mRNA expression in primary rate hepatocytes, 
with no effect of IL-1 on UGT mRNA levels (Strasser et al., 1998). 
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Hepatic mRNA expression of uptake transporters such as Oatp1, Oatp2, Oatp4 and Ntcp 
and that of efflux transporters such as Mrp2, Mrp6, Mdr1a, Bsep was reported to be decreased 
drastically 6 hours after LPS administration in rats. In contrast, LPS increased mRNA levels of 
Mrp1, Mrp3 and Mdr1b concurrently with the down-regulated transporters. Pretreatment with 
dexamethasone, which decreases the release of cytokines, reversed the reduction of Mdr1a, 
Oatp1, Oatp2 and Ntcp mRNA following LPS administration and also prevented the LPS-
mediated increase in Mrp1, Mrp3 and Mdr1b mRNA expression, indicating the involvement of 
cytokines in mediating these responses (Cherrington et al., 2004).  
IL-6 is believed to be involved in the reduction of mdr1a and mdr1b expression during 
acute inflammatory response in rats. Results have shown that reduction in mRNA levels of 
mdr1a and mdr1b observed in vivo in turpentine-induced acute inflammation are mediated 
primarily through a decrease in their gene transcription. Results from the in vitro studies in 
cultured rat hepatocytes demonstrated both an IL-6 mediated reduction in mRNA levels of 
mdr1a and mdr1b as well as IL-6 mediated suppression of mdr1a and mdr1b gene transcription 
(Sukhai et al., 2000). Fang et. al. have reported a decreased expression of mRNA expression of 
nuclear receptors RXRα, PXR, CRA, FXR and LXR , 4 hours after treatment of rats with LPS 
(Fang et al., 2004).  
Study in rat hepatocytes showed that IL-1β and IL-6 have suppressive effects on the 
expression and activity of P-glycoprotein in cultured hepatocytes. Maximal inhibitory effect of 
IL-6 was observed after 24 hours, while maximum inhibition with IL-1β was observed after 72 
hours of treatment, suggesting that IL-6 possibly acted by altering the mRNA expression of P-
glycoprotein and IL-1β altering the protein synthesis and stability (Sukhai et al., 2001). 
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In rat hepatocytes, treatment with interferon (IFN-β) did not significantly affect the P-
glycoprotein activity while interferon (IFN-γ) treatment decreased P-glycoprotein activity. The 
expression of P-glycoprotein however increased after IFN-γ, suggesting impaired maturation or 
dysfunction of the efflux transporter after IFN treatment (Akazawa et al., 2002).  
There are very few studies published documenting the effect of LPS or individual pro-
inflammatory cytokines on human drug transporters. Table 4 summarizes the effect of various 
cytokines on the expression and activity of human drug transporters. Elferrink et. al. have studied 
the effect of LPS on expression of various drug transporters in human liver slices. NTCP mRNA 
was downregulated and showed an inverse correlation with the amounts of TNFα and IL-1β 
produced. In contrast, MRP2 and BSEP mRNA levels were not affected 24 hours after LPS 
challenge, but both proteins were virtually absent in human liver slices suggesting that 
posttranscriptional mechanisms play an important role in LPS- induced regulation of human 
MRP2 and BSEP in liver slices (Elferink et al., 2004). 
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Table 4.  Effect of cytokines on the expression and activity of human drug transporters 
 NTCP MDR1 MRP2 BSEP Reference 
 mRNA Prot. mRNA Prot
. 
Act. mRNA Prot. Act. mRNA Prot.  
LPS ↓a ↓a    ↔a ↓a  ↔a ↓a (Elferink et al., 2004)a 
  ↔b ↓b ↓b ↔b, 
 
 ↑b   (Lee and Piquette-Miller, 2003)b 
 
IL-1β 
     ↓c ↓c    (Hisaeda et al., 2004)c 
IL-2   ↓d ↓d ↓d      (Stein et al., 1996)d 
  ↓b ↓b ↓b ↔b  ↑b   (Lee and Piquette-Miller, 2003)b 
 
IL-6 
  ↑e        (Bertilsson et al., 2001)e 
  ↓b ↓b ↓b ↔b ↓ ↑b   (Lee and Piquette-Miller, 2003)b 
 
TNFα 
  ↔c   ↓c     (Hisaeda et al., 2004)c 
  ↓d ↓d ↓d      (Stein et al., 1996)d IFNγ 
  ↑e        (Bertilsson et al., 2001)e 
a, Human liver slices (LPS = 100 μg/ml); b, Human hepatoma cells (HuH) and HepG2, IL-1β (0.2ng/ml), IL-6 (10 ng/ml) and TNFα 
(0.2ng/ml); c, HepG2 cells, IL-1β (1-20ng/ml) and TNFα (1-20ng/ml); d, HCT15 and HCT116 cells; e, CaCo2 cells. 
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1.5.2. Pharmacokinetic drug-drug interactions contribute significantly to the variability 
in the pharmacokinetics of drugs in transplant patients 
Pharmacokinetic drug interactions involve the effect of one drug on the absorption, 
metabolism, excretion or protein binding of another drug. Important pharmacokinetic 
interactions occur when immunosuppressants are prescribed in combination and with other 
medications. The troughs levels of mycophenolic acid (MPA, the active agent) in 
immunosuppressive regimens combining tacrolimus and mycophenolic mofetil (MMF) are 
higher than in regimens combining cyclosporine and MMF. Drugs such as ketoconazole, 
fluconazole, erythromycin, verapamil, and atorvastatin are reported to increase, while 
carbamazepine, phenobarbital, phenytoin, rifampicin and St. John’s wort decrease trough levels 
of cyclosporine and tacrolimus. Clinically, the most significant pharmacokinetic interactions 
have been observed in HIV positive patients undergoing liver transplantation, where 
immunosuppressive agents are combined with HIV-protease inhibitors such as ritonavir, 
lopinavir and nelfinavair.  
In the presence of nelfinavir (1.5 mg daily dose), the dose of tacrolimus had to be reduced 
to 0.5 mg weekly, which was 1/70 of the normal tacrolimus dose, in order to maintain the 
tacrolimus blood concentration in the desired range of 5-15 ng/ml (Schvarcz et al., 2000).  
A profound interaction between nelfinavir and tacrolimus has been shown in HIV-
positive liver transplant patients. A 10- to 50-fold decrease in tacrolimus dosage was required to 
maintain therapeutic concentrations of tacrolimus, in patients receiving nelfinavir (Jain et al., 
2002c). The interaction between tacrolimus and Kaletra, a combination of ritonavir and 
lopinavir, was found to be more significant compared to that observed with the single protease 
inhibitor nelfinavir. After initiation of Kaletra for the HIV-positive patient after transplantation, 
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tacrolimus half-life was significantly increased (20 days) thus requiring discontinuation of 
tacrolimus for 3-5 weeks, in order to maintain the required tacrolimus blood concentrations (Jain 
et al., 2003). A similar interaction between sirolimus and nelfinavir was observed in a 40-year 
old HIV positive female after liver transplantation. Even with one fifth the recommended dose of 
nelfinavir (250 mg twice a day), a nine-fold increase in the sirolimus trough concentration, three-
fold increase in peak concentration, and 60 % increase in the area under the concentration curve 
(0-24 hours) of sirolimus was observed in this patient, compared to patients not receiving 
nelfinavir (Jain et al., 2002a). To date, no other drug interaction between an immunosuppressant 
drugs and any other drug has been reported that results in such a drastic change in the 
pharmacokinetics of the immunosuppressant drug. A complete evaluation of the mechanism of 
such an interaction has not been carried out.  
1.5.2.1. HIV protease inhibitors - exogenous compounds affecting drug metabolism and 
transporters 
Inhibitors of human immunodeficiency virus (HIV)-encoded protease, combined with 
nucleoside analogues with antiretroviral activity cause profound and sustained suppression of 
viral replication, reduce morbidity and prolong life in patients with HIV infection. 
HIV protease inhibitors were first developed between 1989 and 1994 and were first 
introduced as treatment of HIV-1 infection in 1996, and are today considered part of standard 
therapy. Currently, there are seven HIV protease inhibitors approved by the FDA for the 
treatment of HIV infection. Amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, 
saquinavir and the recently introduced tipranavir are the different HIV-protease inhibitors 
currently on the market. Chemical structures of the commonly used HIV-protease inhibitors are 
shown in Figure 3.  
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In vitro metabolism studies have shown that all the HIV protease inhibitors are 
predominantly metabolized by CYP3A enzymes with a minor contribution from CYP2D6 and 
CYP2C9 (Kumar et al., 1996; Chiba et al., 1997; Fitzsimmons and Collins, 1997).  
HIV protease inhibitors have complex effects on CYP3A family of enzymes. Studies 
done using rat or human microsomes and expressed enzyme systems have shown that HIV- 
protease inhibitors inhibit CYP3A4 enzyme to a varying degree. Ritonavir is by far the most 
potent inhibitor, followed by indinavir, nelfinavir, amprenavir and saquinavir in decreasing order 
of potency (Eagling et al., 1997; Decker et al., 1998; Iribarne et al., 1998; Koudriakova et al., 
1998). Conversely, ritonavir and nelfinavir have also shown to induce CYP3A4 in studies carried 
out in rats and in human colon carcinoma cell lines (Greenblatt et al., 2000; Perloff et al., 2000; 
Venkatakrishnan et al., 2000; Venkatakrishnan et al., 2001). This induction phenomenon is of 
particular interest since all these protease inhibitors are used over an extended period of time in 
clinical practice. The induction of CYP3A4 by protease inhibitors may lead to decreased plasma 
drug levels of co-administered drugs that are substrates of CYP3A4, thus leading to loss of their 
therapeutic efficacy. Characteristics of commonly used HIV-protease inhibitors are listed in 
Table 5. 
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Amprenavir Indinavir 
 
 
 
 
 
Lopinavir Nelfinavir 
 
 
 
Ritonavir Saquinavir 
Figure 3.  Chemical structures of HIV-protease inhibitor  
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Table 5. Characteristics of commonly used HIV- protease inhibitors 
Generic 
name Form Dosing 
Oral 
bioavailability 
Serum half-
life 
(hours) 
Route of 
metabolism 
Adverse effects 
 
GI intolerance, nausea, 
vomiting 
Hyperlipidemia 
Hyperglycemia 
Amprenavir 
(APV) 
15 mg /ml 
oral solution 
1400 mg two 
times/day 
 
- 
 
7.1- 10.6 
CYP3A4 
Transaminase elevation 
400 mg once daily Indirect hyperbilirubinemia 
Hyperglycemia Atazanavir 
(ATV) 
100, 150 and 
200 mg 
capsules 
RTV 100 mg + 
ATV 300 mg once 
daily 
 
- 
 
7 
CYP3A4 
Fat maldistribution 
800 mg every 8 
hours Nephrolithoasis 
GI intolerance, nausea, 
vomiting 
Hyperlipidemia 
Indinavir 
(IDV) 
200, 333 and 
400 mg 
capsules 
RTV 100 or 200 
mg + IDV 800 mg 
every 12 hours 
 
65% 
 
1.5 - 2 
CYP3A4 
Indirect hyperbilirubinemia 
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Generic 
name Form Dosing 
Oral 
bioavailability 
Serum half-
life 
(hours) 
Route of 
metabolism 
Adverse effects 
 
Each capsule 
contains LPV 
133.3 mg + 
RTV 33.3 mg 
GI intolerance, nausea, 
vomiting 
Fat maldistribution 
Hyperlipidemia (esp. 
hypertriglyceridemia) 
Lopinavir + 
Ritonavir 
 
(LPV + 
RTV) 
Oral solution: 
Each 5 ml 
contains LPV 
400 mg + 
RTV 100 mg 
3 capsules or 5 ml 
two time daily - 5 - 6 CYP3A4 
Hyperglycemia 
250 mg 
tablets or 625 
mg tablets 
1250 mg two times 
a day 
GI intolerance, nausea, 
vomiting 
Fat maldistribution 
Hyperlipidemia 
Nelfinavir 
 
(NFV) 50 mg/g oral 
powder 
750 mg three times 
a day 
20- 80 % 3.5 - 5 CYP3A4 
Hyperglycemia 
100 mg 
capsules or GI intolerance, nausea, 
vomiting 
Hyperlipidemia (esp. 
hypertriglyceridemia) 
Hepatitis 
Ritonavir 
 
(RTV) 600 mg /7.5 ml solution 
600 mg every 12 
hours (when used 
alone) 
 3 – 5 
CYP3A4 
CYP2D6 
Hyperglycemia 
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Generic 
name Form Dosing 
Oral 
bioavailability 
Serum half-
life 
(hours) 
Route of 
metabolism 
Adverse effects 
 
200 mg 
capsules or 
GI intolerance, nausea, 
vomiting 
Fat maldistribution 
Hyperlipidemia (esp. 
hypertriglyceridemia) 
Saquinavir 
 
(SQV) 500 mg 
tablets 
RTV 100 mg + 
SQV 1000 mg two 
times/day 
4% (when taken 
as sole PI- not 
generally 
recommended) 
1 -2 
CYP3A4 
CYP2D6 
Hyperglycemia 
Hepatotoxicity 
Fat maldistribution 
Hyperlipidemia (esp. 
hypertriglyceridemia) 
Tipranavir 
 
(TPV) 
250 mg 
capsules 
RTV 200 mg + 
TPV 500 mg two 
times/day 
 
6 hours after 
single dose 
of 
TPV/RTV 
CYP3A4 
 
Hyperglycemia 
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1.6. Mechanism of variability in pharmacokinetics of immunosuppressive agents – role 
of drug metabolizing enzymes and transporters 
It is now realized that the clinically significant variability in the pharmacokinetics of 
drugs can be explained by alterations in the metabolic enzymes and drug transporters that are 
present in the liver and extra-hepatic tissues. These alterations could be due to endogenous 
mediators such as cytokines or exogenous compounds such as co-administered drugs or due to 
genetic factors that result in changes in the enzyme itself, making it more or less functional. 
Drug interactions involving metabolizing enzymes are generally of two types: enzyme 
induction, where metabolism of the substrate drug is increased and enzyme inhibition, where 
metabolism of the substrate drug is reduced, in the presence of co-administered drug. 
Pharmacokinetic drug interactions associated with immunosuppressive drugs can also be 
explained by changes in metabolizing enzymes and/or drug transporters, as most of the 
immunosuppressants used in therapy are substrates of cytochrome P450 (CYP) enzymes and 
various transporters. Table 6 lists the metabolizing enzymes and drug transporters involved in 
hepatic handling of immunosuppressive agents. 
 The major pathway of metabolism of cyclosporine, tacrolimus and sirolimus is via 
CYP3A4 and all these agents are also substrates for the efflux transporter, P-glycoprotein. 
Absorption of these drugs after oral administration is affected by both P-glycoprotein and 
CYP3A4 activity in the intestine, while the hepatic metabolism is dependent on hepatic CYP3A 
activity. Thus, drugs that are either inducers or inhibitors of CYP3A4 enzyme and P-
glycoprotein can alter levels of these drugs by altering its metabolism or transport. 
Mycophenolate mofetil (MMF) is a pro-drug that is rapidly and almost completely absorbed 
from the gut where it is de-esterified to form mycophenolic acid (MPA), the active 
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immunosuppressant. MPA is converted by the uridine diphosphate glucuronyltransferase (UGT) 
family into 7-hydroxy-glucuronide mycophenolic acid (MPAG) which is excreted into bile and is 
not pharmacologically active. UGT1A9 is the main isoform involved, with at least 55 % 
contribution to the hepatic MPAG formation, with UGT1A1 and UGT1A6 accounting for a part 
of MPAG formation in liver. Studies carried out in Mrp2 deficient rats (Eisai hyperbilirubinemic 
rats) have shown that, multidrug resistant protein 2 (Mrp 2), an efflux transporter located on the 
apical side of hepatocytes, is involved in the biliary excretion of MPAG. Cyclosporine mediated 
inhibition of the biliary excretion of MPAG by the Mrp2 transporter is believed to be the 
mechanism responsible for the interaction between cyclosporine and MMF. 
Table 6. Metabolizing enzymes and drug transporters involved in metabolism and 
transport of immunosuppressive agents   
 
Immunosuppressive 
agents Metabolizing enzyme Transporter protein 
Cyclosporine A CYP3A4 P-glycoprotein 
Tacrolimus CYP3A4 P-glycoprotein 
Sirolimus CYP3A4 P-glycoprotein 
Mycophenolic acid UGT1A9, UGT1A1, UGT1A6 MRP2 
 
It is thus evident from the various literature reports that alterations in the metabolizing 
enzymes (CYPs and UGTs) and/or drug transporters (P-glycoprotein, MRP2) can significantly 
alter the pharmacokinetic parameters of immunosuppressive agents. Inhibition of drug 
metabolizing enzymes and /or drug transporters by endogenous and/or exogenous compounds 
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will result in increased levels of immunosuppressive agents leading to toxic effects. Conversely, 
their induction will result in decreased overall body exposure to the drug causing organ rejection.  
Thus, it is important to characterize the effect of various endogenous as well as 
exogenous chemicals on drug metabolizing enzymes and transporters that are involved in the 
metabolism and transport of various immunosuppressive agents.  
In this dissertation, we will discuss the effect of endogenous chemicals such as pro-
inflammatory cytokines and exogenous drugs such as HIV-protease inhibitors on hepatic phase I 
and phase II metabolizing enzymes and drug transporters associated with metabolism and 
transport of immunosuppressants using human hepatocyte culture system.    
1.7. Use of human hepatocytes to study hepatic drug metabolism and drug transport 
There are various in vitro or in vivo in animals or human models to study the hepatic drug 
metabolism and transporters (Table 7). As the complexity of the system increases, the similarity 
to the in vivo situation also increases.  Human studies are believed to be a more accurate 
indicator of drug metabolism, as they comprise all of the biological process that will interact with 
a compound in one contained system. However, due to ethical considerations it is difficult to 
carry out human studies routinely. In vivo animal studies are also considered more accurate 
indicator of drug metabolism, but have the same limitation because of ethical issues and the cost 
involved.  Liver slices and whole perfused livers have the advantages of maintaining the in vivo 
liver architecture, yet, similar to suspended hepatocyte cultures; have the disadvantage of 
viability for only 4-6 hours and the results show poor reproducibility.  
Human hepatocytes are a more releavant in vitro system due to their strong resemblance 
to  in vivo human liver. Primary cultures of human hepatocytes (PCHH) are viable for up to 2 
weeks, or one month if placed in a three-dimensional culture, and retain all cofactors and 
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cosubstrates necessary for phase I and phase II processes, making them a versatile in vitro 
system to study induction and inhibition of drug metabolism (Gebhardt et al., 2003).  They are 
also valuable in characterizing the metabolic profile of a drug, studying the interspecies 
differences in drug metabolism, assessing drug-drug or drug-endogenous compound interactions 
and predicting the in vivo behavior of a drug. 
Table 7.  Systems used to study hepatic drug metabolism and transporters 
 
 
 
 
 
System Complexity Resemblance Ease of use 
   
   
   
Subcellular fractions 
Supersomes 
Microsomes 
Cytosol 
   
   
   
   
   
   
   
Human hepatocyte 
cultures 
Suspended cultures 
Tumor derived cell 
lines 
Cryopreserved 
hepatocytes 
Primary 
hepatocytes 
3D cultures 
   
Liver slices 
 
   
Whole liver perfusion 
 
   
In vivo animal model 
 
   
Human    
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As the use of PCHH has advanced, modified culturing techniques have enabled the 
examination of other processes involved in drug metabolism, namely the uptake and efflux of 
drugs and their metabolites by hepatic drug transporters.  The loss of tight junctions secondary to 
the hepatocyte isolation procedure results in a loss of cellular polarity, or depolarization, and 
results in changes in hepatically expressed genes.  Normal monolayered PCHH show reduced 
albumin secretion over time, increased levels of alpha-fetoprotein, a protein that is associated 
with depolarization and dedifferentiation of hepatocytes, dephosphorylation of cell surface 
receptors responsive to growth factors and, in the case of rat hepatocytes, a rapid loss of drug 
metabolizing activity and MDR1 expression (Luttringer et al., 2002; Richert et al., 2002; Boess 
et al., 2003). The application of extracellular 3D matrix prevents the loss in albumin synthesis, 
leads to the phosphorylation of hepatocyte growth factor receptors and results in cuboidal, polar 
hepatocyte structure. This has been shown to result in relocalization of MDR1 in hepatic 
canalicular membrane (Sidhu and Omiecinski, 1995; Kudryavtseva and Engelhardt, 2003; Engl 
et al., 2004). Hepatocytes in 3D culture have been utilized to document the effects of a variety of 
compounds on MDR, NTCP, MRP2 and BSEP expression and activity (Liu et al., 1999; 
Luttringer et al., 2002; Kostrubsky et al., 2003; Hoffmaster et al., 2004). 
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1.8. Effect of inflammation and HIV protease inhibitors on hepatic drug metabolizing 
enzymes and transporters 
1.8.1. Central hypothesis 
Variation in the expression of nuclear receptors, PXR and CAR will alter the expression 
and activity of enzymes and transporters involved in the metabolism and transport of 
immunosuppressive drugs. The expression of PXR and CAR can be modulated by endogenous 
mediators such as cytokines and exogenous compounds such as HIV-protease inhibitors.  
Cultured human hepatocytes are a valuable tool to evaluate alterations in the expression 
and activity of drug metabolizing enzymes and transporters.  
Hypothesis 1 
We hypothesize that HIV protease inhibitors have a dual effect on CYP3A4 enzyme, with 
different potencies for different protease inhibitors. HIV-protease inhibitors activate PXR, and 
increase CYP mRNA and protein. However, as they are substrates for CYP3A4, despite an 
increase in CYP3A4 mRNA and protein, the activity of CYP3A4 enzyme measured by a probe 
substrate will be decreased in the presence of HIV-protease inhibitors. Combination of protease 
inhibitors with rifampicin, which is a prototypical inducer of CYP3A4, will result in further 
increased CYP3A4 expression and activity. Removal of protease inhibitors from the vicinity of 
the enzyme-binding site after chronic exposure will result in the complete reversal of the effects 
seen on CYP3A4 expression and activity. 
In these studies, we have used primary cultures of human hepatocytes to evaluate the 
concentration-dependent effect of ritonavir, indinavir and amprenavir on CYP3A mRNA 
expression, protein content and enzyme activity. The effect of removal of ritonavir and 
amprenavir, after initial chronic exposure on the recovery of CYP3A4 expression and activity 
was also studied. The effect of HIV- protease inhibitors in combination with rifampicin was also 
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evaluated (Chapter 3).  CYP3A4 enzyme was selected for this study as it is involved in the 
metabolism of several immunosuppressive drugs such as cyclosporine, tacrolimus and sirolimus. 
Hypothesis 2 
We hypothesize that HIV protease inhibitors will ‘indirectly’ modulate the expression 
and activity of UGT1A1 enzyme, by affecting the expression of regulatory pathways such as the 
expression of PXR and CAR.  Primary cultures of human hepatocytes were used to characterize 
the effect of HIV protease inhibitors namely ritonavir, indinavir and amprenavir on the 
expression and activity of UGT1A1. The enzyme UGT1A1 was selected in this study as it is 
involved in the metabolism of mycophenolic acid (an immunosuppressive drug) and bilirubin (a 
byproduct of liver metabolism) (Chapter 4). 
Hypothesis 3 
We hypothesize that HIV protease inhibitors will alter the expression of hepatic drug 
transporters by modulating the expression of PXR and CAR, which are involved in their 
regulation. Primary cultures of human hepatocytes were used to determine the effect of 
increasing concentrations of HIV protease inhibitors such as ritonavir, indinavir and amprenavir 
on the expression of canalicular drug transporters namely P-glycoprotein, MRP2, MRP6 and 
BSEP (Chapter 5). BSEP was selected for this study as it is involved in canalicular transport of 
bile salts that are released in the liver.  
Hypothesis 4 
We hypothesize that in human hepatocytes, cytokines will downregulate the expression 
and activity of hepatic efflux transporters and this suppression will be due to alterations in the 
expression of transcriptional factors, PXR and/or CAR. The effect of increasing concentrations 
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of IL-1β, IL-2, IL-6 and TNFα on the expression and activity of bile salt export pump (BSEP) 
were determined using human hepatocyte cultures. (Chapter 6) 
Hypothesis 5 
We hypothesize that pro-inflammatory cytokines will downregulate expression and 
activity of hepatic UGT1A1 enzyme and this suppression will be due to alterations in the 
expression of transcription factors, PXR and/or CAR. The effect of increasing concentrations of 
cytokines such as IL-1β, IL-2, IL-6 and TNFα on the expression and activity of UGT1A1 were 
studied using primary cultures of human hepatocytes. (Chapter 7) 
  35
 
 
 
 
 
 
 
 
2. Materials and Methods 
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2.1. Chemicals   
A modified Williams E culture medium (HMM), medium supplements, dexamethasone and 
insulin, were obtained from BioWhittaker (Walkersville, MD). Penicillin G/streptomycin was 
obtained from Gibco Laboratories (Grand Island, NY). Rifampicin (RIF), phenobarbital (PB) and 
testosterone (TE) were obtained from Sigma (St. Louis, MO). 6β-Hydroxytestosterone was 
obtained from Steraloids (Wilton, NH). Various protease inhibitors were obtained for research 
purpose from the following sources; amprenavir, ritonavir (Abbott), indinavir (Merck), nelfinavir 
(GMP), lopinavir (Abbott) and saquinavir (Roche). All four cytokines namely IL-1, IL-2, IL-6 
and TNFα were obtained from Sigma.  Falcon 6-well culture plates were obtained from Becton 
Labware (Franklin Lakes, NJ). BSA standard for total protein measurement by Lowri was 
obtained from Sigma. Nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP) 
color developing reagent and alkaline phosphatase-conjugated anti-rabbit and anti-goat 
antibodies were purchased from Bio-Rad (Richmond, CA). Baculovirus-expressed CYP3A4 and 
UGT1A1 were obtained from BD Gentest (Woburn, MA).  Antibodies used to detect CYP3A4 (# 
458334) and UGT1A1 (# 456411) were purchased from BD Genest (Woburn, MA). Reagents for 
reverse transcription were purchased from Promega (Madison, WI).  Forward and reverse 
primers CYP3A4, UGT1A1, BSEP and β-actin were synthesized by Applied Biosystems.  
Primers for all transporters and Taqman probe were purchased from Applied Biosystems.  The 
assay ids are as follows: BSEP (Hs00184824_m1), MRP6 (Hs00184566_m1), PXR 
(Hs0018243666_m1), CAR (Hs00231959_m1). Primer sequence for each gene is found in Table 
8.  All solvents and other chemicals used were of HPLC grade or the highest purity available. 
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Table 8.  Real-Time PCR primers for genes detected by SYBR Green 
Gene Name Forward Primer (5’ to 3’) Detection 
CYP3A4 Forward CTT CAT CCA ATG GAC TGC ATA AAT SYBR Green 
 Reverse TCC CAA GTA TAA CAC TCT ACA CAG ACA A  
    
UGT1A1 Forward TGT TGG TGG AAT CAA CTG CCT SYBR Green 
 Reverse TGC CCA AAG CAT CAG CAA TT  
    
β-actin Forward AGG CAT CCT CAC CCT GAA GTA SYBR Green 
 Reverse CAC ACG CAG CTC ATT GTA GA  
    
MRP2 Forward TGCAGCCTCCATAACCATGAG SYBR Green 
 Reverse GATGCCTGCCATTGGACCTA  
 
2.2. Hepatocyte isolation 
Primary cultures of human hepatocytes (PCHH) were prepared by a three-step collagenase 
perfusion technique (Strom et al., 1996).  Viability of cells was determined by the trypan blue 
exclusion method and cells were used only when the viability was at least 65%.  Briefly, equal 
volumes of trypan blue (0.4%) and cell suspension were mixed and a portion of this suspension 
was then placed on a hemocytometer.  The cells were observed under a light microscopy and the 
numbers of live and dead cells (stained blue), were counted in two fields.  Concentration of cells 
(number of cells / ml) was determined using the following formula:  Live cells in two fields x 
10,000 = # of cells/ml.  Cells were diluted to final volume of 1 x 106 cells per ml.   
Hepatocytes were plated on Falcon 6-well culture plates (1.5 x 106 cells), previously 
coated with rat tail collagen in HMM supplemented with 0.1 μM insulin, 0.1 μM 
dexamethasone, 0.05% streptomycin, 0.05% penicillin, 0.05% amphotericin B and 10% bovine 
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calf serum.  After allowing the cells to attach for 4 to 6 hours, medium was replaced with serum-
free medium containing all of the supplements described above. Cells were maintained in culture 
at 37°C in an atmosphere containing 5% CO2 and 95% air.   
After 24 hours in culture, unattached cells were removed by gentle agitation and the 
medium was changed.  For transporter studies, cells were overlayed with Matrigel™ (0.233 
mg/mL) at this time.  The medium was changed every 24 hours and the hepatocytes were 
maintained in culture between 5 and 9 days depending on the experimental design. 
2.3. General hepatocyte treatment 
Briefly, hepatocytes were maintained in culture in the presence of the chemical under study 
or vehicle control (DMSO 0.1% or MeOH 0.1 %).  On the day of the experiment, cells were 
washed with HMM devoid of insulin, dexamethasone, antibiotics and antifungal drugs.  It is 
assumed that this one-hour period is sufficient to remove residual chemical from the enzyme 
active site.  Following this period, media containing the appropriate probe substrate was applied 
to the cells with media sampled at the appropriate time points. Table 9 summarizes the enzymes 
studied with the respective probe substrates, concentrations used and sampling times.  A variety 
of variations on the traditional methods used to assess drug metabolizing enzyme activity are 
discussed in the subsequent chapters.   
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2.4. Analytical Methods 
Only the analytical methods used to assess enzyme activity that are used in multiple 
chapters are described below.   
2.4.1. HPLC measurement of CYP3A4 activity 
The concentration of 6β-hydroxytestosterone in the medium was measured by HPLC as 
previously described, with the following modifications (Kostrubsky et al., 1999).  One hundred 
microliters of medium were diluted with an equal volume methanol and centrifuged at 13,000 
r.p.m. for 5 minutes.  One hundred microliters of this solution was injected onto a LiChrospher 
100 RP-18 column (4.6 x 250 mm, 5 μm).  6β-hydroxytestosterone was eluted with a mobile 
phase of methanol/water (60:40, v/v) at a flow rate of 1.2 ml/min and the eluents were monitored 
at 242 nm.  The concentration of the metabolite was quantitated by comparing the peak areas in 
samples to a standard curve containing known amount of the metabolite. 
 
2.4.2. HPLC measurement of UGT1A1 activity  
The concentration of estradiol-3-glucuronide in the cell lysate was measured by HPLC as 
previously described, with the following modifications (Alkharfy and Frye, 2002). Medium 
aliquots were centrifuged at 12,000 g for 5 min to remove large particulates.  A 50 µL aliquote of 
lysate was injected directly onto a Alltima C18 column (250 x 4.6 mm, 5 μm; Waters Corp., 
Milford, MA). Estradiol-3-glucuronide was eluted at a flow rate of 1 ml/min using with a mobile 
phase of acetonitrile/50mM ammonium phosphate buffer (pH 3) (35/65, v/v). The metabolite 
was measured using a fluorescence detector (Waters 474) with excitation and emission 
wavelengths of 210 and 300 nm, respectively. 
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Table 9.  Probe substrates to study enzyme and transporter activity in human hepatocyte cultures 
Enzyme Probe substrate Probe Conc. (µM) Metabolite Standard inducer 
Inducer Conc. 
(µM) 
Incubation 
Timea Analysis 
CYP3A Testosterone 250 6β(OH) testosterone Rifampin 10 30 min HPLC 
UGT1A1 Estradiol 250 Estradiol-3-glucuronide Phenobarbitol 2000 60 min HPLC 
BSEP 3[H] taurocholate 1 N/A N/A N/A 20 min 
Scintillation 
counter 
aIn linear portion of concentration versus incubation time profile. 
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2.4.3. Determination of total protein 
After sampling of the medium for metabolite measurements, the remainder of medium 
(0.5 mL) was aspirated from each well.  Cells were then harvested in 150 µL of phosphate buffer 
and stored at -80°C for protein determination by the method of Lowry (Lowry O, 1951).  Briefly, 
the proteins were dissolved in SDS/sodium hydroxide, then 1% sodium tartarate and 1% copper 
sulfate were added, followed by the addition of Folin’s reagent.  The tubes were mixed gently 
and the color was allowed to develop for 45 min.  At the end of 45 minutes, 200 µL aliquotes 
were transferred to 96-well plates and the absorbance was measured at 490 nm.  The 
concentration of the protein was calculated using bovine serum albumin as a protein standard.  
2.4.4. Measurement of immunodetectable protein 
Immunochemical detection of CYP3A and UGT1A1 was performed as previously 
described (Kostrubsky et al., 1995).  Briefly, 20 μg of pooled total cellular protein was loaded 
onto a polyacrylamide gel and subjected to SDS-PAGE at 80 volts for 90 minutes.  Proteins were 
transferred onto a nitrocellulose membrane for 3 hours and blocked overnight at 4°C.  
Membranes were washed and incubated with the appropriate anti-CYP or anti-UGT1A1 
antibody (all diluted 1:1000) for 2 hours at room temp on a rocker table.  The membrane was 
again washed and then incubated with a horseradish perxodase labeled secondary antibody 
diluted 1:10,000 for 1 hour at room temperature on a rocker table.  Blots were developed using a 
Nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate developing reagent.  Relative 
amounts of proteins were assessed by the intensity of immunoblot staining carried out by 
densitometry (ImageJ, v1.34, http://reb.info.nih.gov/ij). All densitometry results were normalized 
to β-actin and then to appropriate vehicle control value. 
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2.4.5. Measurement of mRNA expression of metabolizing enzymes and transporter  
Total RNA was extracted from 1 x 106 cells plated on 6-well plates using 1 mL Trizol 
reagent (Invitrogen, Carlsbad, CA) according to manufacturer’s instructions. RNA was 
quantified spectrophotometrically and subjected to agarose gel electrophoresis to assess the 
integrity of RNA.  Following treatment with RNase-free DNase (Promega, Madison, WI), 2 μg 
of RNA was mixed with 0.5 μg of Random Hexamers (Promega) heated to 70°C for 5 minutes 
then cooled to 4°C.  A reaction mixture containing 200 U MMLV-Reverse transcriptase, 1 mM 
dNTPs and 25 U RNasin (Promega) was added to the previous mixture and incubated at 37°C for 
60 minutes.  The resulting cDNA was diluted 10-fold and stored at -20°C.   
2.4.6. Real-Time PCR   
 Primers for β-actin and CYP3A4 (Bowen et al., 2000) were designed using 
PrimerExpress 1.0 (Applied Biosystems, Foster City, CA). Sequences of primer for UGT1A1 
was obtained from personal correspondence with Dr. Federico Innocenti (University of Chicago, 
Chicago, IL PCR was performed on an ABI Prism 7000 Sequence Detection System (Applied 
Biosystems) using 5 μl of cDNA, 200 pM of forward and reverse primers (SYBR green 
technology) or 1.25 μl Assays on Demand-Mix (TaqMan® technology) and 12.5 µl PCR Master 
Mix (Applied Biosystems) for a total volume of 25 µl.  PCR conditions were 50°C for 2 min, 
95°C for 10 min, followed by 50 cycles with 15 sec at 95°C and 1 min at 60°C.  The relative 
cDNA content was determined from standard curves constructed from serial by diluted cDNA 
and normalized to β-actin in each sample. 
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3. Effect of HIV protease inhibitors on hepatic phase I drug metabolizing enzyme in 
human hepatocytes 
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3.1. Abbreviations 
    
    6β(OH)TE 6β(OH) testosterone 
    APV  amprenavir  
CYP  cytochrome P450 
    CYP3A4 cytochrome P4503A4 
HMM  hepatocyte maintenance medium 
    IDV  indinavir 
    LPV  lopinavir 
    NFV  nelfinavir 
PCHH  primary cultures of human hepatocytes 
    RIF  rifampicin 
    RTV  ritonavir 
    SQV  saquinavir 
    TE  testosterone 
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3.2. Abstract 
Aims:  Clinically significant drug-drug interactions are observed in HIV patients undergoing 
transplantation where immunosuppressive agents are co-administered with HIV-protease 
inhibitors. CYP3A4 being the primary enzyme involved in the metabolism of 
immunosuppressive agents, these interactions are thought to be due to alterations in CYP3A4 
enzyme by HIV-protease inhibitors. The objective of the study was to use primary cultures of 
human hepatocytes (PCHH) to study the concentration-dependent effect of HIV-protease 
inhibitors namely ritonavir, indinavir and amprenavir on CYP3A4 expression and activity. We 
also studied the possible synergistic interaction of HIV-protease inhibitors and a prototype PXR 
activator rifampicin, a potent CYP3A4 inducer. Furthermore, the effect of removal of ritonavir 
and amprenavir, after initial chronic exposure on the recovery of CYP3A4 expression and 
activity was also studied to understand the time course of recovery of enzyme expression and 
activity. 
Methods:  To determine the effect of various concentrations, PCHH were exposed to ritonavir 
(RTV), indinavir (IDV) and amprenavir (APV) (0-10 μM) for 72 hours. In studies involving 
interactions, cells were exposed to the combination of protease inhibitor (10 μM) + rifampicin 
(RIF) (10 μM) for 72 hours. The effect of chronic treatment and subsequent washout of drug was 
studied by treating the cells with either RTV or APV (1 and 10 μM) for 72 hours followed by 72 
hours washout period. CYP3A4 mRNA expression was determined by quantitative Real-time 
PCR, while protein content was evaluated using western blotting. CYP3A4 activity was assessed 
using testosterone (TE) as a probe substrate.    
Results:  Protease inhibitors inhibited CYP3A4 activity in the decreasing order of inhibition 
potency; ritonavir > indinavir > amprenavir, with ritonavir being the most potent inhibitor. 
Protease inhibitors are shown to interact with RIF and maximal interaction was observed for the 
combination of RTV + RIF, where RTV completely masked the CYP3A4 inducing ability of 
RIF. In the recovery study, increased mRNA expression and activity, after APV treatment, 
completely recovered to the baseline value during a 72 hours washout. On the other hand, 
recovery of CYP3A4 activity after RTV (10 μM) was incomplete after 72 hours and was 
predicted to reach the baseline value after 244 hour of drug washout period. 
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 Conclusions:  This study has demonstrated the concentration dependent effect of individual 
protease inhibitors on CYP3A4 expression and activity in a human hepatocyte system. Secondly, 
the interaction potential of these protease inhibitors with currently known CYP3A4 substrates 
and inducers has also been shown. Additionally, the reversible nature of CYP3A4 inhibition or 
induction by protease inhibitors after treatment and removal has been documented. The 
calculation of kinetic parameters such as t1/2 and recovery time for CYP3A4 expression and 
activity after drug discontinuation can help to better understand the duration of the effect of HIV-
protease inhibitors on CYP3A4 expression and activity. 
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3.3. Introduction 
Historically, human immunodeficiency virus (HIV) infection has been considered as an 
absolute contraindication to transplantation because of the high mortality rate of opportunistic 
infection associated with HIV infection and anti-rejection immunosuppression. However, liver 
transplantation is now considered as a treatment of choice in HIV-patients with end stage liver 
disease, because of improvement in immune function and survival made possible by the 
introduction of highly active antiretroviral therapy (HAART) (Ragni et al., 2003; Neff et al., 
2004). Currently there are eight protease inhibitors approved by FDA for treatment of HIV 
infection. Ritonavir, lopinavir, indinavir, nelfinavir, amprenavir and saquinavir, are some of the 
most commonly used HIV protease inhibitors most either alone or in combination 
(http://www.fda.gov/oashi/aids/virals.html) 
Clinically significant pharmacokinetic interactions between immunosuppressive agents 
and HIV- protease inhibitors have been observed in HIV positive patients undergoing liver 
transplantation, requiring dosing adjustments of the immunosuppressive drugs (Sheikh et al., 
1999; Schvarcz et al., 2000; Jain et al., 2002a; Jain et al., 2002b; Jain et al., 2003; Schonder et 
al., 2003). Inhibition of CYP3A4, the principal enzyme involved in the metabolism of most of 
the immunosuppressive agents and P-glycoprotein involved in efflux transport of 
immunosuppressive agents, by HIV-protease inhibitors is considered to be the most likely 
mechanism responsible for these drug interactions.  
In vitro metabolism studies have shown that all the HIV protease inhibitors are 
predominantly metabolized by CYP3A enzymes with a minor contribution from CYP2D6 and 
CYP2C9 (Kumar et al., 1996; Chiba et al., 1997; Fitzsimmons and Collins, 1997). 
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HIV protease inhibitors have complex effects on the CYP3A family of enzymes. Studies 
in rat or human microsomes and expressed enzyme systems have shown that HIV- protease 
inhibitors inhibit CYP3A4 enzyme to a varying degree. Ritonavir is by far the most potent 
inhibitor, followed by indinavir, nelfinavir, amprenavir and saquinavir in decreasing order of 
potency (Eagling et al., 1997; Decker et al., 1998; Iribarne et al., 1998; Koudriakova et al., 
1998). Conversely, ritonavir and nelfinavir have also shown to induce CYP3A4 in studies carried 
out in rats and in human colon carcinoma cell lines (Greenblatt et al., 2000; Perloff et al., 2000; 
Venkatakrishnan et al., 2000). This induction phenomenon is of particular interest since all these 
protease inhibitors are used over an extended period of time in clinical practice. The induction of 
CYP3A4 by protease inhibitors may lead to decreased plasma drug levels of co-administered 
drugs that are substrates of CYP3A4, thus leading to loss of their therapeutic efficacy.  
It is known that CYP3A4 is transcriptionally regulated by the nuclear orphan receptor 
pregnane X receptor (PXR). After ligand binding in the cytosol, PXR translocates to nucleus 
where is heterodimerizes with retinoid X receptor (RXR), and then binds to the CYP3A4 
promotor, resulting in the increased CYP3A4 mRNA expression. In vitro studies have shown 
that ritonavir is a potent activator of PXR (Luo et al., 2002). 
Since most of the studies documenting the inhibitory effect of protease inhibitors on 
CYP3A4 have been carried out either in microsomes, expressed enzyme systems or colon 
carcinoma cell lines, the potential for the induction of CYP3A4 enzyme after exposure to 
protease inhibitors has not been evaluated. Also, there is no systematic study showing the effect 
of variable concentrations of these HIV protease inhibitors on the expression and activity of 
CYP3A4 and on expression of nuclear receptors believed to be responsible for modulating 
activity of drug metabolizing enzymes.  
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We hypothesized that HIV protease inhibitors have a dual effect of inhibition and 
induction on CYP3A4 enzyme with different potencies for different protease inhibitors. We 
hypothesized that HIV-protease inhibitors will activate PXR; increase CYP3A4 mRNA 
expression and protein. However, as they are substrates for CYP3A4, in spite of an increase in 
CYP3A protein, the activity of CYP3A4 as measured with another substrate will be decreased.  
Combination of protease inhibitors with rifampicin, which also activates PXR, will result in 
further increased CYP3A4 expression and activity. Removal of protease inhibitors from the 
vicinity of enzyme binding site after chronic exposure will result in the complete reversal of the 
effects seen on CYP3A4 expression and activity over time. 
We used primary cultures of human hepatocytes where we can simultaneously measure 
mRNA, protein and activity to study the concentration-dependent effect of ritonavir, indinavir 
and amprenavir on CYP3A4 mRNA expression, protein content and enzyme activity. We also 
evaluated the possible drug interaction effect on CYP3A4 when HIV protease inhibitors were 
combined with rifampicin. The effect of removal of ritonavir and amprenavir, after chronic 
exposure on the recovery of CYP3A4 expression and activity was also studied.  
3.4. Methods 
3.4.1. Evaluation of the cytotoxicity of HIV protease inhibitors to human hepatocytes 
Hepatocytes were exposed to HIV protease inhibitors RTV, IDV, and APV (0–50 μM) for 
72 h.  At the end of the treatment period, the media was aspirated and 10% v/v of 5 mg/ml 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to HMM 
followed by 30 minutes of incubation. At 30 min, the medium was aspirated and cells were 
washed with HMM.  Isopropanol (equal volume as the medium) was then added and shaken 
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gently for 2-3 min. Two hundred microliters of this solution was then transferred to a 96-well 
plate, and the absorbance was measured at 570 nm. 
3.4.2. Hepatocyte treatment protocol to study the effect of different HIV protease 
inhibitors on CYP3A 
To determine the effect of increasing concentrations of protease inhibitors on CYP3A4 
enzyme expression and activity, twenty-four hours after plating, cells were exposed to RTV, IDV 
and APV (0-10 μM) for 72 hours.  To study the interaction of various HIV protease inhibitors 
(10 μM) with rifampicin (10 μM), cells were exposed to appropriate combination of these 
chemicals for 72 hours. To evaluate the effect of removal of ritonavir and amprenavir, on the 
CYP3A4 enzyme expression and activity, hepatocytes were first treated with RTV and APV (1 
and 10 μM) for 72 hours. The medium was then replaced with fresh medium every 24 hours for 
next 72 hours.   
 On the day of the study, cells were washed with 1.5 ml of fresh medium for 1 h and then 
incubated in 1.5 ml of medium containing 250μM testosterone for an additional 30 minutes.  At 
the end of that time, 1 mL of medium was sampled and stored at -80°C for 6β(OH) testosterone 
(6β(OH) TE) determination by HPLC.  The remaining media was aspirated, and the cells were 
harvested in phosphate buffer (0.1 M, pH 7.4) and stored at -80°C for protein determination and 
detection of immunoreactive CYP protein (Lowry O, 1951).  The relative amounts of proteins 
were measured by the intensity of immunoblot staining carried out by densitometry (ImageJ, 
v1.34, http://reb.info.nih.gov/ij). 
Cells were also harvested for mRNA by adding 1 mL of Trizol reagent to each well of a 
6-well plate.  The RNA samples were stored at -20°C for Real Time PCR analysis.  Primers for 
CYP3A4, PXR, CAR, β-actin and the PCR procedure have been described in Chapter 2 
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(Materials and Methods, Table 8).  The relative cDNA content was determined from standard 
curves constructed from serially diluted human cDNA samples. The mRNA expression for all 
genes was normalized to β-actin in each sample and expressed as fold change over control 
treatment. 
 
3.4.3. Data analysis 
The data were analyzed using a one-way analysis of variance with a post hoc Tukey’s 
multiple comparison procedure.  p value of ≤ 0.05 was considered statistically significant. All 
statistical analysis was performed using PRISM software version 4.0 (GraphPad Software, Inc., 
San Diego, CA, USA). 
3.5. Results 
Hepatocytes from a total of 16 liver donors were used to conduct the experiments 
outlined in this Chapter. Their relevant demographics, drug history and cell viability information 
is cited in Table 10.   
3.5.1. Effects of chronic exposure of hepatocytes to HIV protease inhibitors on MTT 
reduction 
Chronic exposure (72 hours) of human hepatocytes to RTV, IDV and APV at 
concentrations ≥ 20 μM resulted in significant cellular toxicity as compared to the untreated cells 
(Figure 4). Thus, for all the further experiments, protease inhibitors at concentrations ≤ 10 μM 
were used.  
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Table 10.  Donor information for human hepatocyte preparations used in Chapter 3 
Donor 
HH # Age Sex
a Raceb Cause of deathc Drug History Viability
Percoll 
separation 
1117 68y F C 
ICH/ 
Stroke 
Labetolol, Verapamil, 
Clonidine 82 No 
1118 73y F C Head trauma Atenolol, Imipramine 80 No 
1129 70y F C - None reported  80 No 
1135 53y M C - None reported 88 Yes 
1184 66y F C - None reported 87 Yes 
  1200 53y F C 
CVA/ 
Stroke 
Dopamine 65 Yes 
1201 69y M C 
CA/ 
Anoxia 
Epinephrine, Ampicillin  81 No 
1205 45y M H 
CVA/ 
Stroke 
- 66 No 
1209 30y F C 
CVA/ 
Stroke 
Heparin, Ampicillin, 
Gentamycin, Morphine 66 Yes 
1210 35y F C Head trauma 
Dopamine, Vasopressin, 
hydrocortisone 83 Yes 
1218 50y F C 
CA/ 
Anoxia 
- 85 No 
1222 68y F C - - 93 No 
1227 34y M C 
CVA/ 
Stroke 
- 74 Yes 
1235 65y M C - - 78 No 
1247 3y M - - - 71 No 
1249 59y M H Stroke - 80       No 
aM, male; F, female; bC, Caucasian; H, Hispanic; c CA, cardiac arrest; ICH, intra cranial 
hemorrahage 
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Figure 4.  Effect of HIV protease inhibitors on MTT reduction 
Hepatocytes were treated with A) RTV, B) IDV and C) APV (0–50μM) for 72 hours.  MTT 
reduction was then measured.  The figure shows the mean of triplicate treatments from two 
donors. The means are expressed as a percentage of the value obtained with vehicle treated 
cells, with the S.D. indicated by the vertical bars.  *, significantly different from vehicle 
treated cells, p ≤ 0.05. 
* *
* 
* 
*
*
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3.5.2. Effects of HIV protease inhibitors on CYP3A4 expression and activity 
To determine the effect of increasing concentrations of HIV protease inhibitors on CYP3A4 
enzyme expression and activity, cells were exposed to RTV, IDV or APV (0–10 μM) for 72 
hours.  
Treatment with the prototypical inducer RIF (10 μM) resulted in 31.2 ± 1.5- fold increase in 
the mRNA expression of CYP3A and 6.3 ± 1.2-fold increase in CYP3A4 protein content. After 
RIF (10 μM), the formation rate of 6β(OH) TE was increased 8.5 ± 2.5- fold compared to vehicle 
control. 
3.5.2.1. Effects of ritonavir on CYP3A4 expression and activity 
 
Treatment with RTV significantly increased the CYP3A4 mRNA expression at 
concentrations ≥ 0.5 μM (EC50 = 0.8954μM).  This increase in CYP3A4 mRNA expression was 
10 ± 1.9 fold and 27 ± 7.1 fold at concentrations 0.5 μM and 10 μM, respectively (Figure 5A).  
Ritonavir at concentrations ≥ 1 μM showed a 4-fold increase in the CYP3A4 protein content 
(Figure 5B). The increase in CYP3A4 mRNA and protein expression, however, was not 
associated with increased CYP3A4 enzyme activity. CYP3A4 mediated testosterone metabolism 
was significantly inhibited at all the concentrations of RTV used (IC50 = 0.01907 μM) (Figure 
5C).  At the lowest concentrations of RTV (0.01 μM), 6β(OH) TE formation rate was inhibited 
to 61.2 ± 12.5 %, while at the highest concentration (10 μM), the 6β(OH) TE formation rate was 
2.0 ± 2.8 %, of control activity.   
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Figure 5.  Effect of ritonavir on CYP3A4 mRNA expression, protein content and activity 
Hepatocytes were exposed to RTV (0-10µM) for 72 hours and CYP3A4 A) mRNA 
expression, B) protein content and C) activity were determined.  The figure shows the mean 
of values obtained from three livers, with the S.D. indicated by the vertical bars.  All mRNA 
and protein values are normalized to β-actin expression.  *, significantly different from 
untreated control cells, p ≤ 0.05.  
* 
* 
* 
* 
* 
*  * 
*  *
* 
* 
IC50 = 0.01907 μM 
EC50 = 0.8954 μM 
* 
CYP3A4 
β - ACTIN 
+ 
UN 
RIF 
(10μM) 
Ritonavir (μM) 
2.12   3.24   3.61     4.57   2.20    6.87   
0.5 1 5 10 0.1 
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3.5.2.2. Effects of indinavir on CYP3A4 expression and activity 
 
Exposure of cells to IDV (0-10 μM) did not result in any significant differences in 
CYP3A4 mRNA expression (Figure 6A). Indinavir did not show any significant increase in 
CYP3A4 protein content (Figure 6B). Indinavir significantly inhibited the CYP3A4 mediated 
testosterone metabolism at concentrations ≥ 0.1 μM (IC50 =0.3297 μM). The maximum 
inhibitory effect of IDV was seen at 5 μM. At IDV 5 μM 6β(OH) TE formation rate was 44.6 ± 
2.7 % of control treatment (Figure 6C).   
3.5.2.3. Effects of amprenavir on CYP3A4 expression and activity 
 
Hepatocyte treatment with APV (0-10μM) showed significant increase in CYP3A4 
mRNA expression at concentrations ≥ 1 μM, with the maximal increase being 9.7 ± 1.2-fold 
compared to vehicle control (Figure 7A). This increase in mRNA expression was associated with 
a 4.34-fold increase in CYP3A4 protein content (Figure 7B). Amprenavir at concentrations ≥ 
5μM showed a concentration dependent increase in CYP3A4 activity. At 10 μM APV the 
formation rate of 6β(OH) TE was 1.68 ± 0.2-fold compared to control (Figure 7C). 
 
 
 
 
 
 
 
  57
A. 
Co
ntr
ol Mμ
RI
F 1
0 0
.01 0.0
5 0.1 0.5 1 5 10
0
1
2
3
5
15
25
35
 
 
 
 
 
 
 
 
 
         Indinavir (µM) 
C
Y
P
3A
4 
m
R
N
A
 E
xp
re
ss
io
n
(F
ol
d 
In
du
ct
io
n 
/ C
on
tr
ol
)
 
B.  
C. 
-4 -3 -2 -1 0 1 2
0
20
40
60
80
100
Indinavir Concentration [log μM]
6 β
 (O
H
) T
e 
Fo
rm
at
io
n 
R
at
e
(%
 o
f M
eO
H
 c
on
tr
ol
)
 
Figure 6.  Effect of indinavir on CYP3A4 mRNA expression, protein content and activity 
Hepatocytes were exposed to IDV (0-10µM) for 72 hours and CYP3A4 A) mRNA 
expression, B) protein content and C) activity were determined.  The figure shows the mean 
of values obtained from three livers, with the S.D. indicated by the vertical bars.  All mRNA 
and protein values are normalized to β-actin expression.  *, significantly different from 
untreated control cells, p ≤ 0.05.  
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Figure 7.  Effect of amprenavir on CYP3A4 mRNA expression, protein content and activity 
Hepatocytes were exposed to APV (0 - 10 µM) for 72 hours and CYP3A4 A) mRNA 
expression, B) protein content and C) activity were determined.  The figure shows the mean 
of values obtained from three livers, with the S.D. indicated by the vertical bars.  All mRNA 
and protein values are normalized to β-actin expression.  *, significantly different from 
untreated control cells, p ≤ 0.05.  
* 
* 
* 
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* 
* 
CYP3A4 
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3.5.3. Effect of combination of HIV protease inhibitors with rifampicin on CYP3A4 
expression and activity 
To study the interaction between various HIV protease inhibitors and RIF, hepatocytes 
were exposed to the combination, protease inhibitor (10μM) + RIF (10μM) for 72 hours.   
No cellular toxicity was observed in MTT reduction assay, after combining the protease 
inhibitor (10μM) with RIF (10μM) (Figure 8). 
Treatment with RIF (10μM) showed 14.4 ± 6.4-fold increase in CYP3A4 mRNA 
expression, while the CYP3A4 protein content was increased 5.4-fold compared to control 
treatment. The formation rate of 6β(OH) TE was increased 19.1 ± 13.9-fold at RIF (10μM). 
Figure 9 and Table 11 shows the effect on CYP3A4 expression and activity when RTV, 
IDV and APV were combined with RIF. After RTV (10μM) treatment, CYP3A4 mRNA 
expression was increased 17.3 ± 1.3-folds over control. The combination of RIF and RTV 
resulted in 23.3 ± 0.8 -fold increase in mRNA expression, which was significantly different than 
RIF (10 μM) alone (Figure 9A). Ritonavir (10μM) and RIF + RTV treatment resulted in 3-10 
and 5-13-fold increase in CYP3A4 protein content, respectively (Figure 9B). But, RTV (10μM) 
as well as the combination of RTV + RIF resulted in complete inhibition of CYP3A4 mediated 
testosterone metabolism (Figure 9C).  
Indinavir (10μM) showed a 4.6 ± 1.6-fold increase in mRNA expression, while RIF + IDV 
resulted in 16.7 ± 0.6-fold increase which was significantly different from the IDV (10μM) alone 
but was similar to the increase in CYP3A4 mRNA expression seen after RIF (10μM) alone. 
Indinavir alone did not result in significant increase in CYP3A4 protein content but IDV+RIF 
increased CYP3A4 protein 15.5-fold over control. The formation rate of 6β(OH) TE was 1.9 ± 
1.1-fold and 15.7 ± 4.7-fold of control, after IDV (10 M) alone and RIF + IDV, respectively. 
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 Amprenavir (10μM) alone showed a 8.6 ± 2.1-fold increase in mRNA expression, while 
RIF + APV resulted in 23.6 ± 5.2-fold increase which was similar to the increase in CYP3A4 
mRNA expression seen after RIF (10μM) alone, but was significantly higher than APV treatment 
alone. The formation rate of 6β(OH) TE was 4.0 ± 0.5-fold and 14.2 ± 3.2-fold of control, after 
APV (10 μM) alone and RIF + APV, respectively. Figure 10 and Table 11 shows the effect on 
CYP3A4 expression and activity when LPV, NFV and SQV were combined with RIF. 
 The mRNA expression of CYP3A4 changed from 5.3 ± 0.3-fold (LPV alone) to 16 ± 2.2-
fold in presence of RIF + LPV combination. Similarly, the increase in 6β(OH) TE formation rate 
was changed from 2.19 ± 0.1-fold (LPV alone) to 15.7 ± 4.7-fold in the presence of RIF + LPV 
combination. 
 Nelfinavir (10μM) alone showed an 8.8 ± 4.4-fold increase in mRNA expression, while 
RIF + NFV resulted in 27.2 ± 6.8-fold increase in CYP3A4 mRNA expression. The formation 
rate of 6β(OH) TE was 4.9 ± 3.4-fold and 15.5 ± 4.6-fold of control, after NFV (10μ M) alone 
and RIF + NFV, respectively. The increase in mRNA expression and activity was significantly 
different from that observed with NFV alone, but was not different from that observed after RIF 
treatment alone. 
The mRNA expression of CYP3A4 changed from 3.9 ± 0.1-fold (SQV alone) to 32.9 ± 4.9-
fold in presence of RIF + SQV combination. Similarly, the increase in 6β(OH) TE formation rate 
was changed from 2.2 ± 1.0-fold (LPV alone) to 19.4 ± 4.3-fold in the presence of RIF + SQV 
combination.  
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Figure 8.  Effect of combination of HIV protease inhibitors and rifampicin on MTT reduction 
Hepatocytes were treated with A) RTV, IDV and APV alone (10μM) or in combination with RIF (10 μM) B) LPV, NFV and SQV 
alone (10μM) or in combination with RIF (10 μM) for 72 hours.  MTT reduction was then measured.  The figure shows the mean 
of triplicate treatments from two donors. The means are expressed as a percentage of the value obtained with untreated control 
cells, with the S.D. indicated by the vertical bars.  *, significantly different from vehicle control treated cells, p ≤ 0.05.
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Table 11. Effect of combination of protease inhibitor and rifampicin on CYP3A4 
mRNA expression and activity 
Treatment  
Conc (μM) 
CYP3A4 mRNA expression
(Fold / control) 
6β (OH) Te formation rate  
(Fold / control) 
 
RIF 10 14.4 ± 6.4  19.1 ± 13.9 
RTV 10 17.3 ± 1.3 0.04 ± 0.04a 
RTV 10 + RIF 10 23.3 ± 0.8a 0.03 ± 0.05a 
RIF 10 14.4 ± 6.4 19.1 ± 13.9 
IDV 10 4.6 ± 1.6a 1.9 ± 1.1 
IDV 10 + RIF 10 16.7 ± 0.6b  15.7 ± 4.7b 
RIF 10 14.4 ± 6.4 19.1 ± 13.9 
APV 10 8.6 ± 2.1 4.0 ± 0.5 
APV 10 + RIF 10 23.6 ± 5.2b 14.2 ± 3.2b 
RIF 10 14.4 ± 6.4 19.1 ± 13.9 
LPV 10 5.3 ± 0.3a 2.9 ± 0.1 
LPV 10 + RIF 10 16 ± 2.2b 15.7 ± 4.7b 
RIF 10 14.4 ± 6.4 19.1 ± 13.9 
NFV 10 8.8 ± 4.4 4.9 ± 3.4 
NFV 10 + RIF 10 27.2 ± 6.8b 15.5 ± 4.6b 
RIF 10 14.4 ± 6.4 19.1 ± 13.9 
SQV 10 3.9 ± 0.1 2.2 ± 1.0 
SQV 10 + RIF 10 32.9 ± 4.9a,b 19.4 ± 8.3b 
a, significantly different from RIF treated cells, p≤ 0.05. 
b, significantly different from (corresponding) HIV-protease inhibitor treated cells, p≤ 
0.05. 
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Figure 9.  Interaction of protease inhibitors with rifampicin – effect on CYP3A4 mRNA, protein and activity  
Hepatocytes were treated with RTV, IDV or APV alone (10 µM) or in combination with RIF (10 μM). CYP3A4 A) mRNA 
expression, B) protein content and C) activity were determined.  The figure shows the mean of values obtained from three livers, 
with the S.D. indicated by the vertical bars.  All mRNA and protein values are normalized to β-actin expression.  *, significantly 
different from RIF treated cells;  #, significantly different from protease inhibitor treated cells, p ≤ 0.05. 
* 
# 
# 
*       * 
# 
# 
CYP3A4 
β - ACTIN 
+ UN 
RIF 
(10μM) 
RTV 
(10μM) 
RTV + 
RIF 
IDV 
(10μM) 
IDV +  
RIF
APV 
(10μM) 
APV + 
RIF
12.29  11.01  10.13   2.23  15.5   9.79   15.01   
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Figure 10.  Interaction of protease inhibitors with rifampicin – effect on CYP3A4 mRNA, protein and activity  
Hepatocytes were treated with LPV, NFV or SQV alone (10 µM) or in combination with RIF (10 μM). CYP3A4 A) mRNA 
expression, B) protein content and C) activity were determined.  The figure shows the mean of values obtained from three livers, 
with the S.D. indicated by the vertical bars.  All mRNA and protein values are normalized to β-actin expression.  *, significantly 
different from RIF treated cells;  #, significantly different from protease inhibitor treated cells, p ≤ 0.05. 
* 
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# 
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3.5.4. Effect of chronic treatment and washout of ritonavir and amprenavir on CYP3A4 
expression and activity 
To study the effect of chronic treatment and subsequent washout of drug from the 
hepatocyte system on CYP3A4 expression and activity, hepatocytes were first exposed to RTV 
or APV (1 and 10 μM) for 72 hours.  At the end of this treatment period, the medium was 
replaced with HMM every 24 hours, for the next 72 hours. CYP3A4 mRNA expression, protein 
content and 6β(OH) TE formation rate were determined at the end of the treatment period and 
also at 24 hour intervals during the washout period.  
  The effect of exposure of hepatocytes to RTV (1 μM and 10 μM) for 72 hour followed 
by a 72 hours washout period, on CYP3A4 mRNA expression and activity, is summarized in 
Table 12 and Figure 11. Ritonavir treatment for 72 hourss resulted in increased CYP3A4 mRNA 
expression. This increase was 3.5 ± 0.4 and 9.6 ± 1.3 fold compared to control, at RTV 1μM and 
10 μM, respectively. During the subsequent washout period, CYP3A4 mRNA expression 
decreased consistently until expression, after 72 hours of washout, was comparable to the control 
value.  
 Exposure of hepatocytes to 1 μM of RTV inhibited the CYP3A4 mediated TE metabolism to 
0.291 ± 0.01-fold of control, while exposure to 10 μM RTV completely inhibited the CYP3A4 
activity. During the washout period, the activity in the 1μM RTV treated cells recovered 
completely and became significantly higher than the control value after 72 hours of washout. In 
the 10 μM RTV treated cells, the activity gradually increased but remained significantly lower 
than the control value even after 72 hours.  
The effect of exposure of hepatocytes to APV (1μM and 10 μM) for 72 hours followed 
by a 72 hours washout period, on CYP3A4 mRNA expression and activity, is summarized in 
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Table 13 and Figure 12. After 72 hours treatment, CYP3A4 expression was increased 4.9 ± 1.04 
and 17.8 ± 1.7 fold compared to control, at APV 1 μM and 10 μM, respectively. Similarly, 
formation rate of 6β(OH) TE was increased 3.2 ± 1.1 and 11.3 ± 1.2 fold over control after 1 μM 
and 10 μM APV treatment for 72 hours. During the subsequent washout period, CYP3A4 
mRNA expression as well as activity decreased consistently and were comparable to the control 
values after a 72-hour washout period.  The APV effect after washout was similar to that seen 
with the prototypical inducer RIF (10 μM). 
3.5.5. Calculation of t1/2 and recovery time of CYP3A4 mRNA expression and activity  
The CYP3A4 mRNA expression and activity values after 72 hours treatment with RTV 
and APV (1 and 10 μM), followed by a washout period were analyzed to calculate the t1/2 and 
recovery time. Recovery time was defined as the total time elapsed post treatment to attain 
baseline mRNA expression and activity.  
The recovery of CYP3A4 mRNA expression after RTV treatment followed first order 
kinetics, while the recovery of CYP3A4 activity followed zero order kinetics (Figure 11). The 
calculated t1/2 value and recovery time for mRNA expression was 17.4 hours and 96.5 hours 
respectively (Table 14). Post RTV (10 μM) treatment, the CYP3A4 activity did not recover after 
a 72 hours washout and was predicted to recover completely after 244.7 hours. The decrease in 
mRNA expression and activity after APV (10 μM) treatment also followed first order kinetics 
(Figure 12). The t1/2 and recovery time values are shown in Table 14.  
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Table 12. Effect of chronic ritonavir treatment followed by washout on CYP3A4 mRNA 
expression and activity 
CYP3A4 mRNA expression 
(Fold / control) 
6β (OH) Te formation rate  
(Fold / control) 
 
 
 
Treatment 
Time 
(hours) 
RTV (1μM) RTV (10μM) RTV (1μM) RTV (10μM) 
 
+ RTV  72 
 
3.59 ± 0.4c 
 
9.65 ± 1.3c 0.2 ± 0.01c 0.02 ± 0.0c 
24 
 
4.03 ± 0.2c 
 
19.0 ± 3.4a,c 0.4 ± 0.09
c 0.18 ± 0.01a,c 
48 
 
2.64 ± 0.1a,b,c 
 
 
6.1 ± 1.1b,c 1.3 ± 0.1a,b,c 0.32 ± 0.04a,b,c 
 
 
RTV 
 
Wash out 
 
72 
 
1.22 ± 0.0a,b 
 
2.8 ± 0.6a,b 2.1 ± 0.1a,b,c 0.39 ± 0.01a,b,c 
Table 13. Effect of chronic amprenavir treatment followed by washout on CYP3A4 mRNA 
expression and activity 
CYP3A4 mRNA expression 
(Fold / control) 
6β (OH) Te formation rate  
(Fold / control) 
 
 
 
Treatment 
Time 
(hours) 
APV (1μM) APV (10μM) APV (1μM) APV (10μM) 
 
+ APV  72 
 
4.9 ± 1.0c 
 
17.8 ± 1.7c 3.2 ± 1.1c 11.3 ± 1.2c 
24 
3.4 ± 0.2a,c 11.7 ± 1.3a,c 
2.0 ± 0.9 5.2 ± 0.2a,c 
48 2.3 ± 0.1
b,c 
 
6.9 ± 1.2a,b,c 
1.3 ± 0.2a 2.5 ± 0.05a,b,c 
 
 
APV 
 
Wash out 
 72 
1.1 ± 0.06a,b 2.6 ± 0.5a,b 
1.5 ± 0.01 1.0 ± 0.002a 
a, significantly different from 72 hour treatment value, p≤ 0.05. 
b, significantly different from 24 hour washout value, p≤ 0.05. 
c, significantly different from control treatment for each day, p≤ 0.05. The baseline or control 
value was taken to be 1, since all the data was normalized to the expression or activity obtained 
with untreated cells, for each day.  
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Figure 11.  Effect of chronic ritonavir treatment followed by washout period on CYP3A4 
mRNA expression, protein content and activity 
Hepatocytes were treated with MeOH (closed bars), RTV 1 μM (dotted bars) and RTV 
10 μM (checkered bars) for 72 hours. Medium was then changed with HMM every 24 
hours for next 72 hours.  CYP3A4 A) mRNA expression, B) protein content and C) 
activity were determined.  The figure shows the mean of triplicate treatments, with the 
S.D. indicated by the vertical bars.  All mRNA and protein values are normalized to β-
actin expression.  *, significantly different from control treatment, p ≤ 0.05. 
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Figure 12.  Effect of chronic amprenavir treatment followed by washout period on 
CYP3A4 mRNA expression, protein content and activity  
Hepatocytes were treated with MeOH (closed bars), APV 1 μM (dotted bars) and APV 
10 μM (checkered bars) for 72 hours. Medium was then changed with HMM every 24 
hours for next 72 hours.  CYP3A4 A) mRNA expression, B) protein content and C) 
activity were determined.  The figure shows the mean of triplicate treatments, with the 
S.D. indicated by the vertical bars.  All mRNA and protein values are normalized to β-
actin expression.  *, significantly different from control treatment, p ≤ 0.05. 
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Table 14. Calculation of t1/2 and recovery time of CYP3A4 mRNA expression and activity 
after treatment with ritonavir and amprenavir 
CYP3A4 mRNA expression 
(Fold / control) 
6β (OH) Te formation rate  
(Fold / control) 
 
 
 
Treatment 
t1/2 (hours) Recovery Time 
(hours)a 
(time to attain 
baseline expression) 
t1/2 (hours) Recovery Time 
(hours)a 
(time to attain 
baseline activity) 
 
RTV 
(10 μM)  
 
17.4 
 
96.5 - 244.7 
 
APV 
(10 μM) 
 
26.9 
 
115.7 20.9 74 
a, recovery time is equal to total time elapsed post 72 hour treatment to achieve baseline value. 
 
3.6. Discussion 
Most of the studies to date documenting the effect of HIV protease inhibitors on CYP3A4 
have been carried out in microsomes or expressed enzyme systems. These systems are suited for 
studying inhibitory effects, but do not lend themselves well to evaluate the inductive potential of 
drugs. Primary cultures of human hepatocytes offer several advantages over these in vitro 
systems. Hepatocytes in culture offer an intact system containing all the necessary cofactors for 
oxidative, reductive and conjugative metabolism of drugs along with the various regulatory 
elements need to maintain and induce/inhibit the expression of enzymes. The effect of a variety 
of HIV protease inhibitors on CYP3A4 enzyme expression and activity has been extensively 
studied in this work. 
In the first part of the current study, we evaluated the effect of increasing concentrations 
of three HIV protease inhibitors namely ritonavir, indinavir and amprenavir, on CYP3A4 mRNA 
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expression, protein content and activity measured as formation rate of 6β(OH) TE. The 
concentrations of protease inhibitors used in this study ranged from 0-10 μM, which are 
clinically relevant concentrations typically observed after oral administration of these drugs in 
humans (product Monographs).  
Human hepatocytes when exposed to ritonavir (0–10 μM), showed a concentration 
dependent increase in CYP3A4 mRNA expression (EC50 = 0.9 μM) comparable to that of 
prototypical CYP3A4 inducer RIF (EC50 = 0.5 μM) (Sahi et al., 2000). The maximum magnitude 
(Emax) of CYP3A4 mRNA induction with RTV was also comparable to that of RIF. The increase 
in mRNA expression resulted in a moderate (2.5-4 folds) increase in CYP3A4 protein content. 
Luo et. al. have reported a similar increase in CYP3A4 mRNA expression (20-fold) and protein 
content (1.5-fold) when human hepatocytes were  exposed to 10μM RTV (Luo et al., 2002).  
A significant observation in our study was the complete inhibition of the CYP3A4 
activity despite a large increase in CYP3A4 mRNA expression and a moderate increase in 
protein content. In the present study, ritonavir inhibited the CYP3A4 mediated metabolism of 
testosterone  (IC50 = 0.0197 μM). This IC50 value is in agreement with the previously reported 
inhibitory constants for RTV in human liver microsomes (IC50 = 0.017 μM)  (Kumar et al., 
1996).  
Complete inhibition of CYP3A4 enzyme activity by RTV and appearance of somewhat 
smeared CYP3A4 protein bands after RTV treatment, suggests the possibility of covalent 
binding of RTV to CYP3A4 thus making the enzyme ‘nonfunctional’. This possibility of 
mechanism-based inhibition or inactivation of CYP3A4 in presence of RTV is supported by the 
study of (Kumar et al., 1996), that documents the high affinity of RTV for CYP3A4 binding 
sites. 
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The present study showed no correlation between mRNA levels of CYP3A4 and PXR 
after RTV treatment. Thus, the increase in mRNA expression post RTV treatment is not 
attributable to PXR mRNA expression. An earlier study conducted by (Luo et al., 2002) has 
shown a correlation between CYP3A4 mRNA expression and PXR activation, after RTV 
treatment (10 μM) in human hepatocytes. However, to the best of our knowledge, there are no 
reports in the literature that document increased PXR mRNA expression after RTV treatment, 
although PXR activation is seen in a reporter gene assay system.  
Treatment with IDV did not result in significant changes in mRNA expression of 
CYP3A4, while CYP3A4 mediated testosterone metabolism was inhibited (IC50 = 0.33 μM). 
This shows that IDV is a less potent inhibitor of CYP3A4 compared to RTV, which is in 
agreement with the studies done in human liver microsomes. 
In all previous studies, APV was reported to be a weak inhibitor of CYP3A4 mediated 
metabolism.  In our study, chronic treatment of human hepatocytes with APV (0-10 μM) showed 
increased mRNA expression, protein content and activity of CYP3A4. At a 10 μM 
concentration, the increase in mRNA expression with APV is 31% of that observed with RIF (10 
μM). Similarly, the increase in activity with APV (10 μM) is 20% of that observed with RIF (10 
μM). 
Based upon the present study, it can be concluded that in human hepatocytes, ritonavir 
and indinavir inhibit CYP3A4 activity, ritonavir being more potent inhibitor than indinavir. On 
the other hand, amprenavir acts as CYP3A4 inducer. In summary, it is shown that HIV protease 
inhibitors have differential effects on CYP3A4 expression and activity. Consistent with the 
observations in human hepatocytes, RTV administration decreased metabolism of 
immunosuppressive drugs.  One example is the interaction between tacrolimus and Kaletra, a 
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combination of ritonavir and lopinavir. After initiation of Kaletra in HIV-positive patient after 
transplantation, tacrolimus half-life was significantly increased (20 days) thus requiring 
discontinuation of tacrolimus for 3-5 weeks, in order to maintain the required tacrolimus blood 
concentration levels. This interaction was found to be more significant compared to that 
observed with single protease inhibitor nelfinavir, where the tacrolimus half-life was increased to 
10.3 days (Jain et al., 2003). 
Patients taking HIV protease inhibitors take multiple medications most of which are 
metabolized by CYP3A4. Thus the modulation of CYP3A4 expression and activity by protease 
inhibitors can possibly lead to drug interactions. Rifampicin was chosen to study the drug-drug 
interaction with protease inhibitors, since it is a potent PXR activator and a known inducer of 
CYP3A4. Rifampicin induces CYP3A4 by increasing mRNA, protein and CYP3A4 activity. We 
showed that RTV, by itself, also increases CYP3A4 expression and hence might be expected to 
enhance the effect of rifampicin, when given in combination. On the contrary, we observed a 
predominant inhibition of CYP3A4 activity by RTV, thereby completely masking the induction 
effect of RIF. The inactivation of CYP3A4 enzyme activity in the presence of RTV may be 
responsible for loss of RIF mediated induction of CYP3A4. In the presence of RTV, the 
inductive effect of RIF was completely masked. This observation predicts the dominance of its 
inhibitory effect on CYP3A4 activity even in presence of potent inducers.  
For the other protease inhibitors, namely amprenavir, indinavir, lopinavir and saquinavir 
when given in combination with RIF, it was clearly observed that the effect on mRNA 
expression, protein and CYP3A4 activity is dominated by RIF. These protease inhibitors are 
known to be less potent than RTV in inhibiting CYP3A4 activity and hence do not modulate the 
induction effect of RIF. 
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Amprenavir, by itself, showed a significant increase in CYP3A4 activity and hence was 
expected to accentuate the inductive effect of RIF, when given in combination.  It was observed 
in this study that the combination effect of APV and RIF was not additive, which could 
potentially be due to the saturable (capacity limited) nature of CYP3A4 enzyme.  
This study predicts that the inhibitory effect of protease inhibitor on CYP3A4 
predominates during chronic treatment. However, after sudden withdrawal, there is no more 
inhibition but the CYP3A4 system may remain induced for a few days. Based upon this 
prediction, we treated human hepatocytes with RTV and APV for three days and studied the 
withdrawal effect of protease inhibitors on CYP3A4 expression and activity by washing the 
drugs out for a further 72 hours. This study showed that CYP3A4 mRNA expression increased 
during treatment with RTV (1 and 10 μM) and exhibited first order decline during the washout 
period with t1/2 of 17.4 hours. During the treatment period, RTV completely inhibited the 
CYP3A4 activity at 1 and 10 μM. During the washout period, the CYP3A4 activity in cells 
treated with 1μM RTV, recovered to the baseline value following zero order kinetics in 48 hours 
with a further increase in activity post 72 hours of washout. In 10 μM RTV treated cells, the 
recovery process followed zero order kinetics but was delayed and a total of 244 hours washout 
period is predicted for complete recovery to the baseline value.  It can be speculated that physical 
binding of RTV at the CYP3A4 enzyme site results in metabolically inactive enzyme. Removal 
of RTV from the enzyme-binding site along with synthesis of new mRNA and protein, results in 
recovery of CYP3A4 metabolic activity back to the control value. 
A similar washout study with APV showed increased mRNA expression and activity 
during the treatment period. The decline in expression and activity, after removal of APV, 
followed first order kinetics with t1/2 = 26.9 hours and 20.9 hours for mRNA expression and 
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activity, respectively. The prototypical inducer RIF showed similar decrease in CYP3A4 
expression and activity after chronic treatment followed by a washout period.  
In summary, this is the first study to the best of our knowledge, showing a concentration 
dependence effect of individual protease inhibitors on CYP3A4 expression and activity in a 
human hepatocyte system. Secondly, the interaction potential of these protease inhibitors with 
currently known CYP3A4 substrates and inducers was studied. Thirdly, the reversible nature of 
CYP3A4 inhibition or induction by protease inhibitors after treatment and removal has been 
shown. The calculation of kinetic parameters such as t1/2 and recovery time for CYP3A4 
expression and activity after drug discontinuation can help further understanding of the time 
course of the effect of protease inhibitors on CYP3A4. 
This systematic study characterizing the effect of protease inhibitors on CYP3A4 
enzymes will also help in better understanding of the clinically observed complex drug-drug 
interactions with other CYP3A4 substrate drugs. With reference to immunosuppressive drugs, 
the effect of RTV will be seen immediately as an inhibition of metabolism and will persist as 
long as RTV is in use. When RTV is stopped, the recovery of activity of CYP3A4 involved in 
the metabolism will be restored to normal values over a four day time period. Careful adjustment 
in the dose of immunosuppressive rugs is warranted during this time period. To the best of our 
knowledge, the greatest inhibition of immunosuppressive drug metabolism is seen with ritonavir 
and this does contributes to a significant reduction in dose of immunosuppressive drugs in 
transplant patients.  
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4. Effect of HIV protease inhibitors on hepatic phase II drug metabolizing enzyme in 
human hepatocytes 
  77
4.1. Abbreviations 
    
     
APV  Amprenavir 
CAR  Constitutive androgen receptor 
CYP  Cytochrome P450 
E3G  Estradiol-3-glucuronide 
HMM  Hepatocyte maintenance medium 
    IDV  Indinavir 
    LPV  Lopinavir 
    NFV  Nelfinavir 
    PB  Phenobarbital 
PCHH  Primary cultures of human hepatocytes 
PXR  Pregnane X receptor 
    RIF  Rifampicin 
    RTV  Ritonavir 
SQV  Saquinavir 
    UGT  UDP-glucuronosyl transferase 
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4.2. Abstract 
Aims: Amongst hepatic phase II drug metabolizing enzymes, UGT1A1 is an important isoform, 
responsible for the glucuronidation of endogenous compounds such as bilirubin, estradiol and 
testosterone and of drugs like mycophenolic acid, acetaminophen commonly used in transplant 
patients. The use of the HIV-protease inhibitor indinavir is associated with unconjugated 
hyperbilirubinemia thought to be due to inhibition of UGT1A1 by indinavir. UGT1A1 is known 
to be transcriptionally regulated by nuclear hormone receptors PXR and CAR. We hypothesized 
that HIV- protease inhibitors will modulate the expression of UGT1A1 by altering their 
regulatory pathways. In the present study we have evaluated the effect of different HIV protease 
inhibitors on UGT1A1 expression and activity using primary cultures of human hepatocytes.  
Methods:  To determine the effect on UGT1A1 Expression and activity, PCHH were exposed to 
ritonavir (RTV), indinavir (IDV) and amprenavir (APV) (0-10 μM) for 72 hours. Quantitative 
Real-time PCR technique was used to determine UGT1A1 mRNA expression, while UGT1A1 
protein was determined using western blotting. Estradiol was used as a probe substrate to 
determine UGT1A1 activity. 
 Results:  Ritonavir (1-10 μM) significantly increases the mRNA expression of UGT1A1 (EC50= 
0.857 μM), while increasing the protein content up-to 2 fold. UGT1A1 activity was increased 
after RTV treatment (EC50= 0.473 μM). Indinavir increases UGT1A1 mRNA expression 2-fold, 
but no significant changes in protein content were observed. Indinavir at lower concentrations (≤ 
0.5μM) increased UGT1A1 activity, while it inhibited UGT1A1 activity by 43% at the highest 
concentration (10 μM). Amprenavir treatment resulted in increased mRNA expression, a 2-fold 
increase in protein content and a 1.6-fold increase in UGT1A1 activity. Though the basal mRNA 
expression of UGT1A1 was not variable among the livers used, a great deal of variability in the 
inducibility of UGT1A1 was observed after treatment with the prototypical inducer PB and also 
after treatment with ritonavir and amprenavir.  
Conclusions: This work shows that HIV-protease inhibitors have differential effects on the 
expression and activity of UGT1A1. The modulation of UGT1A1 activity by HIV protease 
inhibitors could possibly affect the clearance of drugs and endogenous compounds metabolized 
by glucuronidation.  
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4.3. Introduction 
Hepatic phase II metabolizing enzymes, such as UDP-glucoronosyltransferases (UGTs), 
play a pivotal role in glucuronidation of several drugs namely mycophenolic acid, 
acetaminophen and morphine, all of which are used in transplant patients. Factors modulating the 
expression and activity of UGTs will impact clearance of these drugs and will contribute to the 
observed variability in the pharmacokinetics of immunosuppressive drugs. 
UGTs are also responsible for glucuronidation of several endogenous compounds such as 
bilirubin, estradiol and testosterone. Bilirubin, the major product of heme catabolism, is cleared 
from the circulation by conjugation to glucuronic acid in hepatocytes by the microsomal enzyme 
UDP-glucuronosyltransferase (UGT) and then by secretion into bile. In HIV infected patients, it 
has been reported that the use of protease inhibitors such as indinavir and atazanavir, is 
associated with 6-25% incidence of asymptomatic, unconjugated hyperbilirubinemia in the 
absence of histological liver injury, which often leads to development of clinical jaundice and 
interruption of HIV treatment. Of the total 15 human UGT isoforms identified so far, UGT1A1 is 
considered to be exclusively responsible for bilirubin glucuronidation Thus, it is believed that 
elevated unconjugated bilirubin concentration after indinavir treatment is due to inhibition of 
UGT1A1 enzyme. 
Unconjugated hyperbilirubinemia in rats after administration of indinavir was attributed 
to direct competitive inhibition of UGT1A1 by indinavir. Experiments carried out in expressed 
enzyme system and human liver microsomes indicate a direct inhibition of UGT1A1 mediated 
bilirubin glucuronidation by atazanavir and indinavir (Zhang et al., 2005). A strong association 
between UGT1A1*28 allele and risk of developing unconjugated hyperbilirubinemia while 
intaking indinavir, has also been reported (Zucker et al., 2001; Rotger et al., 2005). Since 
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previous studies reporting the inhibition of UGT1A1 after treatment with HIV protease inhibitors 
have been conducted in rat or human microsomes, the potential for the induction of UGT1A1 
enzyme has not been evaluated.  
The phase II metabolizing enzyme UGT1A1 is transcriptionally regulated by the nuclear 
orphan receptor such as pregnane X receptor (PXR) and constitutive androstane receptor (CAR). 
In vitro studies have shown that ritonavir is a potent activator of PXR, though PXR activating 
potential of other HIV protease inhibitors is not yet reported. 
We hypothesized that HIV protease inhibitors will ‘indirectly’ modulate the expression 
and activity of UGT1A1 enzyme, by affecting the expression of regulatory pathways such as the 
expression of PXR and CAR.  The aim of this study was to use primary cultures of human 
hepatocytes to characterize the effect of HIV protease inhibitors namely ritonavir, indinavir and 
amprenavir on UGT1A1 expression and activity. UGT1A1 was selected as a prototype UGT 
enzyme, as it is the primary enzyme required for the glucuronidation of most drugs. 
4.4. Methods 
4.4.1. Hepatocyte treatment protocol to study the effect of HIV protease inhibitors on 
expression and activity of UGT1A1  
To determine the effect of HIV protease inhibitors on UGT1A1 mediated metabolism and 
on the expression of various hepatic drug transporters, twenty-four hours after plating, cells were 
exposed to RTV, IDV and APV (0 - 10 μM) for 72 hours. On the day of the study, cells were 
washed with 1.5 ml of fresh medium for 1 hour. To measure UGT1A1 enzyme activity, cells 
were then incubated in medium containing 200μM estradiol for an additional 60 minutes.  At the 
end of that time, medium along with cell lysate was sampled and stored at -80°C for estradiol-3-
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glucuronide (E-3-G) determination by HPLC (Alkharfy and Frye, 2002). Cells were also 
harvested in phosphate buffer (0.1 M, pH 7.4) and stored at -80°C for protein determination and 
detection of immunoreactive UGT1A1 protein (Lowry O, 1951).  The relative amounts of 
proteins were measured by the intensity of immunoblot staining carried out by densitometry 
(ImageJ, v1.34, http://reb.info.nih.gov/ij)   
Cells were also harvested for mRNA by adding 1 mL of Trizol reagent to each well of a 
6-well plate.  The RNA samples were stored at -20°C for Real Time PCR analysis.  The PCR 
procedure used is described in Chapter 2 (Materials and methods) Primers used for UGT1A1, 
PXR, CAR and β-actin detection are described in Table 8. The relative cDNA content in each 
sample was determined from standard curves constructed from serially diluted human cDNA 
samples. The mRNA expression for each gene was normalized to β-actin in each sample and 
expressed as fold change over control treatment.  
 
4.4.2. Data analysis 
The data were analyzed using a one-way analysis of variance with a post hoc Tukey’s 
multiple comparison procedure. A p value of ≤ 0.05 was considered statistically significant. All 
statistical analysis was performed using PRISM software version 4.0 (GraphPad Software, Inc., 
San Diego, CA, USA). 
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Table 15.  Donor information for human hepatocyte preparations used in Chapter 4 
Donor 
HH # Age Sex
a Raceb Cause of deathc Drug History Viability
Percoll 
separation 
1117 68y F C 
ICH/ 
Stroke 
Labetolol, Verapamil, 
Clonidine 82 No 
1118 73y F C Head trauma Atenolol, Imipramine 80 No 
1184 66y F C - None reported 87 Yes 
1210 35y F C Head trauma 
Dopamine, Vasopressin, 
hydrocortisone 83 Yes 
1218 50y F C 
CA/ 
Anoxia 
- 85 No 
aF, female; bC, Caucasian; c ICH, intra cranial hemorrhage; CA, cardiac arrest 
 
 
 
 
4.5. Results 
Hepatocytes from a total of 5 liver donors were used to conduct the experiments outlined in 
this Chapter. Their relevant demographics, drug history and cell viability information is cited in 
Table 15.   
Chronic exposure of PCHH to RTV, IDV and APV (0- 50 μM) resulted in cellular toxicity 
at concentrations greater than or equal to 20 μM (Figure 4, Chapter 3). Therefore, to study the 
effect on UGT1A1 expression and activity, protease inhibitors at concentrations ≤ 10 μM were 
used. To determine the effect of increasing concentrations of RTV, IDV and APV on UGT1A1 
enzyme expression and activity, cells were exposed to RTV, IDV or APV (0, 0.1, 0.5, 1, 5 and 
10 μM) for 72 hours. PB (2mM), a prototypical inducer of UGT1A1 enzyme, was used as a 
positive control in all the experiments.   
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4.5.1. Effects of ritonavir on UGT1A1 expression and activity 
Ritonavir treatment resulted in a significant increase in UGT1A1 mRNA expression, in a 
concentration dependent manner (EC50 = 0.857 ± 0.038 μM) (Figure 13A). The increase in 
UGT1A1 mRNA expression varied considerably among different hepatocyte isolates, with 3.9 to 
14.2-fold increase over control being seen after RTV (10 μM) treatment. Ritonavir (0.1 and 0.5 
μM) did not alter UGT1A1 protein content but concentrations of 1, 5 and 10 μM increased 
UGT1A1 protein content up to 2-fold (Figure 13B). The formation rate of E-3-G significantly 
increased in a concentration dependent manner after treatment with RTV (EC50= 0.473 μM), 
indicating increased UGT1A1 activity (Figure 13C).  The increase in E-3-G formation rate 
observed was 2.7 ± 0.07 and 2.2 ± 0.09 fold, at 5 and 10 μM RTV, respectively.   
 
4.5.2. Effects of indinavir on UGT1A1 expression and activity 
Treatment with IDV (0-10 μM) increased the UGT1A1 mRNA expression 2-fold compared 
to control and this effect was not concentration dependent (Figure 14A). Indinavir did not alter 
the UGT1A1 protein content significantly at the concentrations used in this study (Figure 14B). 
Since there was not much induction in UGT1A1 mRNA expression, less inter-individual 
variability was observed after IDV treatment. Indinavir at lower concentrations (0.1 and 0.5μM) 
increased E-3-G formation rate 1.66 and 1.37-fold over control, while at higher concentration 
(10μM) the formation rate of E-3-G was reduced to 57.2 ± 1.59 % of control (Figure 14C). 
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Figure 13.  Effect of ritonavir on UGT1A mRNA expression, protein content and activity  
Hepatocytes were exposed to RTV (0 - 10 µM) for 72 hours and UGT1A1 A) mRNA expression, 
B) protein content and C) activity were determined. Each figure shows the mean of values 
obtained from three livers, with the S.D. indicated by the vertical bars.  All mRNA and protein 
values are normalized to β-actin expression.  *, significantly different from vehicle treated cells, 
p ≤ 0.05 
 
EC50 = 0.857 ± 0.038 μM 
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Figure 14.  Effect of indinavir on UGT1A mRNA expression, protein content and activity  
Hepatocytes were exposed to IDV (0 - 10 µM) for 72 hours and UGT1A1 A) mRNA expression, 
B) protein content and C) activity were determined. Each figure shows the mean of values 
obtained from three livers, with the S.D. indicated by the vertical bars.  All mRNA and protein 
values are normalized to β-actin expression.  *, significantly different from vehicle treated cells, 
p ≤ 0.05 
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  86
4.5.3. Effects of amprenavir on UGT1A1 expression and activity 
Hepatocytes treated with APV (0-10 μM) showed a significant increase in UGT1A1 mRNA 
expression, in concentration dependent manner. Similar to the effect seen after RTV treatment, 
the increase in UGT1A1 mRNA expression was considerably variable within the different 
hepatocyte isolates tested; with 3.1 to 16.8-fold induction seen after treatment with highest 
concentration of APV (10 μM) (Figure 15A). A 2-fold increase in the UGT1A1 protein content 
was seen at ATV concentrations 5 and 10 μM (Figure 15B). The formation rate of E-3-G was not 
altered at lower concentrations of APV (0-5 μM), where as the 10 μM APV increased the E-3-G 
formation rate 1.6 ± 0.07 fold over control (Figure 15C)   
The basal mRNA expression of UGT1A1 was not variable among the hepatocytes obtained 
from different donors (CT = 20.78 ± 0.89). But, a large inter-individual variability was seen in 
the inducibility of UGT1A1 mRNA expression. Cells when exposed to PB (2 mM) showed 4.0 
to 16.6-fold increase in UGT1A1 mRNA expression compared to vehicle treated cells (Figure 
15). PB (2 mM) treatment increased UGT1A1 protein content 2-fold; while estradiol-3-
glucuronide (E-3-G) formation rate was increased 1.97 ± 0.17- fold over control treatment.  
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Figure 15.  Effect on UGT1A1 mRNA induction after chronic treatment with amprenavir 
Hepatocytes were treated with PB (2mM) or APV (0-10 µM) for 72 hours and UGT1A1 mRNA 
expression was determined. The figure represents data from two donors, HH1184 showing least 
UGT1A1 mRNA induction (black bars) and HH1210 showing maximum UGT1A1 mRNA 
induction (diagonal thatched bars). All mRNA values are normalized to β-actin expression in 
each sample. *, Significantly different from untreated control cells for each liver, p ≤ 0.05.  
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Figure 16.  Effect of amprenavir treatment on UGT1A1 protein content and activity  
Hepatocytes were treated with APV (0-10 µM) for 72 hours and UGT1A1 A) protein content and 
B) activity were determined. The figure shows a representative immunoblot from HH1210. All 
protein values are normalized to β-actin expression.  The estradiol-3-glucuronide formation rate 
values are the mean of treatments from three livers, with the S.D. indicated by the vertical bars.  
*, significantly different from vehicle treated cells, p ≤ 0.05 
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4.5.4. Correlation between mRNA expression of UGT1A1 and nuclear receptors after 
treatment with protease inhibitors 
To determine if the induction of UGT1A1 mRNA expression after treatment with RTV, 
IDV and APV is due to increased mRNA expression of nuclear receptors such as PXR and CAR, 
a correlation analysis was carried out using PRISM software version 4.0 (GraphPad Software, 
Inc., San Diego, CA, USA). 
Figure 17A shows that after RTV (0-10 μM) treatment, the increase in UGT1A1 mRNA 
expression correlated well with a corresponding increase in PXR mRNA expression (Pearson’s 
correlation coefficient, r2=0.692, p=0.040 or Spearman’s correlation coefficient, ρ =1.00, p 
=0.0083) while there was a lack of correlation between UGT1A1 and CAR mRNA expression 
(Pearson’s correlation coefficient, r2=0.057, p=0.349 or Spearman’s correlation coefficient, ρ 
=0.3, p =0.3417) (Figure 17B).   
After treatment with IDV (Figure 18A), there was a lack of correlation between UGT1A1 
and PXR mRNA expression (Pearson’s correlation coefficient, r2=0.56, p=0.067 or Spearman’s 
correlation coefficient, ρ =0.71, p =0.068). Additionally, no correlation was observed between 
UGT1A1 and CAR mRNA expression (Pearson’s correlation coefficient, r2=0.579, p=0.068 or 
Spearman’s correlation coefficient, ρ =0.7, p =0.116) after treatment with IDV (0-10 μM) as 
shown in Figure 18B. 
Increased UGT1A1 mRNA expression, after APV treatment (0-10 μM), correlated well 
with increased PXR mRNA expression (Pearson’s correlation coefficient, r2=0.651, p=0.026 or 
Spearman’s correlation coefficient, ρ =0.943, p =0.0083) and also with increased CAR 
expression (Pearson’s correlation coefficient, r2=0.899, p=0.002 or Spearman’s correlation 
coefficient, ρ =0.943, p =0.0083) (Figure 19A and Figure 19B, respectively).   
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Figure 17.  Correlation between the induction of expression of nuclear receptors and 
UGT1A1 mRNA after ritonavir treatment  
Hepatocytes were treated with RTV (0-10 µM) for 72 hours and mRNA expression of UGT1A1, 
PXR and CAR was determined. The figure represents the correlation between UGT1A1 mRNA 
induction and A) PXR mRNA induction and B) CAR mRNA induction. Each value represents 
the mean of treatments from three livers. All mRNA values are normalized to β-actin expression. 
Correlations were measured by Pearson’s correlation coefficient (r ) and Spearman’s Rho (ρ). A 
p value of 0.05 was considered statistically significant. 
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Figure 18.  Correlation between the induction of expression of nuclear receptors and 
UGT1A1 mRNA after indinavir treatment  
Hepatocytes were treated with IDV (0-10 µM) for 72 hours and mRNA expression of UGT1A1, 
PXR and CAR was determined. The figure represents the correlation between UGT1A1 mRNA 
induction and A) PXR mRNA induction and B) CAR mRNA induction. Each value represents 
the mean of treatments from three livers. All mRNA values are normalized to β-actin expression. 
Correlations were measured by Pearson’s correlation coefficient (r ) and Spearman’s Rho (ρ). A 
p value of 0.05 was considered statistically significant. 
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Figure 19.  Correlation between the induction of expression of nuclear receptors and 
UGT1A1 mRNA after amprenavir treatment  
Hepatocytes were treated with APV (0-10 µM) for 72 hours and mRNA expression of UGT1A1, 
PXR and CAR was determined. The figure represents the correlation between UGT1A1 mRNA 
induction and A) PXR mRNA induction and B) CAR mRNA induction. Each value represents 
the mean of treatments from three livers. All mRNA values are normalized to β-actin expression. 
Correlations were measured by Pearson’s correlation coefficient (r ) and Spearman’s Rho (ρ). A 
p value of 0.05 was considered statistically significant. 
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4.6. Discussion 
Primary cultures of human hepatocytes represent an intact and physiologically relevant 
model useful for studying the modulation of hepatic UGT1A1 in humans. Studies carried out in 
expressed enzymes or microsomes cannot be used to evaluate the regulation of UGTs.  
Currently there are very few studies demonstrating the effect of HIV protease inhibitors 
on human UGT1A1 enzyme expression and activity. The present study carried out using primary 
cultures of human hepatocytes addresses various issues related to the effect of protease inhibitors 
on UGT1A1 enzyme, including concentration dependent effects of protease inhibitors, 
interindividual variability and correlations with the expression of nuclear receptors such as PXR 
and CAR.   
UGT1A1 catalytic activities were determined by the quantification of estradiol-3-
glucuronide (E-3-G) formation rate. Estradiol was chosen as a specific probe substrate for 
hepatic UGT1A1 catalytic activity based on previous work demonstrating that E-3-G was a 
selective UGT1A1 metabolite in human liver (Soars et al., 2004). 
 In the present study, we have shown that ritonavir increases the UGT1A1 mRNA 
expression in a concentration dependent manner (EC50 = 0.857 ± 0.038 μM), with a maximum 
3.93 to 14.21-fold increase over control after RTV (10 μM) treatment. Recently, Smith et al. 
have also observed large inducing effects (> 17-fold) on UGT1A1 mRNA levels after treatment 
with 10 μM RTV in human hepatocyte culture system. We observed about a 2-fold increase in 
the UGT1A1 protein content after RTV treatment which was consistent with the previous report 
showing a more than 2-fold increase in UGT1A1 protein at 10 μM RTV concentration (Smith et 
al., 2005). We observed a concentration dependent increase in UGT1A1 catalytic activity as 
reflected by the increased formation rate of estradiol-3-glucuronide (EC50= 0.473 μM). The EC50 
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values for UGT1A1 activity after treatment with a prototypical inducers namely RIF, 3-MC and 
PB, have been reported to be 0.4 μM, 0.8 μM and 107 μM, respectively (Smith et al., 2005). 
After comparing the EC50 values, RTV can be considered as a potent inducer of hepatic 
UGT1A1 expression and activity.  The observed increase in UGT1A1 activity in PCHH after 
RTV treatment was contradictory to the report by Zhang et.al. They have reported inhibition of 
human UGT1A1 enzyme expressed in baculovirus-infected insect cells by RTV (IC50 = 19 μM) 
(Zhang et al., 2005). This discrepancy may be due to the lack of regulatory cofactors and nuclear 
receptors in the expressed enzyme model system used.   
There are no previous reports demonstrating the effect of amprenavir on UGT1A1 mediated 
metabolism in human hepatocytes. In our study, amprenavir increased the mRNA expression 3.1 
to 16.8-fold, while a 2-fold increase in the UGT1A1 protein content was observed. At the highest 
concentration used in the present study, APV (10 μM) increased the E-3-G formation rate 1.6-
fold, comparable to that seen after PB (2 mM) and RTV (10 μM).  
Indinavir, on the other hand, showed only a slight increase in UGT1A1 mRNA expression 
(2-fold), with no significant changes in UGT1A1 protein expression. Surprisingly, IDV at lower 
concentrations increased E-3-G formation rate (1.66-fold) comparable to that of PB (2 mM), 
while significantly inhibiting the UGT1A1 mediated estradiol metabolism to 57.2 % at 10 μM 
concentration.  Since UGT1A1 mRNA and protein expression was not altered, this inhibition at a 
higher concentration of IDV is considered to be a ‘direct’ effect on the UGT1A1 enzyme. Zhang 
et al. have reported a similar inhibitory effect of IDV on UGT1A1 activity (IC50 = 87 μM) 
(Zhang et al., 2005). There are no literature reports documenting that HIV-protease inhibitors are 
good substrates of UGT enzymes, barring one study where a glucuronide metabolite of indinavir 
has been identified. Indinavir is suggested to bind UGT1A1 and act as partial competitive 
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inhibitor of UGT1A1 (Balani et al., 1996). Thus, the direct inhibition of UGT1A1 activity at 
higher concentrations of IDV observed in our study using human hepatocytes has precedence. 
This observation also supports the occurrence of hyperbilirubinemia after indinavir treatment to 
be mediated by inhibition of UGT1A1 enzyme. 
We observed that the basal mRNA expression of UGT1A1 was consistent among the 
various hepatocyte cultures used (CT = 20.78 ± 0.89), but the increase in UGT1A1 mRNA 
expression after treatment with the prototypical inducer PB (2mM) or after treatment with RTV 
and APV varied considerably (3 to 18-fold). Other investigators have reported large inter-
individual differences in hepatic UGT1A1 expression and/or activity. Smith et al. have reported 
35-fold and 6-fold differences in UGT1A1 protein levels and catalytic activity, respectively 
(Smith et al., 2005).  Though no information was available regarding the UGT1A1 genotype of 
the liver donors, the possibility of polymorphism in the promoter region of UGT1A1 gene cannot 
be excluded and hence warrants further study.  
It has been recently discovered that UGT1A1 contains both PXR and CAR binding motifs 
in its promoter region (Sugatani et al., 2001; Xie et al., 2003). Thus, similar to CYP3A4 enzyme, 
UGT1A1 is also believed to be under transcriptional control. Ritonavir is shown to be a potent 
PXR activator (Luo et al., 2002), while there are no reports documenting indinavir or amprenavir 
as PXR activators. We observed a good correlation between increased UGT1A1 mRNA and 
increased PXR mRNA expression after RTV treatment, while there was no correlation with 
changes in CAR mRNA expression. Increased UGT1A1 mRNA expression after amprenavir 
treatment showed a good correlation with increased PXR as well as increased CAR expression. 
We thus predict amprenavir to be an activator of PXR as well as CAR, though further studies 
measuring PXR activation after amprenavir treatment will be needed to support this observation. 
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A poor correlation was seen in UGT1A1 expression and PXR or CAR expression in presence of 
IDV. This observation supports our previous finding that IDV did not have any effect on 
UGT1A1 mRNA expression but inhibits UGT1A1 activity by direct binding to the enzyme.   
In summary, our studies document the effect of ritonavir, indinavir and amprenavir on the 
expression and activity of UGT1A1 enzyme. This is the first study to the best of our knowledge 
to report the effect of increasing concentrations of protease inhibitors on UGT1A1 mediated 
metabolism in human hepatocytes, and to document EC50 values for UGT1A1 induction after 
RTV treatment. Furthermore, our studies have demonstrated the use of primary cultures of 
human hepatocytes in clarifying induction or inhibition discrepancies due to absence of cofactors 
in other in vitro model systems. We also demonstrated that the effect of ritonavir and amprenavir 
on UGT1A1 is ‘indirect’ and is possibly mediated through nuclear receptors, while the inhibitory 
effect of indinavir on UGT1A1 activity does not appear to involve regulation by PXR and CAR. 
This study also shows that protease inhibitors can significantly modulate the expression and 
activity of UGT1A1 thereby affecting the clearance of drugs and endogenous compounds 
metabolized by glucuronidation.  
UGT1A1 being the primary enzyme involved in the glucuronidation of drugs used in 
transplant patients such as acetaminophen, morphine and mycophenolic acid, modulation of 
UGT1A1 expression and activity by HIV-protease inhibitors will alter glucuronidation of these 
drugs. Our observations indicate that HIV-protease inhibitors have a moderate effect on 
UGT1A1 expression and activity and other factors should also be considered while explaining 
the large variability in pharmacokinetics of the drugs used in liver transplant patients.  
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5. Effect of HIV protease inhibitors on the expression of hepatic drug transporters in 
human hepatocytes 
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5.1. Abbreviations 
    
     
APV  amprenavir 
BSEP  bile salt export pump 
CAR  constitutive androgen receptor  
HPIs  HIV protease inhibitors 
HMM  hepatocyte maintenance medium 
    IDV  indinavir 
MDR1  multidrug resistant protein 1 
MRP2  multidrug resistance associated protein 2 
MRP6  multidrug resistance associated protein 6 
PCHH  primary cultures of human hepatocytes 
PXR  pregnane X receptor 
P-gp  P-glycoprotein 
RIF  rifampicin 
    RTV  ritonavir 
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5.2. Abstract 
Aims:  Hepatic canalicular membrane transporters such as P-glycoprotein (P-gp), multidrug 
resistance protein 2 (MRP2) and bile salt export pump (BSEP) are involved in removal of drugs 
and endogenous substances from the blood circulation. Immunosuppressive agents are substrates 
for these transporters. Thus alterations in expression and activity of transporters are thought to 
alter the pharmacokinetics of immunosuppressive agents. The objective of the present study was 
to use primary cultures of human hepatocytes (PCHH) to study the concentration-dependent 
effect of HIV-protease inhibitors, namely ritonavir, indinavir and amprenavir, on the expression 
of canalicular transporters, namely P-gp, MRP2, MRP6 and BSEP. Additionally, the possible 
involvement of pregneane X receptor (PXR) and constitutive androgen receptor (CAR) in the 
regulation of drug transporters after treatment with HIV-protease inhibitors was also studied. 
Methods:  To determine the effect of concentration, hepatocytes coated with MatrigelTM (0.233 
mg/ml) were exposed to ritonavir (RTV), indinavir (IDV) and amprenavir (APV) (0-10 μM) for 
72 hours. The mRNA expression of various hepatic transporters such as MDR1, MRP2, MRP6 
and BSEP and that of nuclear receptors, PXR and CAR was measured by quantitative Real-time 
PCR. The mRNA expression of each gene was normalized to β-actin in each sample and 
expressed as fold change over control treatment. 
 Results:  After ritonavir treatment, mRNA expression of MDR1, MRP2 and BSEP was 
increased and correlated well with increased PXR expression, while no correlation with CAR 
expression was observed. Similarly, after APV treatment, increase in mRNA expression of 
MDR1 and MRP2 was correlated with PXR but not with CAR mRNA expression. Decrease in 
mRNA expression of MRP6 after RTV treatment was associated with increased PXR mRNA 
expression. But, no changes in MRP6 mRNA expression were observed after indinavir and 
amprenavir treatment. 
Conclusions:  This study has demonstrated that increasing concentrations of HIV-protease 
inhibitors have differential effects on expression of drug efflux transporters namely P-gp 
(MDR1), MRP2, MRP6 and BSEP in a human hepatocyte system. The modulation of transporter 
expression is possibly mediated via mechanisms involving nuclear receptors such as PXR. Given 
the magnitude of changes in the transporter expression observed in this study due to HIV-
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protease inhibitors treatment, it can be concluded that effects of HIV-protease inhibitors on 
immunosuppressive drugs is mainly due to alteration of CYP3A4, rather than transporters. 
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5.3. Introduction 
Hepatic canalicular membrane transporter proteins such as P-glycoprotein (MDR1), 
multidrug resistance associated proteins (MRP2, MRP6) and bile salt export pump (BSEP) are 
efflux transporters involved in the removal of endogenous substances such as bile acids and 
exogenous substances such as drugs used in transplantation namely cyclosporine, tacrolimus and 
mycophenolic acid. Factors inhibiting or inducing these transporters can therefore affect the 
intracellular concentration of drugs, thereby altering pharmacokinetics and pharmacodynamic 
profiles of the drugs or of endogenous substances, affecting the normal physiological processes 
in the liver. 
HIV protease inhibitors administered in conjunction with immunosuppressive agents 
show significant potential for drug-drug interactions, which can be mediated through alteration 
in drug transporters. A strong induction of P-glycoprotein expression by ritonavir, amprenavir 
and nelfinavir in the human colon carcinoma cell line has been documented (Perloff et al., 2003). 
A recent report has documented the inhibition of human breast cancer resistance protein (BCRP) 
by ritonavir, saquinavir and nelfinavir (Gupta et al., 2004). Additionally, ritonavir, saquinavir 
and indinavir have been shown to be high affinity substrates for P-glycoprotein and MRP2 (Kim 
et al., 1998; Huisman et al., 2002; Williams et al., 2002).  Interestingly, along with drug 
metabolizing enzymes like CYP3A4, hepatic efflux transporters such as P-glycoprotein and 
MRP2 are also transcriptionally regulated by the nuclear orphan receptors pregnane X receptor 
(PXR) and constitutive androgen receptor (CAR). In vitro studies have shown that ritonavir is a 
potent activator of PXR (Luo et al., 2002). Since protease inhibitors modulate PXR activity and 
CYP3A4 enzyme, they might also alter expression and activity of several drug transporters. 
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There are no reports documenting the effect, if any, of these protease inhibitors on the 
expression of efflux transporters in primary cultures of human hepatocytes. Based on this 
background, we hypothesize that HIV protease inhibitors will alter the expression of hepatic drug 
transporters by modulating the expression of PXR and CAR involved in their regulation. Thus, 
the aim of this study was to use human hepatocytes in culture to characterize the effect of 
increasing concentrations of HIV protease inhibitors such as ritonavir, indinavir and amprenavir 
on the expression of canalicular drug transporters namely P-glycoprotein, MRP2, MRP6 and 
BSEP.  
5.4. Methods 
5.4.1. Hepatocyte treatment protocol to study the effect of HIV protease inhibitors on 
expression of hepatic drug transporters 
Twenty-four hours after plating, hepatocytes were coated with MatrigelTM (0.233 mg/ml). 
Cells were then exposed to RTV, IDV and APV (0 - 10 μM) for 72 hours in order to determine 
the effect on the expression of hepatic drug transporters namely P-glycoprotein, MRP2, MRP6 
and BSEP and on nuclear receptors PXR and CAR. 
Cells were harvested for mRNA by adding 1 mL of Trizol reagent to each well of a 6-
well plate.  The RNA samples were stored at -20°C for Real Time PCR analysis.  The PCR 
procedure and primers used for MDR1, MRP2, MRP6, BSEP, PXR, CAR and β-actin detection 
are described in Chapter 2 (Materials and Methods). The relative cDNA content in each sample 
was determined from standard curves constructed from serially diluted human cDNA samples. 
The mRNA expression for each gene was normalized to β-actin in each sample and expressed as 
fold change over control treatment. 
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5.4.2. Data analysis 
All values were calculated as mean ± S.D. The data were analyzed using a one-way analysis 
of variance with a post hoc Tukey’s multiple comparison procedure. A p value of ≤ 0.05 was 
considered statistically significant. All statistical analysis as well as the correlation analysis was 
performed using PRISM software version 4.0 (GraphPad Software, Inc., San Diego, CA, USA).  
 
Table 16.  Donor information for human hepatocyte preparations used in Chapter 5 
Donor 
HH # Age Sex
a Raceb Cause of deathc Drug History Viability
Percoll 
separation 
1112 69y F C 
Anoxia/ 
CA 
Dopamine 80 No 
1117 68y F C 
ICH/ 
Stroke 
Labetolol, Verapamil, 
Clonidine 82 No 
1118 73y F C 
Head 
trauma 
Atenolol, Imipramine 80 No 
1184 66y F C - None reported 87 Yes 
1210 35y F C Head trauma 
Dopamine, Vasopressin, 
hydrocortisone 83 Yes 
1218 50y F C 
CA/ 
Anoxia 
- 85 No 
aF, female; bC, caucasian; cCA, cardiac arrest; ICH, intra cranial hemorrhage 
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5.5. Results 
Hepatocytes from a total of 6 liver donors were used to conduct the experiments outlined in 
this Chapter. Their relevant demographics, drug history and cell viability information is cited in 
Table 16.   
Chronic exposure of hepatocyte culture to RTV, IDV and APV (0- 50 μM) resulted in 
cellular toxicity at concentrations greater than or equal to 20 μM (Figure 4, Chapter 3). Thus, in 
this study all protease inhibitors were used at concentrations ≤ 10 μM. To determine the effect of 
increasing concentrations of protease inhibitors on expression of transporters, cells were exposed 
to RTV, IDV or APV (0, 0.1, 0.5, 1, 5 and 10 μM) for 72 hours. RIF (10 μM) was used as a 
positive control in all the experiments.   
5.5.1. Effect of ritonavir on mRNA expression of MDR1, MRP2, MRP6 and BSEP 
Figure 20 shows the effect of RTV on the mRNA expression of MDR1, MRP2, MRP6 and 
BSEP. Ritonavir (10μM) showed 8.2 ± 0.3-fold and 2.6 ± 0.6-fold increase in the mRNA 
expression of MDR1 and MRP2, respectively. Additionally, the increase in mRNA expression of 
MDR1 and MRP2 was dependent on RTV concentration. BSEP mRNA expression was 
increased to 2-fold up to 5 μM RTV concentration, but was found not to be significantly different 
from the control value at 10μM.  On the other hand, with increasing concentrations of RTV, 
MRP6 expression gradually decreased to 60.6 % of control value at 10μM concentration.  
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Figure 20.  Effect of ritonavir on mRNA expression of hepatic drug transporters 
Hepatocytes were treated with RTV (0 –10 μM) and mRNA expression of A) MDR1, B) MRP2, C) MRP6 and D) BSEP was 
measured. The figure shows the mean of values obtained from four donors, with the S.D indicated by vertical bars. All mRNA values 
are normalized to β-actin expression. *, significantly different from vehicle treated cells, p ≤ 0.05. 
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5.5.2. Effect of indinavir on mRNA expression of MDR1, MRP2, MRP6 and BSEP 
Indinavir increased the mRNA expression of MDR1, MRP2 and BSEP up to 2-fold, but this 
effect was not observed to be concentration dependent. Indinavir did not show any significant 
changes in the mRNA expression of MRP6 (Figure 21). 
 
5.5.3. Effect of amprenavir on mRNA expression of MDR1, MRP2, MRP6 and BSEP 
Figure 22 shows that after treatment with APV, a concentration dependent increase in 
MDR1 and MRP2 mRNA expression was observed. APV (10μM) showed 4.0 ± 0.2-fold and 1.9 
± 0.07-fold increase in the mRNA expression of MDR1 and MRP2, respectively. BSEP mRNA 
expression was significantly increased (1.3-fold over control) only at the highest concentration of 
APV (10μM).  There was no significant effect on MRP6 mRNA expression after APV treatment. 
The positive control RIF (10μM) used in this study increased MDR1 and MRP2 mRNA 
expression 8.4 ± 1.9-fold and 3.8 ± 0.7-fold of control value, respectively. MRP6 mRNA 
expression was not altered, while BSEP mRNA expression was decreased to 76.6 % of control 
after RIF (10 μM) treatment. 
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Figure 21.  Effect of indinavir on mRNA expression of hepatic drug transporters 
Hepatocytes were treated with IDV (0 –10 μM) and mRNA expression of A) MDR1, B) MRP2, C) MRP6 and D) BSEP was 
measured. The figure shows the mean of values obtained from four donors, with the S.D indicated by vertical bars. All mRNA 
values are normalized to β-actin expression. *, significantly different from vehicle treated cells, p ≤ 0.05. 
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Figure 22.  Effect of amprenavir on mRNA expression of hepatic drug transporters 
Hepatocytes were treated with APV (0 –10 μM) and mRNA expression of A) MDR1, B) MRP2, C) MRP6 and D) BSEP was 
measured. The figure shows the mean of values obtained from four donors, with the S.D indicated by vertical bars. All mRNA 
values are normalized to β-actin expression. *, significantly different from vehicle treated cells, p ≤ 0.05 
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5.5.4. Correlation between mRNA expression of transporters and nuclear receptors 
after treatment with protease inhibitors 
The mRNA expression of PXR and CAR was increased up to 2.5-fold after treatment with 
RTV, IDV and APV treatment (0-10μM) (Figure 23). 
To determine if the changes in the mRNA expression of transporters after treatment with 
RTV, IDV and APV were due to changes in the mRNA expression of nuclear receptors, PXR 
and CAR, a correlation analysis was carried out using PRISM software version 4.0 (GraphPad 
Software, Inc., San Diego, CA, USA). Table 17 and Table 18 show the corresponding correlation 
coefficients for PXR and CAR, respectively. After RTV (0-10 μM) treatment, increase in mRNA 
expression of MDR1, MRP2, and BSEP was associated with a corresponding increase in PXR 
mRNA expression. On the other hand, changes in mRNA expression of MDR1, MRP2, MRP6 
and BSEP did not correlate with changes in CAR expression after RTV treatment (Figure 24 and 
Figure 25).  
After IDV (0-10 μM) treatment, mRNA expression of MRP2 and BSEP correlated well 
with increased PXR and CAR mRNA expression, while MDR1 and MRP6 expression was not 
correlated with either PXR or CAR mRNA expression (Figure 26 and Figure 27, respectively) 
After APV (0-10 μM) treatment, mRNA expression of MDR1 and MRP2 correlated well 
with PXR mRNA expression, while only MRP2 and BSEP expression correlated well with CAR 
expression (Figure 28 and Figure 29).  
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Figure 23.  Effect of protease inhibitors on mRNA expression of PXR and CAR 
Hepatocytes were treated with A) RTV, B) IDV and C) APV (0 –10 μM) and mRNA expression 
of PXR (closed bars) and CAR (diagonal thatch bars) was measured. The figure shows the mean 
of values obtained from four donors, with the S.D indicated by vertical bars. All mRNA values 
are normalized to β-actin expression. *, significantly different from vehicle treated cells, p ≤ 0.05 
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Table 17.  Correlation between mRNA expression of transporters and PXR after treatment with protease inhibitors 
Drug Gene Pearson’s CC  ( r2 ) p-value
 Correlation Spearman’s CC  (ρ) p-value
 Correlation 
MDR1 0.715 0.035 Yes 1.000 0.0083 Yes 
MRP2 0.971 0.001 Yes 0.9 0.041 Yes 
MRP6 0.694 0.039 Yes -0.9 0.041 Yes 
RTV 
BSEP 0.793 0.021 Yes 0.9 0.041 Yes 
MDR1 0.373 0.098 No 0.942 0.0083 Yes 
MRP2 0.621 0.031 Yes 0.942 0.0083 Yes 
MRP6 0.404 0.0875 No 0.257 0.329 No 
IDV 
BSEP 0.861 0.0038 Yes 0.942 0.0083 Yes 
MDR1 0.874 0.0031 Yes 0.885 0.016 Yes 
MRP2 0.965 0.0002 Yes 0.942 0.0083 Yes 
MRP6 0.734 0.0146 Yes -0.657 0.087 No 
APV 
BSEP 0.440 0.075 No 0.6 0.12 No 
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Table 18.  Correlation between mRNA expression of transporters and CAR after treatment with protease inhibitors 
Drug Gene Pearson’s CC  ( r2 ) p-value
 Correlation Spearman’s CC  (ρ) p-value
 Correlation 
MDR1 0.074 0.328 No 0.3 0.341 No 
MRP2 0.489 0.094 No 0.4 0.258 No 
MRP6 0.113 0.29 No -0.1 0.475 No 
RTV 
BSEP 0.118 0.285 No 0.1 0.475 No 
MDR1 0.443 0.074 No 0.885 0.016 Yes 
MRP2 0.766 0.011 Yes 1.00 0.001 Yes 
MRP6 0.369 0.1 No 0.371 0.248 No 
IDV 
BSEP 0.958 0.0003 Yes 1.00 0.001 Yes 
MDR1 0.502 0.057 No 0.885 0.016 Yes 
MRP2 0.654 0.025 Yes 0.942 0.0083 Yes 
MRP6 0.446 0.073 No -0.657 0.087 No 
APV 
BSEP 0.807 0.007 Yes 0.6 0.120 No 
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Figure 24.  Correlation between transporter mRNA expression and PXR expression after ritonavir treatment 
Hepatocytes were treated with RTV (0 –10 μM) and mRNA expression of MDR1, MRP2, MRP6, BSEP and PXR was measured. 
The figure shows the correlation between PXR mRNA expression and A) MDR1, B) MRP2, C) MRP6 and D) BSEP mRNA. Each 
value represents the mean of values obtained from four livers. All mRNA values are normalized to β-actin expression. For 
correlations a p-value of 0.05 was considered statistically significant. 
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Figure 25.  Correlation between transporter mRNA expression and CAR expression after ritonavir treatment 
Hepatocytes were treated with RTV (0 –10 μM) and mRNA expression of MDR1, MRP2, MRP6, BSEP and CAR was measured. 
The figure shows the correlation between CAR mRNA expression and A) MDR1, B) MRP2, C) MRP6 and D) BSEP mRNA. Each 
value represents the mean of values obtained from four livers. All mRNA values are normalized to β-actin expression. For 
correlations a p-value of 0.05 was considered statistically significant. 
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Figure 26.  Correlation between transporter mRNA expression and PXR expression after indinavir treatment 
Hepatocytes were treated with IDV (0 –10 μM) and mRNA expression of MDR1, MRP2, MRP6, BSEP and PXR was measured. 
The figure shows the correlation between PXR mRNA expression and A) MDR1, B) MRP2, C) MRP6 and D) BSEP mRNA. Each 
value represents the mean of values obtained from four livers. All mRNA values are normalized to β-actin expression. For 
correlations a p-value of 0.05 was considered statistically significant. 
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Figure 27.  Correlation between transporter mRNA expression and CAR expression after indinavir treatment 
Hepatocytes were treated with IDV (0 –10 μM) and mRNA expression of MDR1, MRP2, MRP6, BSEP and CAR was measured. 
The figure shows the correlation between CAR mRNA expression and A) MDR1, B) MRP2, C) MRP6 and D) BSEP mRNA. Each 
value represents the mean of values obtained from four livers. All mRNA values are normalized to β-actin expression. For 
correlations a p-value of 0.05 was considered statistically significant. 
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Figure 28.  Correlation between transporter mRNA expression and PXR expression after amprenavir treatment 
Hepatocytes were treated with APV (0 –10 μM) and mRNA expression of MDR1, MRP2, MRP6, BSEP and PXR was measured. 
The figure shows the correlation between PXR mRNA expression and A) MDR1, B) MRP2, C) MRP6 and D) BSEP mRNA. Each 
value represents the mean of values obtained from four livers. All mRNA values are normalized to β-actin expression. For 
correlations a p-value of 0.05 was considered statistically significant. 
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Figure 29.  Correlation between transporter mRNA expression and CAR expression after amprenavir treatment 
Hepatocytes were treated with IDV (0 –10 μM) and mRNA expression of MDR1, MRP2, MRP6, BSEP and CAR was measured. 
The figure shows the correlation between CAR mRNA expression and A) MDR1, B) MRP2, C) MRP6 and D) BSEP mRNA. Each 
value represents the mean of values obtained from four livers. All mRNA values are normalized to β-actin expression. For 
correlations a p-value of 0.05 was considered statistically significant. 
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5.6. Discussion 
In the present study, we have characterized the effect of protease inhibitors on the 
expression of drug transporters namely P-glycoprotein, MRP2, MRP6 and BSEP in a human 
hepatocyte culture system. Human hepatocyte cultures represent an intact and physiologically 
relevant model useful for studying modulation of hepatic drug transporters. These cells are 
capable of synthesizing normal bile acids from their cholesterol precursors, formation of their 
conjugated metabolites, and the canalicular efflux of both parent and metabolite. They also have 
all the cofactors and various regulatory elements needed to maintain and induce expression of 
transporter proteins. The application of extracellular 3-D matrix in the form of MatrigelTM 
prevents the loss of albumin synthesis, leads to phosphorylation of hepatocyte growth factors and 
epidermal growth factor receptors and results in cuboidal, polar hepatocyte structure (Sidhu and 
Omiecinski, 1995; Toritsuka et al., 2001; Engl et al., 2004). Previous studies carried out in our 
laboratory have shown that the basal expression of the transporters such as BSEP, MDR1 and 
MRP2 is significantly higher in cultures coated with MatrigelTM compared to normal 
monolayered hepatocyte cultures. 
Currently there are very few studies documenting the effect of HIV protease inhibitors on 
drug transporters. In the present study, we have shown that ritonavir has a differential effect on 
various hepatic efflux transporters. After RTV treatment, the inductive effect on MDR1 mRNA 
expression is most pronounced (8.2-fold), followed by that on MRP2 (2.6-fold) and BSEP (2-
fold). On the other hand, RTV treatment decreased the expression of MRP6 to 60.6%. The 
increase in mRNA expression of MDR1 and MRP2 is comparable to that observed after 
rifampicin (10 μM) treatment. These observations are in agreement with previous studies that 
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have similarly shown to increase the expression and activity of P-glycoprotein in LS180V cells 
after RTV treatment (Perloff et al., 2003).  
In the current study, indinavir showed a moderate effect on MDR1, MRP2 and BSEP 
expression with a 2-fold increase in the expression of these transporters, with no effect on MRP6 
expression. After amprenavir (10μM) treatment, increase in mRNA expression is highest for 
MDR1 followed by MRP2 and BSEP with no significant effect on MRP6. There are no previous 
reports in literature documenting the effect of indinavir and amprenavir on the expression and 
activity of hepatic efflux transporters.  
Earlier studies have shown that ritonavir is a potent PXR activator (Luo et al., 2002). 
Hepatic efflux transporters such as P-glycoprotein, MRP2 and BSEP are also transcriptionally 
regulated by the nuclear orphan receptor such as pregnane X receptor (PXR) and constitutive 
androgen receptor (CAR). After ligand binding in the cytosol, PXR or CAR translocate to the 
nucleus where they heterodimerize with retinoid X receptor (RXR) and then bind to promoter 
region on respective transporter gene resulting in increased mRNA expression of corresponding 
transporter. Therefore, in the present study, correlation analysis was carried out to determine if 
the effects of protease inhibitors on expression of transporters is mediated through regulation of 
PXR and/or CAR. 
It is shown that after RTV treatment, increase in mRNA expression of MDR1, MRP2 and 
BSEP correlated well with increased PXR expression, thus suggesting the role of PXR in mRNA 
induction of the above transporters. On the contrary, no involvement of CAR is observed in 
modulating the expression of MDR1, MRP2 and BSEP. Similarly, after APV treatment, increase 
in mRNA expression of MDR1 and MRP2 is potentially mediated mainly through PXR with 
minimal contribution of CAR. Inconclusive data were obtained for regulation of BSEP after 
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APV treatment. After IDV treatment, increase in mRNA expression of MRP2 and BSEP is 
mediated through a mechanism involving both PXR and CAR.  
Decrease in mRNA expression of MRP6 after RTV treatment was associated with 
increased PXR mRNA expression. But, no changes in MRP6 mRNA expression were observed 
after indinavir and amprenavir treatment. This suggests that possibly other nuclear receptors or 
transcriptions factors are involved in the regulation of MRP6, which warrants further study. 
In summary, this is the first study to report that increasing concentration of HIV-protease 
inhibitors have differential effects on expression of drug efflux transporters namely P-
glycoprotein, MRP2, MRP6 and BSEP in human hepatocyte system. The modulation of 
transporter expression is possibly mediated via mechanisms involving nuclear receptors such as 
PXR and/or CAR. Knowing the effects of protease inhibitors on the expression and activity of 
hepatic transporters will prove highly beneficial in understanding the pharmacokinetic behavior 
of drugs that are transported via P-glycoprotein, MRP2, MRP6 and BSEP. Given the magnitude 
of change in transporter activity that is observed in this study, HIV-protease inhibitors are seem 
to contribute more towards pharmacokinetics interactions with immunosuppressive drugs due to 
their effect on CYPs and not as much due to their effect on transporters.  
 
 
 
  122
 
 
 
 
 
 
 
 
6. Effect of pro-inflammatory cytokines on hepatic drug transport in human hepatocytes 
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6.1. Abbreviations 
    
[3H]TC [3H] taurocholate 
BSEP  bile salt export pump 
CAR  constitutive androgen receptor 
CsA  cyclosporine A 
FXR  farnesoid X receptor 
HMM  hepatocyte maintenance medium 
    IL-1β  interleukin-1β 
    IL-2  interleukin-2 
IL-6  interleukin-6 
LPS  lipopolysaccharides 
MDR1  multidrug resistant protein 1 
MRP2  multidrug resistance associated protein 2 
Ntcp sodium-dependent taurocholate cotransporting 
protein 
PCHH  primary cultures of human hepatocytes 
P-gp  P-glycoprotein 
PXR  pregnane X receptor 
    TNFα  Tumor Necrosis Factor-α 
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6.2. Abstract 
Aims:  Hepatic canalicular membrane transporters such as P-glycoprotein (P-gp), multidrug 
resistance protein 2 (MRP2) and bile salt export pump (BSEP) are involved in removal of drugs 
and endogenous substances from the blood. Immunosuppressive agents are substrates for these 
transporters. Thus alterations in expression and activity of transporters are though to alter the 
pharmacokinetics of immunosuppressive agents. Cytokines released during infection have shown 
to downregulate various hepatic drug transporters in rat in vivo and in vitro model systems, but 
very limited data on the regulation of human transporters is available. The objective of the 
present study was to evaluate the effect of different cytokines on the expression and activity of 
hepatic drug transporters such as BSEP using primary cultures of human hepatocytes. 
 Methods:  Human hepatocytes in MatrigelTM coated cultures were exposed to IL-1, IL-2, IL-6 
and TNFα (0-10 ng/ml) and the effect on BSEP mRNA expression and activity were studied. 
The mRNA expression was measured using quantitative Real-time PCR. BSEP activity was 
measured by [3H] taurocholate ([3H] TC) efflux. 
 Results:  Exposure of human hepatocytes to IL-1, IL-2, IL-6 and TNFα resulted in decreased 
mRNA expression and activity of BSEP, with maximal suppression being observed after 72 
hours of treatment. IL-1 decreased BSEP mRNA expression by 80%, while decreasing the BSEP 
mediated [3H] TC efflux by more than 70%. IL-2 did not significantly alter BSEP mRNA 
expression and activity, while IL-6 at higher concentration increased BSEP mRNA expression 
along with decrease in BSEP activity by only 20%. TNFα significantly decreased both, BSEP 
mRNA expression and activity, by 70 %. 
Conclusions:  Duration of human hepatocytes to cytokine is an important factor affecting 
downregulation of BSEP mRNA expression and activity. Different cytokines exhibit different 
inhibition potential in downregulating BSEP expression and activity which can be ranked as IL-
1≅ TNFα > IL-6 >IL-2. Alteration of these cytokines in diseased states such as infection, cancer 
or organ rejection after transplantation will modulate the expression and activity of drug 
transporters, thereby impacting the pharmacokinetics of substrate drugs and bile secretion 
process in liver leading to cholestasis.  
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6.3. Introduction 
Hepatobiliary transport and subsequent bile flow play an important role in the removal of 
endogenous and exogenous substances from the body (Faber et al., 2003). Hepatic efflux 
transporters such as P-glycoprotein (P-gp) and multidrug resistance protein 2 (MRP2) are 
involved in the clearance of drugs used in transplantation such as cyclosporine, tacrolimus and 
mycophenolic acid, while bile salt export pump (BSEP) is integral in the canalicular handling of 
conjugated and unconjugated bile salts, such as taurocholate (Gerloff et al., 1998). Alterations in 
the expression and activity of these transport proteins thus can lead to changes in the 
pharmacokinetics of drugs transported by these proteins and also can affect the normal 
physiological processes in the liver. 
A number of studies suggest that inflammatory response involving various cytokines 
such as interleukin-1 (IL-1), interleukin –6 (IL-6) and tumor necrosis factor-α (TNFα) are 
significantly involved in the downregulation of various hepatic drug transporters (Piquette-Miller 
et al., 1998; Lee and Piquette-Miller, 2001; Sukhai et al., 2001; Lee and Piquette-Miller, 2003; 
Cherrington et al., 2004; Siewert et al., 2004).  In vitro and in vivo studies in rats indicate that 
lipopolysaccharides (LPS), TNFα, IL-1 and IL-6 decrease the uptake and secretion of bile 
components by altering the expression and activity of hepatic transporters, such as Ntcp, Bsep 
and Mrp2, thus leading to cholestatic conditions (Green et al., 1994; Whiting et al., 1995; Green 
et al., 1996; Muhlfeld et al., 2003).  
There are very few reports documenting the effect of cytokines on human hepatic 
transporters. Studies done in human cell lines and in human liver slices have reported 
downregulation in expression of transporters such as MDR1, MRP2, MRP3 and BSEP after 
exposure to LPS or individual cytokines and this downregulation is thought to be due to 
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posttranscriptional changes in transporter gene by cytokines (Elferink et al., 2004; Hisaeda et al., 
2004). 
Transcriptional factors such as pregnane X receptor (PXR), constitutive androgen 
receptor (CAR) and farnesoid X receptor (FXR) play an important role in the regulation of drug 
transporters. Downregulation of these nuclear receptors has been reported after administration of 
endotoxin in rats. Based upon the above studies, we hypothesized that in human hepatocytes, 
cytokines will downregulate expression and activity of hepatic efflux transporters and this 
suppression will be due to alterations in the expression of transcriptional factors, PXR and/or 
CAR. 
In the present study, we have evaluated the effect of increasing concentrations of IL-1β, 
IL-2, IL-6 and TNFα on the expression and activity of bile salt express pump (BSEP) using 
human hepatocyte cultures. 
6.4. Methods 
6.4.1. Evaluation of the cytotoxicity of pro-inflammatory cytokines to human 
hepatocytes 
Hepatocytes in 3D cultures were exposed to individual cytokines IL-1, IL-2, IL-6 and TNFα (0–
50 ng/ml) for 72 hours.  Following aspiration of media, 10% v/v of 5 mg/ml 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to HMM and 
incubated for 30 min. At 30 min, the medium was aspirated and cells washed with HMM.  
Isopropanol (same volume as the medium) was then added and shaken gently for 2 min. Two 
hundred microliters of this solution was transferred to a 96-well plate, and the absorbance was 
measured at 570nm. 
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6.4.2. Hepatocyte treatment protocol to study the effect of pro-inflammatory cytokines 
on transporters  
Twenty-four hours after plating, cells were coated with MatrigelTM (0.233 mg/ml). The 
effect of time on the expression of various transporters and on BSEP mediated [3H] taurocholate 
([3H] TC) efflux was evaluated by exposing the 3D hepatocyte cultures to 5 ng/ml of IL-1, IL-2, 
IL-6 and TNFα for 24-72 hours. To study the effect of different concentrations of individual 
cytokines on transporter expression and BSEP activity, hepatocytes were exposed to individual 
cytokines (0–10 ng/ml) for 72 hours.  
Cells were harvested for mRNA by adding 1 mL of Trizol reagent to each well of a 6-
well plate.  The RNA samples were stored at -20°C for Real Time PCR analysis.  Primers for 
BSEP, PXR, and CAR for the house keeping genes, β-actin and GAPDH were described in 
Chapter 2. The relative cDNA content was determined from standard curves constructed from 
serially diluted cDNA samples. The mRNA expression for all genes was normalized to GAPDH 
in each sample and expressed as fold change over control treatment. 
 
6.4.3. Evaluation of BSEP activity 
At the end of the treatment with cytokines, HMM was replaced with Hank’s balanced salt 
solution (HBSS) containing cations (calcium and magnesium) for 20 minutes.  After this period, 
1 μM [3H]-taurocholate was added in fresh HBSS (with cations) for 20 minutes.  Uptake was 
stopped by aspirating the buffer solution and cells were washed three times with ice cold HBSS 
(with cations).  Fresh HBSS, with and without cations, was then added to the cells for 20 
minutes.  After this time period, media was sampled and cells harvested in 1 mL of NaOH/SDS 
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solution.  Each sample (0.5 mL) was then counted using a liquid scintillation counter.  Aliquots 
of harvested cells were stored at -80°C for protein determination (Lowry et al., 1951). 
 
6.4.4. Data analysis 
All values were calculated as mean ± S.D. For the cytotoxicity analysis (MTT assay), 
comparisons between treatment groups and untreated control group were made by using a one-
way analysis of variance with a post hoc Dunnett’s procedure. Data from all other experiments 
were analyzed using a one-way analysis of variance with a post hoc Tukey’s multiple 
comparison procedure. A p value of ≤ 0.05 was considered statistically significant and all 
calculations were performed were performed using PRISM software version 4.0 (GraphPad 
Software, Inc., San Diego, CA, USA). 
6.5. Results 
Hepatocytes from a total of 12 liver donors were used to conduct the experiments 
outlined in this Chapter and their relevant demographics, drug history and cell viability can be 
found in Table 19.  
6.5.1. Effect of chronic exposure of hepatocytes to cytokines on MTT reduction  
Chronic exposure (72 hours) of human hepatocytes to IL-1, IL-2 and TNFα at 
concentrations ≥ 20 ng/ml and IL-6 at concentration ≥ 50 ng/ml resulted in significant cellular 
toxicity as compared to the untreated cells (Figure 30). Thus all the further experiments were 
carried out with cytokine concentrations at or below 10 ng/ml.   
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Table 19.  Donor information for human hepatocyte preparations used in Chapter 6  
Donor 
HH # Age Sex
a Raceb Cause of deathc Drug History Viability (%) 
Percoll 
separation  
1117 68y F C 
ICH/ 
stroke 
Labetolol, Verapamil, Clonidine 82 No 
1118 73y F C HT Atenolol, Imipramine 80 No 
1180 52y M C 
CVA/ 
stroke 
Dopamine 75 No 
1184 66y F C - None reported 87 Yes 
1196 56y F C Asystole Metoprolol, cholesterol medications (not specified) 79 Yes 
  1200 53y F C 
CVA/ 
stroke 
Dopamine 65 Yes 
1205 45y M H 
CVA/ 
stroke 
- 66 No 
1209 30y F C 
CVA/ 
stroke 
Heparin, Ampicillin, Gentamycin, 
Morphine 66 Yes 
1210 35y F C Head trauma Dopamine, Vasopressin, hydrocortisone 83 Yes 
1222 68y F C - - 93 No 
1225 56y M C - Atenolol, aspirin 77 No 
1247        
aM, male; F, female; bC, Caucasian; H, Hispanic; c ICH, intra cranial hemorrhage; CA, cardiac arrest 
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Figure 30.  Effect of cytokines on MTT reduction 
Human hepatocytes were exposed to A) IL-1, B) IL-2, C) IL-6 and D) TNFα (0-50 ng/ml) for 72 hours in MG overlay cultures and 
MTT reduction was measured. The figure shows the mean of triplicate treatments from two donors and is expressed as percentage of 
the value in untreated cells, with S.D. indicated by the vertical bars. *, significantly different from untreated cells, p ≤ 0.05. 
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* * 
* 
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6.5.2. Effect of duration of cytokine exposure on expression and activity of BSEP  
To determine the effect of culture times on expression and activity of BSEP, hepatocytes 
coated with MatrigelTM (0.233 mg/ml) were exposed to each cytokine (IL-1, IL-2, IL-6 and 
TNFα) at a concentration of 5ng/ml for 24-72 hours. [3H] taurocholate TC ([3H]TC) efflux was 
used as a measure of BSEP activity.  Figure 31A, Figure 32A, Figure 33A and Figure 34A show 
the effect of IL-1, IL-2, IL-6 and TNFα on the mRNA expression of BSEP, respectively. 
Maximal suppression of BSEP mRNA expression was observed 72 hours after treating the cells 
with 5ng/ml of individual cytokines. Similarly, maximal suppression of BSEP mediated [3H]TC 
efflux was observed 72 hours after treating the cells with 5ng/ml of individual cytokines. BSEP 
mediated [3H]TC efflux was suppressed to 16.7 ± 5.7 %, 70.6 ± 2.3 % , 79.2 ± 4.1 % and  37.9 ± 
0.7 % of control value, after IL-1, IL-2, IL-6 and TNFα treatment, respectively (Figure 31B, 
Figure 32B, Figure 33B and Figure 34B). 
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Figure 31.  Effect of duration of IL-1 exposure on mRNA expression and activity of BSEP 
Hepatocytes were exposed to HMM (closed bars) and 5ng/ml IL-1 (diagonal thatch bars) for 
24, 48 and 72 hours in 3D cultures. BSEP A) mRNA expression B) [3H] taurocholate efflux 
were determined. The figure shows the mean of values obtained from three livers, with S.D. 
indicated by the vertical bars. All mRNA values are normalized to GAPDH expression. *, 
significantly different from control; #, significantly different from 24 hour value, p≤ 0.05.
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Figure 32. Effect of duration of IL-2 exposure on mRNA expression and activity of BSEP 
Hepatocytes were exposed to HMM (closed bars) and 5ng/ml IL-2 (diagonal thatch bars) for 
24, 48 and 72 hours in 3D cultures. BSEP A) mRNA expression B) [3H] taurocholate efflux 
were determined. The figure shows the mean of values obtained from three livers, with S.D. 
indicated by the vertical bars. All mRNA values are normalized to GAPDH expression. *, 
significantly different from control; #, significantly different from 24 hour value, p≤ 0.05. 
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Figure 33.  Effect of duration of IL-6 exposure on mRNA expression and activity of BSEP 
Hepatocytes were exposed to HMM (closed bars) and 5ng/ml IL-6 (diagonal thatch bars) for 24, 48 
and 72 hours in 3D cultures. BSEP A) mRNA expression B) [3H] taurocholate efflux were 
determined. The figure shows the mean of values obtained from three livers, with S.D. indicated by 
the vertical bars. All mRNA values are normalized to GAPDH expression. *, significantly different 
from control; #, significantly different from 24 hour value, p≤ 0.05. 
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Figure 34.  Effect of duration of TNFα exposure on mRNA expression and activity of BSEP 
Hepatocytes were exposed to HMM (closed bars) and 5ng/ml TNFα (diagonal thatch bars) for 24, 
48 and 72 hours in 3D cultures. BSEP A) mRNA expression B) [3H] taurocholate efflux were 
determined. The figure shows the mean of values obtained from three livers, with S.D. indicated by 
the vertical bars. All mRNA values are normalized to GAPDH expression. *, significantly different 
from control; #, significantly different from 24 hour value, p≤ 0.05. 
 
* 
* 
* 
# 
# 
* 
# 
# 
  136
6.5.3. Effect of cytokine concentration on BSEP expression and activity 
From the previous results, it was found that maximum suppression of BSEP mRNA 
expression and activity was observed after 72 hours of cytokine treatment. Hence, exposure time 
of 72 hours was chosen for studying the effect of cytokine concentrations on BSEP expression 
and activity.  Hepatocytes were treated with IL-1, IL-2, IL-6 and TNFα (0-10 ng/ml) for 72 
hours. Cyclosporine (CsA) (10 μM), which is an inhibitor of BSEP, was used as a positive 
control in this study. 
 Exposure of hepatocytes to IL-1 significantly decreased the mRNA expression of BSEP at 
all concentrations with a maximum decrease to 10.7 ± 3.95% of control value at 10 ng/ml 
(Figure 35A). Similarly, exposure to IL-1 resulted in a concentration dependent decrease in 
[3H]TC efflux values which were reduced to 46.8 ± 15.8 % and 27.03 ± 3.8% of control , at 
concentrations of 0.3 ng/ml  and 10 ng/ml, respectively (Figure 35B).      
Treatment with IL-2 did not significantly change the mRNA expression of BSEP at the 
concentration used. Only after 1 ng/ml IL-2 treatment, BSEP mRNA expression reduced to 53.7 
± 13 % of control (Figure 36A). The efflux of [3H]TC was decreased to 70.15 ± 9.27 % of 
control value at 10 ng/ml IL-2 (Figure 36B).  
IL-6 exposure showed no effect on BSEP mRNA expression (at concentration ≤ 5 ng/ml). 
At 10 ng/ml of IL-6, BSEP mRNA expression was increased 1.73 ± 0.49-fold over control value 
(Figure 37A). After IL-6 treatment, maximum decrease in BSEP mediated [3H] TC efflux was 
seen at 5 ng/ml and was 70.02 ± 1.58 % of control value (Figure 37B). 
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Figure 35.  Effect of IL-1 exposure on BSEP mRNA expression and [3H] taurocholate 
efflux 
Human hepatocytes were exposed to IL-1 (0–10 ng/ml). A) BSEP mRNA expression and B) 
[3H] TC efflux were then determined. The figure shows the mean of values obtained from 
three livers, with S.D. indicated by the vertical bars. All mRNA values are normalized to 
GAPDH expression. *, significantly different from untreated cells, p≤ 0.05.  
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Figure 36.  Effect of IL-2 exposure on BSEP mRNA expression and [3H] taurocholate 
efflux 
Human hepatocytes were exposed to IL-2 (0–10 ng/ml). A) BSEP mRNA expression and B) 
[3H] TC efflux were then determined. The figure shows the mean of values obtained from 
three livers, with S.D. indicated by the vertical bars. All mRNA values are normalized to 
GAPDH expression. *, significantly different from untreated cells, p≤ 0.05.  
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Figure 37.  Effect of IL-6 exposure on BSEP mRNA expression and [3H] taurocholate 
efflux 
Human hepatocytes were exposed to IL-6 (0–10 ng/ml). A) BSEP mRNA expression and B) 
[3H] TC efflux were then determined. The figure shows the mean of values obtained from 
three livers, with S.D. indicated by the vertical bars. All mRNA values are normalized to 
GAPDH expression. *, significantly different from untreated cells, p≤ 0.05.  
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Treatment with TNFα showed a significant concentration dependent decrease in both BSEP 
mRNA expression as well as activity. At TNFα 10 ng/ml, BSEP mRNA expression was 
decreased to 36.8 ± 8 % (Figure 38A), while [3H] TC efflux was decreased to 5.07 ± 6.3 % of 
untreated cells (Figure 38B).   
Cyclosporine (CsA) (10 μM) reduced BSEP mRNA expression to 75.2 ± 1.1 % and [3H] 
TC efflux to 9.5 ± 6.7 % of control value.  
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Figure 38.  Effect of TNFα exposure on BSEP mRNA expression and [3H] taurocholate 
efflux 
Human hepatocytes were exposed to TNFα (0–10 ng/ml). A) BSEP mRNA expression and B) 
[3H] TC efflux were then determined. The figure shows the mean of values obtained from 
three livers, with S.D. indicated by the vertical bars. All mRNA values are normalized to 
GAPDH expression. *, significantly different from untreated cells, p≤ 0.05.  
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6.6.  Discussion 
In the present study, we have measured the effect of cytokines (IL-1, IL-2, IL-6 and 
TNFα) on the mRNA expression and activity of BSEP.  
Most of the studies involving use of cytokines are carried out in rodents or using  ‘in 
vitro’ systems such as rat hepatocytes or human intestinal or hepatic cell lines. Since different 
cell types are unique in their ability to produce and release cytokines, it is important to use an 
appropriate model system to study the effects of cytokines on human hepatic metabolism and 
transporters.   
Modified culture techniques have enabled the use of primary cultures of human 
hepatocytes to study uptake and efflux of drugs and their metabolites by hepatic drug 
transporters. Human hepatocytes in culture contain all the necessary cofactors as well as the 
regulatory elements required to maintain and modulate the transporter proteins and are hence 
extremely well suited for conducting these studies. Results from preliminary studies conducted 
in our laboratory and also by others have shown that the basal expression of transporters such as 
BSEP, MDR1 and MRP2 is significantly higher in cultures coated with MatrigelTM compared to 
normal monolayered hepatocyte cultures. The loss of tight junctions during the hepatocyte 
isolation procedure results in a loss of cellular polarity and is believed to affect the expression 
and activity of some drug transporters by affecting the cellular localization of transporters. The 
application of an extracellular 3D matrix results in a cuboidal, polar hepatocyte structure and 
results in a relocalization of transporter proteins such as MDR1, MRP2 and BSEP in hepatic 
canalicular membrane (Sidhu and Omiecinski, 1995; Toritsuka et al., 2001; Kudryavtseva and 
Engelhardt, 2003; Engl et al., 2004). For our experiments, Matrigel, which is a mixture of 
laminin, collagen (IV) heparin sulfate proteoglycans containing growth factors, was chosen as a 
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matrix because its constituents are thought to more closely mimic those found in human liver 
(Kleinman et al., 1982; Rodriguez-Antona et al., 2002). 
 As efflux of taurocholate into bile canaliculi is mainly mediated by bile salt export 
pump, [3H] Taurocholate ([3H] TC) was used to measure BSEP activity. After treatment with 
cytokines, [3H] TC efflux was measured in 3D cultures of hepatocytes in absence and presence 
of the cations containing calcium and magnesium. Only those cells exposed to cation containing 
medium retain their tight junctions that allow for the formation of canalicular structure 
(Kostrubsky et al., 2003). [3H] TC, in cells without cations (1mM EDTA is added to medium to 
chelate residual cation), accounts for all the processes (passive leakage + active transport) by 
which [3H] TC enter the media. Efflux measured in cells exposed to cation containing medium, 
reflects only the passive leakage of [3H] TC from the cells. Thus, the difference in these two 
values (with and without cations) will account for the BSEP mediated transport of [3H] TC into 
the canalicular spaces, which has been used as an indirect measure of BSEP activity. 
In the present study, we have shown that the duration of cytokine exposure to human 
hepatocytes is an important factor affecting downregulation of BSEP expression and activity. In 
human hepatocyte system, exposure to all cytokines studied in this work showed maximum 
downregulation of expression as well as BSEP mediated efflux of [3H]TC after 72 hours 
exposure. These observations are consistent with another study, where, in human hepatocytes IL-
1 and IL-6 are shown to downregulate CYP3A4 mediated testosterone metabolism, with the 
maximum suppression being seen at 72 hours (Sunman et al., 2004). 
 Among all the cytokines studied in this work, IL-1 is shown to be most effective in 
downregulating the mRNA expression and activity of BSEP leading to ~85-90% inhibition in 
mRNA expression and ~50-75% decrease in BSEP activity. Although there are no reports 
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showing direct effect of IL-1 on BSEP mRNA expression and activity in human in vitro systems, 
LPS (100 μg/ml) treatment in human liver slices has shown to downregulate BSEP protein 
content with no changes in mRNA expression (Elferink et al., 2004). In general, IL-1 is shown to 
downregulate the expression of rodent hepatic efflux transporters such as Mrp2 and Mdr1a and 
Bsep (Hartmann et al., 2002). Additionally, in HepG2 cells, IL-1 is shown to decrease expression 
and activity of MRP2 and MDR1 (Hisaeda et al., 2004). The above cited literature findings 
regarding decreased expression of transporters by IL-1 seem to be consistent with our 
observations of reduced BSEP expression and activity.  
IL-2 did not show any significant decrease in mRNA expression, while showing only 
~20-30% decrease in BSEP activity. Sunman et al. (2004) have documented failure of IL-2 in 
decreasing CYP3A4 mediated metabolism of testosterone in human hepatocyte cultures. 
However, in the same study, it was shown that in hepatocyte/ Kupffer cell co-cultures, after IL-2 
treatment, CYP3A4 activity was decreased by 50-70%. This suggests that IL-2 inhibits CYP3A4 
activity ‘indirectly’ through Kupffer cells by mediating the release of IL-1, IL-6 or TNFα, which 
are responsible for downregulating CYP3A4 activity. Failure of IL-2 to show any significant 
suppression of BSEP in our experiments may be attributed to the absence of Kupffer cells in the 
model system used. 
Unlike the behavior of other cytokines used, IL-6 treatment resulted in 1.74-fold increase 
in BSEP mRNA expression at 10 ng/ml, while showing a decrease of 20-30% in BSEP activity. 
Contrary to these findings, IL-6 has been shown to significantly decrease the mRNA expression 
of Bsep by 50-75 % in rat hepatocytes. Thus, the response shown by IL-6 appears to vary in 
different species with more significant suppression seen in rat hepatocyte compared to human 
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hepatocytes. Other In vitro studies in rat hepatocytes have shown that IL-6 treatment causes a 
similar decrease in the expression and activity of P-glycoprotein (Sukhai et al., 2001).  
 TNFα exhibits a concentration dependent decrease in mRNA expression with 70% 
inhibition at the highest concentration (10 ng/ml) with 50-85% inhibition of BSEP activity. 
These findings are in agreement with earlier studies in HepG2 cells, which showed decreased 
MRP2 and MDR1 expression and activity with TNFα at 1-20 ng/ml (Hisaeda et al., 2004). On 
the other hand, in mice studies, TNFα did not significantly affect Bsep and Mrp2 expression 
(Hartmann et al., 2002). Cyclosporine (CsA) is a nonspecific inhibitor of BSEP. CsA does not 
inhibit mRNA expression of BSEP but decreases activity significantly. On the other hand, 
cytokines decrease BSEP mRNA expression as well as activity. 
In summary, it has been shown that in human hepatocytes, maximum suppression in 
mRNA expression and BSEP activity occurs after 72 hours of cytokine treatment. Different 
cytokines exhibit different inhibition potential which can be ranked in decreasing order of 
inhibition as IL-1 ≅ TNFα > IL-6 > IL-2. Alteration of these cytokines in diseased states such as 
infection, cancer or rejection after transplantation, will modulate the expression and activity of 
hepatic BSEP, thus impacting the pharmacokinetics of substrate drugs and/or bile secretion 
leading to cholestasis. Response to cytokines varies between species and caution must be 
examined in extrapolating studies done in animals to humans. With cytokine studies, co-culture 
of hepatocytes with Kupffer cells may provide a better system in simulating in vivo condition. 
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7. Effect of pro-inflammatory cytokines on phase II metabolizing enzyme, UGT1A1, in 
human hepatocytes 
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7.1. Abbreviations 
    
CAR  constitutive androgen receptor 
E3G  estradiol-3-glucuronide 
FXR  farnesoid X receptor 
HMM  hepatocyte maintenance medium 
HNF  hepatocyte nuclear factors   
IL-1β  interleukin -1β 
    IL-2  interleukin -2 
IL-6  interleukine-6 
LPS  lipopolysaccharides 
PB  phenobarbital 
PCHH  primary cultures of human hepatocytes 
PXR  pregnane X receptor 
    TNFα  tumor Necrosis Factor-α 
    UGT    UDP- glucuronosyl transferases 
UN  untreated cells      
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7.2. Abstract 
Aims:  Hepatic phase II enzymes, UGTs, play an important role in drug disposition and 
clearance of drugs used in transplant patients, such as mycophenolic acid, acetaminophen and 
morphine. UGT1A1 is an important isoform involved in the glucuronidation of several drugs as 
well as endogenous compounds such as bilirubin, estradiol and testosterone. In rat and pig 
hepatocytes, cytokines are shown to downregulate expression and activity of UGTs while in 
human liver biopsies, decreased UGT1A4, UGT2B4 and UGT2B7 mRNA levels were observed 
with increased inflammation. Based on these literature reports, the current study was undertaken 
to study the effect of different cytokines on expression and activity of hepatic UGT1A1 enzyme, 
using primary cultures of human hepatocytes. Additionally, the effect of cytokines on mRNA 
expression of nuclear receptors, namely PXR and CAR that are involved in UGT1A1 regulation 
was also studied.  
Methods:  Human hepatocytes in MatrigelTM coated cultures were exposed to IL-1, IL-2, IL-6 
and TNFα (0-10 ng/ml) and effect on mRNA expression of UGT1A1, PXR and CAR was 
determined using quantitative Real-time PCR. UGT1A1 protein was determined using western 
blotting, while UGT1A1 activity was determined by using estradiol as a probe substance. 
 Results:  Increasing concentrations of IL-1 (0-10 ng/ml) significantly inhibited UGT1A1 
mRNA expression, protein content as well as activity with maximal inhibition to 55 %, 47 % and 
41 % of control, respectively, at 10 ng/ml. The mRNA expression of PXR and CAR was also 
decreased to 50–55 % after IL-1 treatment.  IL-2 showed slight increase in UGT1A1 mRNA 
expression with no significant effect on protein content, while UGT1A1 activity was decreased 
to 80 % of control. IL-2 suppressed PXR and CAR expression only at the highest concentration. 
IL-6 at higher concentrations showed increase in UGT1A1 mRNA, but protein content and 
activity were decreased. The mRNA expression of PXR and CAR were also increased at high 
concentrations of IL-6. Treatment with TNFα resulted in decreased UGT1A1 protein content (54 
%) and activity (75%), with no changes in mRNA expression. 
Conclusions:  Cytokine treatment in general resulted in suppressed the expression and activity 
of UGT1A1. Different cytokines exhibit different inhibition potential in downregulating 
UGT1A1 activity and the rank order of potency was IL-1 >IL-6 ≅ TNFα > IL-2, with maximal 
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inhibition seen after IL-1 exposure. The lowered UGT1A1 activity can affect conjugation of 
bilirubin during inflammation process along with decreasing the metabolism of drugs conjugated 
by UGT1A1. 
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7.3. Introduction 
Hepatic phase II metabolizing enzymes, such as UDP- glucuronosyltransferases (UGTs), 
play an important role in drug disposition and clearance, along with phase I enzymes (CYPs) and 
various drug transporters.  Many drugs used in transplant patients, such as mycophenolic acid; 
acetaminophen and morphine are mainly metabolized by glucuronidation. In addition, several 
endogenous compounds such as bilirubin, estradiol and testosterone also undergo 
glucuronidation.  
The regulation of CYP enzymes in models of infection and inflammatory diseases has 
been studied extensively. The activity and expression of most of the CYP enzymes is shown to 
be downregulated by pro-inflammatory cytokines. Downregulation of CYP activities or protein 
levels during inflammation are also generally accompanied by a decrease in the respective CYP 
mRNA expression (Morgan, 1997; Morgan, 2001). Thus it is suggested that transcriptional 
suppression could be the primary mechanism for the decrease in CYP mRNA expression during 
inflammation. Downregulation of transcription factors such as hepatocyte nuclear factors 
(HNFs), NF-κB along with several nuclear receptors such as pregnane X receptor (PXR) and 
constitutive androgen receptor (CAR) has been proposed to be responsible for the suppression of 
CYPs by inflammatory stimuli (Iber et al., 2000; Ke et al., 2001; Beigneux et al., 2002).  There is 
relatively little information about regulation of phase II enzymes during inflammation. However, 
it is known that PXR and CAR also regulate Phase II enzymes.  
Thus, we hypothesized that pro-inflammatory cytokines will downregulate expression 
and activity of hepatic UGT1A1 enzyme and this suppression will be partly due to alterations in 
the expression of transcription factors, PXR and/or CAR. 
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In the present study we have evaluated the effect of increasing concentrations of IL-1β, 
IL-2, IL-6 and TNFα on the expression and activity of UGT1A1 using primary cultures of 
human hepatocytes.  
7.4. Methods 
7.4.1. Evaluation of the cytotoxicity of cytokines to human hepatocytes 
Hepatocytes in 3D cultures were exposed to individual cytokines IL-1β, IL-2, IL-6 and 
TNFα (0–50 ng/ml) for 72 hours.  Following aspiration of media, 10% v/v of 5 mg/ml 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to HMM and 
incubated for 30 min. At 30 min, the medium was aspirated and cells washed with HMM.  
Isopropanol (same volume as the medium) was then added and shaken gently for 2 min. Two 
hundred microliters of this solution was transferred to a 96-well plate, and the absorbance was 
measured at 570nm. 
 
7.4.2. Hepatocyte treatment protocol to study the effect of individual cytokines on 
UGT1A1 expression and activity 
Twenty-four hours after plating, cells were coated with MatrigelTM (0.233 mg/ml). Cells 
were then exposed to IL-1β, IL-2, IL-6 and TNFα (0, 0.3, 1, 5 and 10 ng/ml) for 72 hours. On the 
day of study, cells were washed with 1.5 ml of fresh medium for 1 h and then incubated in 1.5 ml 
of medium containing 250 μM estradiol for an additional 60 minutes.  At the end of that time, 
cell lysate along with the medium was sampled and stored at -80°C for estradiol-3-glucuronide 
(E-3-G) determination by HPLC.  Cells were harvested in phosphate buffer (0.1 M, pH 7.4) and 
stored at -80°C for protein determination (Lowry O, 1951) and detection of immunoreactive 
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UGT1A1 protein. The relative amounts of proteins were assessed by the intensity of immunoblot 
staining carried out by densitometry (ImageJ, v1.34, http://rsb.info.nih.gov.ij) 
 Cells were also harvested for mRNA by adding 1 mL of Trizol reagent to each well of a 
6-well plate.  The RNA samples were stored at -20°C for Real Time PCR analysis.  Primers for 
UGT1A1, PXR, CAR and GAPDH were described in Chapter 2. The relative cDNA content was 
determined from standard curves constructed from serially diluted cDNA samples. The mRNA 
expression for all genes was normalized to GAPDH in each sample and expressed as fold change 
over control treatment. 
 
7.4.3. Data analysis 
All values were calculated as mean ± S.D. Comparisons among various treatment groups 
were carried out using a one-way analysis of variance with a post hoc Tukey’s multiple 
comparison procedure. A p value of ≤ 0.05 was considered statistically significant and all 
calculations were performed were performed using PRISM software version 4.0 (GraphPad 
Software, Inc., San Diego, CA, USA). 
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Table 20.  Donor information for human hepatocyte preparations used in Chapter 7 
Donor 
HH # Age Sex
a Raceb Cause of deathc Drug History 
Viability 
(%) 
Percoll 
separation 
1117 68y F C 
ICH/ 
stroke 
Labetolol, Verapamil, 
Clonidine 82 No 
1118 73y F C HT Atenolol, Imipramine 80 No 
1180 52y M C 
CVA/ 
stroke 
Dopamine 75 No 
1184 66y F C - None reported 87 Yes 
1196 56y F C Asystole 
Metoprolol, cholesterol 
medications (not 
specified) 
79 Yes 
  1200 53y F C 
CVA/ 
stroke 
Dopamine 65 Yes 
1205 45y M H 
CVA/ 
stroke 
- 66 No 
1209 30y F C 
CVA/ 
stroke 
Heparin, Ampicillin, 
Gentamycin, Morphine 66 Yes 
aM, male; F, female; bC, Caucasian; H, Hispanic; c ICH, intra cranial hemorrhage; CA, cardiac 
arrest 
 
7.5. Results 
Hepatocytes from a total of 8 liver donors were used to conduct the experiments outlined 
in this Chapter and their relevant demographics, drug history and cell viability can be found in 
Table 20.  
Chronic exposure (72 hours) of human hepatocytes to IL-1, IL-2 and TNFα at 
concentrations ≥ 20 ng/mL and IL-6 at concentration ≥ 50 ng/ml resulted in significant cellular 
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toxicity as compared to the untreated cells (Figure 30, Chapter 6). Thus, these experiments were 
carried out using cytokine concentrations at or below 10 ng/ml.  
 
7.5.1. Effect of cytokines on UGT1A1 mRNA expression, protein content and activity 
Hepatocytes in 3D culture system were treated with IL-1, IL-2, IL-6 and TNFα (0, 0.3, 1, 
5 and 10 ng/ml) for 72 hours and the effect on UGT1A1 mRNA, protein expression and activity 
was determined.  
Figure 39A shows that increasing concentrations of IL-1 significantly inhibited UGT1A1 
mRNA expression. At the highest concentration of IL-1 (10 ng/ml), UGT1A1 mRNA expression 
was inhibited to 57.7 ± 3.4 % of the untreated control. Similarly, the UGT1A1 protein expression 
was reduced to 66 % and 47 % of the control value, at IL-1 concentrations 1ng/ml and 10 ng/ml, 
respectively (Figure 39B). This decrease in UGT1A1 mRNA and protein expression was 
reflected in a decreased formation rate of estradiol-3-glucuronide (E-3-G). Figure 39C shows 
that E-3-G formation rate was decreased to 41.2 ± 3.1 % of control value, at 10 ng/ml of IL-1. 
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Figure 39.  Effect of IL-1 on UGT1A1 mRNA expression, protein content and activity 
Hepatocytes were exposed to IL-1 (0-10 ng/ml) for 72 hours and UGT1A1 A) mRNA 
expression, B) protein content and C) activity were determined.  The figure shows the mean 
of values obtained from three livers, with the S.D. indicated by the vertical bars.  All mRNA 
values are normalized to GAPDH while and protein values are normalized to β-actin 
expression.  *, significantly different from control cells, p ≤ 0.05.  
 
* 
* 
* 
* 
* 
* 
* 
UGT1A1 
β - ACTIN 
+ HMM 
PB  
(2mM) 10 1 
IL-1 (ng/ml) 
5.22   0.66   0.47   
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IL-2 at concentrations 0.3 ng/ml and 1 ng/ml showed 1.27-fold and 1.23-fold increase in 
UGT1A1 mRNA expression, respectively (Figure 40A). IL-2 did not show any significant effect 
on UGT1A1 protein content (Figure 40B), while UGT1A1 activity was inhibited significantly 
only at 10ng/ml. The formation rate of E-3-G was 83.2 ± 5.2 % of control after treatment with 10 
ng/ml IL-2 (Figure 40C). 
 Surprisingly, IL-6 at higher concentrations showed significant increase in UGT1A1 
mRNA expression. This increase was 1.7 ± 0.2-fold and 1.6 ± 0.3-fold compared to control, at 
5ng/ml and 10 ng/ml IL-6, respectively (Figure 41A). UGT1A1 protein content, on the other 
hand, was decreased to 88 % and 53 % of control after exposure to IL-6 at concentration 1ng/ml 
and 10 ng/ml (Figure 41B). Similarly, formation rate of E-3-G was decreased to 88.3± 5.3 %, 
82.1± 4.8 % and 72.7± 4.2 % of control value, at 1 ng/ml, 5 ng/ml and 10 ng/ml of IL-6 (Figure 
41C). 
TNFα treatment did not significantly alter UGT1A1 mRNA expression, but decreased 
the UGT1A1 protein content to 77 % and 54 % of control at 1 ng/ml and 10 ng/ml, respectively 
(Figure 42A and Figure 42B, respectively). But, with increasing concentrations of TNFα, the 
formation rate of E-3-G was decreased up to 76.5 ± 3.6 % of control, at 10ng/ml (Figure 42C). 
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Figure 40.  Effect of IL-2 on UGT1A1 mRNA expression, protein content and activity 
Hepatocytes were exposed to IL-2 (0-10 ng/ml) for 72 hours and UGT1A1 A) mRNA 
expression, B) protein content and C) activity were determined.  The figure shows the mean 
of values obtained from three livers, with the S.D. indicated by the vertical bars.  All mRNA 
values are normalized to GAPDH while and protein values are normalized to β-actin 
expression.  *, significantly different from control cells, p ≤ 0.05.  
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Figure 41.  Effect of IL-6 on UGT1A1 mRNA expression, protein content and activity 
Hepatocytes were exposed to IL-6 (0-10 ng/ml) for 72 hours and UGT1A1 A) mRNA 
expression, B) protein content and C) activity were determined.  The figure shows the mean 
of values obtained from three livers, with the S.D. indicated by the vertical bars.  All mRNA 
values are normalized to GAPDH while and protein values are normalized to β-actin 
expression.  *, significantly different from control cells, p ≤ 0.05.  
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Figure 42.  Effect of TNFα on UGT1A1 mRNA expression, protein content and activity 
Hepatocytes were exposed to TNFα (0-10 ng/ml) for 72 hours and UGT1A1 A) mRNA 
expression, B) protein content and C) activity were determined.  The figure shows the mean 
of values obtained from three livers, with the S.D. indicated by the vertical bars.  All mRNA 
values are normalized to GAPDH while and protein values are normalized to β-actin 
expression.  *, significantly different from control cells, p ≤ 0.05.  
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7.5.2. Effect of cytokines on mRNA expression of PXR and CAR  
The mRNA expression of PXR and CAR was determined using RT-PCR in the cells 
treated with IL-1, IL-2, IL-6 and TNFα (0, 0.3, 1, 5 and 10 ng/ml) for 72 hours. 
Figure 43A shows that mRNA expression of both PXR and CAR was decreased to 56.8 ± 
2 % and 49.3 ± 3 % of control, respectively, at 10 ng/ml IL-1 concentration. IL-2 did not show 
any changes in PXR and CAR at lower concentrations, but showed a significant decrease in PXR 
and CAR expression at higher concentrations (10 ng/ml). The PXR and CAR expression was 
decreased to 83 ± 2 % and 81 ± 3 %, respectively, at 10 ng/ml IL-2 (Figure 43B). Figure 44A 
shows that mRNA expression of both PXR and CAR was increased to 1.34 ± 0.07 % and 1.9 ± 
0.03 % of control, respectively, at 10 ng/ml IL-6 concentration. TNFα did not show any changes 
in PXR and CAR concentrations ≤ 1ng.ml, while mRNA expression of PXR was increased 1.5-
fold over control at TNFα (10 ng/ml) (Figure 44B).     
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Figure 43.  Effect of IL-1 and IL-2 on mRNA expression of PXR and CAR 
Hepatocytes were exposed to A) IL-1 and B) IL-2 (0-10 ng/ml) for 72 hours and the mRNA 
expression of PXR (closed bars) and CAR (thatched bars) was determined.  The figure shows 
the mean of values obtained from three livers, with the S.D. indicated by the vertical bars.  
All mRNA values are normalized to GAPDH expression.  *, significantly different from 
control cells, p ≤ 0.05.  
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Figure 44.  Effect of IL-6 and TNFα on mRNA expression of PXR and CAR 
Hepatocytes were exposed to A) IL-6 and B) TNFα (0-10 ng/ml) for 72 hours and the 
mRNA expression of PXR (closed bars) and CAR (thatched bars) was determined.  The 
figure shows the mean of values obtained from three livers, with the S.D. indicated by the 
vertical bars.  All mRNA values are normalized to GAPDH expression.  *, significantly 
different from control cells, p ≤ 0.05.  
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7.6.  Discussion 
In humans, 16 different UGT isoforms have been classified into either 1A or 2B 
subfamilies (Tukey and Strassburg, 2000). Among the UGT family, UGT1A1 is involved in the 
glucuronidation of various endogenous substrates such as bilirubin and estradiol, and drugs like 
acetaminophen, thus making it the most important UGT isoform (Cheng et al., 1998; Court et al., 
2001). Limited data have been published on the effects of pro-inflammatory cytokines on the 
expression and activity of UGT1A1. Small decreases in hepatic UGT activity were reported after 
administration of lipopolysaccharides (LPS) in rats. In isolated pig hepatocytes, IL-1α and TNFα 
caused an early inhibition of glucuronidation (Monshouwer et al., 1996). In a single study with 
human liver biopsies, decreased UGT1A4, UGT2B4 and UGT2B7 mRNA levels were observed 
with increased inflammation (Congiu et al., 2002). Most studies have used rat and pig livers and 
are limited due to analysis of UGT mRNA levels only or activity only. 
In the present study we have used human hepatocyte cultures to study the effect and dose 
dependency of IL-1, IL-2, IL-6 and TNFα on UGT1A1 expression and activity. Hepatocytes in 
culture provide an intact system containing all the necessary cofactors for oxidative, reductive 
and conjugative metabolism as well as all the various regulatory elements required to maintain 
and modulate the expression of the enzymes.  
UGT1A1 catalytic activity was determined by measuring the formation rate of estradiol-
3-glucuronide. The conjugation of the phenolic 3-OH group of estradiol has been reported to be 
mediated mainly by UGT1A1 in humans (Senafi et al., 1994; Soars et al., 2004). Therefore, 
estradiol was chosen as a probe substrate to measure UGT1A1 activity.   
In the present study we have shown that IL-1 (0-10 ng/ml) down regulates UGT1A1 
expression and activity, in a concentration dependent manner. Our observations are consistent 
  164
with the report by Monshouwer et. al., (1996) where IL-1 (10-1000 U/ml) inhibited the UDPGT-
dependent enzyme activities by more than 20- 60% when pig hepatocytes were exposed to IL-1 
for 12 hours. Treatment of human prostate cells, LNCaP cells, with IL-1 has been reported to 
inhibit dihydrotestosterone (DHT) glucuronidation by 70% (Levesque et al., 1998). In contrast a 
study by Strasser et. al., (1998) has reported that exposure of rat hepatocytes to IL-1 in a 
concentration range of 5-50 U/ml did not result in any significant alterations in UGT1*1 or 
UGT2B3 mRNA levels.    
Downregulation of UGT1A1 mRNA expression along with decreased protein content and 
activity after IL-1 treatment suggests that IL-1 possibly acts by altering the transcriptional 
process. PXR and CAR are the transcriptional factors involved in the regulation of UGT1A1 
(Mackenzie et al., 2003). In the present study, IL-1 decreased the mRNA expression of both 
PXR and CAR to 50% of control value. This supports our hypothesis that IL-1 downregulates 
UGT1A1 by altering the mRNA expression of nuclear receptors, PXR and CAR that control 
expression of UGT1A1. 
IL-2 showed a 1.2–fold increase in UGT1A1 mRNA expression at lower concentration, 
while there was no effect at higher concentration. Also, IL-2 did not alter the UGT1A1 protein 
content at the concentrations used in the study. UGT1A1 activity remained unchanged when 
hepatocytes were exposed to IL-2 concentrations ≤ 5 ng/ml and was inhibited to 83.2 % of 
control at 10 ng/ml IL-2.  There are no published studies documenting the effect of IL-2 on 
UGT1A1 expression and activity. Interleukin-2 (IL-2) in rat primary hepatocytes downregulates 
CYP3A activity within 24 hours, with only transient suppression of CYP3A4 activity in human 
hepatocytes (Tinel et al., 1999). Sunman et. al. (2004) have shown no sustained suppression of 
CYP3A activity with IL-2 in human hepatocyte cultures. However, in hepatocyte/Kupffer cell 
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cocultures, a concentration dependent 50-70% decrease in CYP3A activity was observed with 
IL-2 at 72 hours. This suggests that IL-2 mediates its inhibitory effect ‘indirectly’ through 
Kupffer cells by mediating release of IL-1, IL-6 or TNFα which in turn downregulate CYP3A4 
activity. Failure of IL-2 to show any significant suppression of UGT1A1 in our experiment may 
be attributed to the absence of Kupffer cells in the model system used.  
 In our experiments, IL-6 decreased UGT1A1 protein content to 53% - 88% and activity 
to 72.2 % - 88.3% of control at concentrations greater than 1 ng/ml. Surprisingly, at higher 
concentrations IL-6, UGT1A1 mRNA expression was increased up to 1.7-fold of control. 
Monshouwer et. al., (1996) have reported only 20% inhibition of UDPGT-dependent enzyme 
activities after IL-6 treatment (1000 U/ml) in pig hepatocytes. In rat hepatocytes, IL-6 has been 
shown to suppress the mRNA expression of UGT1A1 to 77% of control and UGT2B3 to 60% of 
control (Strasser et al., 1998). In the present study, the mRNA expression of transcriptional 
factors PXR and CAR were also measured in IL-6 treated cells. PXR mRNA was increased 1.3-
fold, while CAR mRNA expression was increased 1.9-fold over control value, at 10 ng/ml IL-6. 
Increased mRNA expression of UGT1A1 along with increased PXR and CAR expression with 
decreased protein content and UGT1A1 activity suggests that IL-6 mediated suppression of 
UGT1A1 may be associated with post transcriptional changes. The exact mechanism by which 
IL-6 decreases UGT1A1 activity cannot be explained by the present data. 
TNFα did not significantly alter UGT1A1 mRNA expression, but with increasing 
concentrations of TNFα, the UGT1A1 protein content and formation rate of E-3-G was 
decreased to 54 % and 75 % of control, respectively. The mRNA expression of PXR and CAR 
remained unchanged after TNFα treatment but increased at highest concentration used. This 
suggests that possibly TNFα mediated its effect on UGT1A1 enzyme by affecting the 
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translational processes such as affecting the stability of protein. There is only one study in pig 
hepatocytes, where TNFα (10 –1000 U/ml) has been shown to mediate a 20- 60 % reduction in 
UDPGT-dependent enzyme activities at a 12-hour treatment period (Monshouwer et al., 1996).  
In summary, this is the first study to the best of our knowledge documenting the effect of 
IL-1, IL-2, IL-6 and TNFα on human UGT1A1 expression and activity in human hepatocytes. 
Given that previous studies were carried out in rat or pig hepatocytes or in artificial cell culture 
systems, our observations provide important insight into the differential effect of cytokines on 
UGT1A1 expression and activity. All four cytokines inhibited the formation rate of estradiol-3-
glucuronide thus inhibiting UGT1A1 activity to different extent. The rank order of inhibition 
potency was IL-1 >IL-6 ≅ TNFα > IL-2, with maximum inhibition seen after IL-1 treatment. The 
lowered UGT1A1 activity during the inflammation process can decrease the conjugation of 
bilirubin and increase the concentration of bilirubin in bile and serum. The metabolism of drugs 
that are conjugated by UGT1A1 will be decreased during inflammation and dosing adjustments 
of such drugs are necessary in patients. Our observations indicate that cytokines contribute at 
most a 2-fold change in activity of UGT1A1. Other factors may be of more importance in the 
observed variation in glucuronide conjugation in liver transplant patients. The overall effect of 
cytokines on UGT1A1 in general appears to be modest downregulation of this enzyme.  
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8. Discussion and summary 
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8.1. Discussion and Summary 
The objective of the work carried out in this dissertation was to evaluate the effect of 
endogenous mediators such as cytokines and exogenous chemicals such as HIV protease 
inhibitors on hepatic drug metabolizing enzymes and transporters. In this research work, we 
systematically studied the effect of clinically used HIV-protease inhibitors on phase I and phase 
II metabolizing enzymes as well as on drug transporters. Extending earlier findings in our 
laboratory, we also investigated the effect of cytokines on phase II enzymes and drug 
transporters. Our findings have been used to postulate and predict potential mechanisms 
responsible for modulation of drug metabolizing enzymes and transporters. Several key findings 
were generated in this work, which are summarized in the following section. 
We have used primary cultures of human hepatocytes (PCHH), which provide several 
advantages over other systems used to study drug metabolism and drug transporters.  The PCHH 
contain all the necessary cofactors for oxidative, reductive and conjugative metabolism as well as 
various regulatory elements required to maintain and induce/inhibit the expression of enzymes. 
The PCHH system is also well suited to study the role of nuclear receptors such as pregnane X 
receptor (PXR) and constitutive androgen receptor (CAR), which are involved in the regulation 
of metabolizing enzymes and hepatic transporters.  
In the first part of this study, we found a concentration dependent effect of individual 
protease inhibitors on CYP3A4 expression and activity in a human hepatocyte system. mRNA 
expression, protein content and activity were used as key metrics to determine the interaction 
potential of the protease inhibitors with different CYP3A4 substrates. The interaction potential of 
different protease inhibitors was determined to be widely different and a relative ranking of this 
interaction potential has been generated. We have also reported that the CYP3A4 inhibition or 
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induction by protease inhibitors after treatment and removal is a slowly reversible over time. The 
kinetic parameters such as t1/2 and recovery time for CYP3A4 expression and activity, after drug 
discontinuation, have been calculated. These parameters can quantify the effect of protease 
inhibitors on CYP3A4 and may prove useful in further studies. The findings from this study thus 
can provide insight into the clinically observed complex drug-drug interactions with other 
CYP3A4 substrate drugs. 
In the second part of this work, we have studied the effect of ritonavir, indinavir and 
amprenavir on the expression and activity of the UGT1A1 enzyme. This is the first study to the 
best of our knowledge, to report the effect of increasing concentrations of protease inhibitors on 
UGT1A1 mediated metabolism in human hepatocytes and to document EC50 values for UGT1A1 
induction after RTV treatment. We also demonstrated that the effect of ritonavir and amprenavir 
on UGT1A1 is ‘indirect’ and is possibly mediated through the nuclear receptors, while the 
inhibitory effect of indinavir on UGT1A1 activity is direct. This study shows that protease 
inhibitors can significantly modulate the expression and activity of UGT1A1 thereby affecting 
the clearance of drugs and endogenous compounds metabolized by glucuronidation. In contrast 
to the effect of inhibition of CYP3A, HIV-protease inhibitors generally appear to moderately 
induce UGT1A1. 
The third part of this work aimed to study the effect of HIV-protease inhibitors on drug 
efflux transporters. This is among the first few studies in the human hepatocyte system to report 
that increasing concentration of HIV-protease inhibitors have differential effects on expression 
of drug efflux transporters such as P-glycoprotein, MRP2, MRP6 and BSEP. By monitoring and 
measuring the concomitant regulation of PXR and CAR expression during HIV-protease 
inhibitor treatment, we have postulated that transporter expression is mediated via mechanisms 
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involving nuclear receptors such as PXR and/or CAR for MDR1, MRP2 and BSEP and other 
nuclear receptors as in the case of MRP6. Knowing the effects of HIV-protease inhibitors on the 
expression and activity of hepatic transporters, such as those studied in this work may hence 
prove highly beneficial in understanding the pharmacokinetic behavior of drugs that are 
transported via P-glycoprotein, MRP2, MRP6 and BSEP. 
Another objective of this research work was to determine the effect of individual 
cytokine exposure on hepatic drug transporter expression and activity. We studied the 
concentration and time dependence of cytokine exposure on BSEP expression and activity. It 
was shown that maximum suppression in mRNA expression and BSEP activity occurs after 72 
hours of cytokine treatment. Different cytokines exhibit different inhibition potential which can 
be ranked as IL-1 ≅ TNFα > IL-6 > IL-2 in decreasing order of inhibition. These findings 
indicate that any alteration of above-cited cytokines in deceased states such as infection, cancer 
or rejection after transplantation will modulate the expression and activity of hepatic BSEP and 
thus impact the pharmacokinetics of substrate drugs and/or bile secretion leading to cholestasis. 
The last part of this dissertation aimed to study the effect of IL-1, IL-2, IL-6 and TNFα 
on UGT1A1 expression and activity in human hepatocytes. Most of the studies reported in 
literature have been carried out in rat or pig hepatocytes or in artificial cell culture systems. Our 
study is among the first studies conducted on human hepatocytes and thus provides important 
insight into the differential effect of cytokines on UGT1A1 expression and activity. All four 
cytokines inhibited formation rate of estradiol-3-glucuronide thus inhibiting UGT1A1 activity to 
a different extent. The rank order of inhibition potency was IL-1 >IL-6 > TNFα > IL-2, with 
maximum inhibition seen after IL-1 treatment. The lowered UGT1A1 activity during 
inflammation process can decrease the conjugation of bilirubin and increase the concentration of 
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bilirubin in bile and serum. The metabolism of drugs that are conjugated by UGT1A1 will be 
decreased during inflammation thereby necessitating the dosing adjustments of such drugs in 
patients.  
8.2. Clinical Implications 
1. HIV-protease inhibitors will contribute to the observed variability in the 
pharmacokinetics of immunosuppressive drugs to the maximum extent of all the 
variables tested in our laboratory. This effect is primary mediated through inactivation of 
CYP3A enzymes. Significant reduction in the doses of all substrates of CYP3A4 is 
necessary in transplant patients receiving concomitant HIV-protease inhibitors. 
2. The inhibitory effect of HIV-protease inhibitors is immediate (based on previous studies 
in our laboratory). Significant decrease in doses of CYP3A4 substrate drugs is necessary 
immediately after the addition of HIV-protease inhibitors to the therapeutic regimen in 
transplant patients. However, the recovery of inhibition of CYP3A is time dependent. It 
will take approximately 8-10 days for complete recovery of inhibition of CYP3A. 
Specific attention must be paid to the dosing regimen of CYP3A substrates during this 
time period. 
3. The contribution of cytokines to the observed variability in CYP3A mediated metabolism 
has been previously reported in our laboratory to be modest at best. Levels of CYP3A 
enzymes will be modestly decreased in the presence of elevated cytokines. 
4. With regard to the variability in activity of UGT1A1, HIV-protease inhibitors will 
modestly contribute to the observed variabilility in the pharmacokinetics of the drugs that 
are conjugated by this enzyme. In contrast to the effect of inhibition of CYP3A, HIV-
protease inhibitors will increase expression and activity of possibly UGT1A1 through the 
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induction of PXR and CAR. Dosing regimen of drugs metabolized by UGT1A1 must be 
increased in the presence of HIV-protease inhibitors. 
5. The inhibitory effect of cytokines on UGT1A1 appears to be modest. Similar to their 
effect on CYP3A, cytokines decreased the expression and activity of UGT1A1. 
Decreased dosing of UGT1A1 substrates is necessary in patients with elevated 
inflammatory cytokine levels. 
6. The effect of HIV-protease inhibitors on transporters is modest as compared to their 
effects on CYP3A. Due to their effect on PXR and CAR, HIV-protease inhibitors tend to 
increase expression of certain transporters. The uptake and efflux of the substrates of the 
transporters will be higher in patients taking HIV-protease inhibitors. The effect of HIV-
protease inhibitors on CYP3A is likely to override the effects of HIV-protease inhibitors 
on transporters like P-glycoprotein. 
7. Consistent with the effect on CYP3A and UGT1A1, cytokines decrease expression and 
activity of several transporters. The effect of cytokines appears to be greater on 
transporters than on CYPs and UGTs. This requires decreased dosing of drugs during 
elevated cytokine levels. 
8.3. Limitations and Future directions 
1. While this is the first report of a systematic evaluation of HIV-protease inhibitors and 
cytokines on phase I enzymes, phase II enzymes and transporters, all the studies were 
carried out in primary cultures of human hepatocytes. Coculture using Kupffer cells will 
provide additional information that may be more relevant to in vivo situation, especially 
with regards to the effect of cytokines, as Kupffer cells play an important role in vivo 
during inflammatory process.  
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2. The observations of this study are limited to CYP3A and UGT1A1. Additional studies 
need to document the effect of HIV-protease inhibitors and cytokines on other drug 
metabolizing enzymes. 
3. While we evaluated the activity of BSEP only, activity of other hepatic transporters need 
to be evaluated in future studies using specific substrates for transporters such as 
bromosulphthalein for MRP2 and rhodamine123 for P-glycoprotein. 
4. While effects of individual cytokines were studied, future studies should include 
combination of cytokines to determine potential additive or synergistic effects. 
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